Novel linkers for prostate-specific prodrug systems by Miller, Christian Karl
        
University of Bath
PHD








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. May. 2019




for the degree of PhD 
of the University of Bath 
2006
COPYRIGHT
The research work contained within this thesis has been carried out in the Department 
of Pharmacy and Pharmacology, under the supervision of Dr Michael D. Threadgill.
Attention is drawn to the fact that copyright of this thesis rests with its author. This 
copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and that no quotation 
from the thesis and no information derived from it may be published without the prior 
written consent of the author.
This thesis may be available for consultation within the University Library and may be 
photocopied or lent to other libraries for the purpose of consultation.
UMI Number: U204003
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U204003
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
. ■'• - - r  h a t
IfC 1 5 r ? ’  S!S
f t ' J : ........
fr
ABSTRACT
Prostate carcinoma is an increasing cause of male mortality in the West. Doxorubicin 
is the most effective treatment for hormone-independent prostate cancer but many 
patients relapse. A prodrug system to deliver doxorubicin selectively to the prostate 
would improve treatment. Polymeric prodrugs are selectively retained in solid tumours 
by the EPR-effect. Prostate specific antigen (PSA) is a serine protease, which is 
catalytically active only in the prostate. Thus, a water-soluble polymeric prodrug 
system in which the doxorubicin is linked to the polymer through a PSA-cleavable 
peptide was designed. This prodrug system would have binary selectivity: the EPR 
effect and the PSA localisation.
Since PSA is reported to release arylamines but not alkylamines from its specific 
substrate sequence SSKLQ, it was necessary to interpose a self-immolative molecular 
clip between the peptide and the drug. Aminobenzyloxycarbonyl and 
aminophenylpropargyloxycarbonyl clips were studied. Initial synthetic approaches to 
dip-less constructs were severely hampered by the insolubility of tripeptide derivatives 
containing glutamine.
Attempts to prepare the constructs containing the peptide and a model drug (2-[4- 
nitrophenyljethylamine (NPEA)) linked by the aminobenzyloxycarbonyl clip 
foundered on very poor coupling yields of glutamine derivatives with appropriate 
anilines and, again, on the insolubility of glutamine derivatives. Model experiments on 
assembly of aminophenylpropargyloxycarbonyl clips were not encouraging, as simple 
4-amidophenylpropargyl alcohols failed to form the corresponding N-nitrophenylethyl 
carbamates. However, using an alternative retrosynthetic disconnection, a 
Sonogashira coupling of Bocglutamine-4-iodoanilide with propargyl N-2-(4- 
nitrophenyl)ethyl carbamate successfully formed Bocglutamine-alkynefCZ/Z^-NPEA. 
The utility of this material in further elaboration of the peptide, was demonstrated by 
deprotection and coupling with a Bocleucine-active ester. Thus, a potential route to 
the target peptide-CLZP-model drug construct has been established.
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Prostate cancer is one of the most common malignant diseases for which health-care intervention is 
sought worldwide, and in many developed countries it is the most common non-cutaneous malignant 
disease7.
Prostate cancer is die sixth most common cancer in the world (in the number of new cases), the third 
most common cancer in men, and the most common cancer in men in Europe, North America, and some 
parts of Africa9.
{The Lancet 2003]
The term acancer ” refers to a condition in which the regulation of cell growth is lost and cells grow 
uncontrollably. Prostate cancer occurs when cells within the prostate grow uncontrollably, creating a 
small malignant growth or tumour.
Most cells in the body are constantly under going cell division, thus dividing, maturing and then dying 
in a tightly intricate controlled process. Unlike normal cells, the growth of cancer cells is no longer well 






1.1 P ro sta te  C an cer
1.1.1 What is the prostate (anatom y & Junction)?
The prostate is a gland that surrounds the neck of the bladder and proximal urethra 
(Figure 1). The prostate gland consists of five lobes (zones), separated by the 
ejaculatory ducts and by the urethra. Two lateral lobes and an anterior lobe enclose 
the urethra, with the two lateral lobes being marked by a posterior midline groove 
(Figure 2), palpable on rectal examination1.
Figure 1. A sagittal section of the male reproductive system
The two lateral lobes are also known as the pre-prostatic tissue lobe and the transition 
lobe, respectively. The pre-prostatic tissue lobe contains muscles that are responsible 
for preventing semen from flowing backward into the bladder during ejaculation. The 
transition lobe can be highly susceptible towards ‘Benign Prostatic Hyperplasia’ (BPH),
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and can enlarge upon the formation of a non-cancerous over-growth of the glandular 
tissue (see section 1.1.5.2)2. This is also prominent in the middle lobe as well, which 
lies between the ejaculatory ducts and the urethra and is involved in the connection of 
the seminal vesicles to the prostate. The middle lobe also contains approximately 25% 
of the organ’s glands in total. The peripheral lobe, known also as the posterior lobe, is 
located at the rear of the prostate behind the ejaculatory ducts, contains roughly 75% 
of the glands in the prostate and is where most prostate cancer occurs. The anterior 
lobe, which is primarily smooth muscle tissue, is situated near the front of the prostate.
A normal prostate gland weighs about 20 g and is enclosed in a fibrous capsule1. It is a 
single, doughnut-shaped gland about the size of a golf ball3. Within the prostate, there 
are three main groups of glands arranged concentrically around the urethra, the inner 
peri-urethral group, the submucosal gland and the external group or main prostatic 
glands. The ducts of all three groups, all their ducts converge and open into the 
prostatic urethra1. The blood supply to the prostate comes from the main iliac artery 
and prostatic veins drain to the prostate plexus around the gland and then to the 
internal iliac veins1.
The function of the prostate is to secrete a thin, milky, alkaline substance that 
constitutes to about 31% of the seminal fluid volume4. It contains calcium, citrate ion, 
phosphate ion, a clotting enzyme, and a profibrinolysin (plasminogen)5. During 
emission, the capsule (a layer of cells covering the prostate) contracts simultaneously 
with that of the vas deferens, so that the thin, milky fluid of the prostate adds further 
bulk to the semen5. Its alkalinity helps protect the sperm from the acidity in the male 
urethra and that of the female vagina, which is very important for successful 
fertilization4*5. The acidity of vaginal secretions are at a pH of 3.5 -  4.0 and, for 
optimum sperm motility, the conditions have to be at least that at of pH 6.0 -  6.5. It is 
probable that the slightly alkaline prostatic fluid helps neutralise the acidity of the 
other seminal fluids during ejaculation and thus enhances the fertility of sperm5. If the 
acidity is too great, it can depress or, if strong enough, kill the sperm altogether4.
3
1.1.2 Bulbourethral glands (Cawper’s  glands)
The paired bulbourethral glands, also known as Gowper’s glands, resemble peas in 
both size and shape4. As shown in (Figure 1), the location of these tubuloalveolar 
glands are inferior to the prostate on either side of the membranous urethra within the 
genital diaphragm and their ducts (approximately 2.5 cm long) connect and open into 
the spongy, penile portion of the urethra3. Like the prostate, these glands secrete an 
alkaline fluid (approximately 5% of the total seminal fluid volume)4 into the urethra for 
counteracting the acidic environments from both the male urethra and the vagina (as 
mentioned in section 1.1) 3*4. These glands are also responsible for secreting a mucus 
that lines the urethra and the end of the penis for limiting the number of sperm 
deimaged mechanically during ejaculation4*5.
1.1.3 Sem inal vesicles
There are two seminal vesicles, one located on each side of the prostate. Each vesicle is 
a convoluted, loculated tube lined with a secretory epithelium that secretes a mucous 
containing of 2m abundance of fructose, citric acid and other nutrient substances, as 
well as large quantities of fibrinogen and prostaglandins5. It is believed that 
prostaglandins are responsible towards aiding fertilisation in two ways:
1. by reacting with the female cervical mucus, triggering a more receptive response to 
sperm movement.
2. by causing reverse perist2iltic contractions in the uterus and fallopian tubes to help 
move the sperm towards the ovaries.
During the process of emission and ejaculation, each vesicle empties its contents into 
the prostatic end of the 2tmpulla (the part of the vas deferens that joins to the seminal 
vesicles) and the contents of the 2impulla then pass into an ejaculatory duct; this occurs 
shortly after the vas deferens empties the sperm carried from the testes. All the 
contents are then carried through the body of the prostate gland, where they are 
released into the internal prostatic urethra for emission to the exterior2*5.
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1.1.4 Testes
The testes are two small oval-shaped organs, that are somewhat flattened from side to 
side, measuring at an average length of 4-5 cm, with a weight of approximately 10 -  
15 g. They are both located below the penis in a suspended pouch of skin called the 
scrotum (Figure 1), where usually, the left testicle is located about 1 cm lower to that of 
the right4. Each testis is composed of up to 900 tightly coiled seminiferous tubules, 
each averaging more than half a metre long, in which sperm are formed5. This process 
is otherwise known as spermatogenesis.
The collecting tubules inside the testicle join together to form a tube called the 
epididymis, which itself is another coiled tube of about 6 metres long5. Sperm then 
empty into the epididymis to where the tube (known as the vas deferens) carries on to 
the outside of the testis where it widens. It can be felt as a soft swelling at the back of 
the testis. The vas deferens (also known as the spermatic cord) then enlarges into the 
ampulla and it is here where the sperm meets the contents of the seminal vesicles 
(section 1.1.3), and continues to form a short tube called the ejaculatory duct. This 
duct immediately opens into the urethra (the tube from the bladder to the penis) as it 
enters the body of prostate gland4’5 (Figure 1).
1.1.4.1 Male sex hormones
The testes are not only responsible for the development of sperm in the aid of 
reproduction but also for the production of male sex hormones, collectively known as 
androgens. All androgens are steroid-type compounds (e.g. testosterone (1) and its 
metabolite, dihydrotestosterone (2), see (Scheme 1)) and can be synthesised either from 
cholesterol or directly from acetyl coenzyme A5. Testosterone is largely responsible for 
initiating and maintaining the sex drive (libido) in men4’5 and is the main cause of the 
development of male characteristics such as a deep voice, beard growth, muscle 
development and the growth of vital sex organs. Testosterone is significantly more 
abundant than other male sex hormones, such that one can consider it to be the 
primary testicular hormone, even though most of it is converted to dihydrotestosterone 
in target tissues such as the prostate gland3. The proportion of testosterone that does
5
not become fixed to the tissues is rapidly converted and metabolised, mainly by the 
liver, into androsterone (Scheme 1) and subsequently conjugated as either 
glucuronides or sulphates, which are secreted into the gut by way of liver or into the 





Schem e 1. Chemical structures o f the male sex hormones testosterone, dihydrotestosterone and 
androsterone
1.1.4.1.1 Intracellular mechanism of action of testosterone
The prostate gland is one of the organs most affected by testosterone and other 
androgens5. Almost all of the effects of testosterone result in an increased rate of 
protein formation in the target prostatic cells. However, the rate at which testosterone 
is formed and thus secreted to the prostate gland is dependent on the controlled 
secretion of the gonadotropin-releasing hormone (GnRH)6. This hormone is secreted 
by the hypothalamust(P7) and in conjunction it stimulates the pituitary glandtt(P7) which 
releases two more very important hormones (glycoproteins), namely follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH)5>6. The former is the hormone 
responsible for the stimulation of spermatogenesis, while the latter is the primary 
stimulus in the secretion of testosterone by the interstitial cells of Leydig2’6. Therefore,
6
it is important to mention that, in the absence of GnRH production from the 
hypothalamus, the gonadotropes within the pituitary gland secrete almost no LH or 
FSH6 and, thus a decrease in the secretion of testosterone occurs. Once testosterone 
enters the prostatic cells within the prostate gland, it encounters an intracellular 
enzyme, 5a-reductase, and is converted to dihydrotestosterone. This now-active 
androgen then binds to a cytoplasmic receptor protein and this complex translocates to 
the cell nucleus, where it binds with nuclear proteins and induces DNA-RNA 
transcription5. Furthermore, this promotes prostatic cell proliferation. Testosterone 
stimulates production of proteins not only in the prostate and other target organs but 
virtually everywhere in the body by this mechanism3*5.
1.1.5 Benign prostate disease
While the prostate gland remains relatively small throughout childhood, it begins to 
grow at puberty under the stimulus of testosterone. The prostate gland reaches an 
almost stationary size at the age of 20 years and generally remains at this size until the 
age of 50 years. Generally, in men over the age of 50 years, the prostate tends to 
involute with a decreased production of testosterone by the testes5.
It is beyond the age of 50 years that men generally become susceptible to prostatic 
diseases1, such as chronic urinary problems and benign prostatic fibroadenoma. This 
condition can be characterised as hypertrophy, or enlargement of the prostate5. This 
hypertrophy is an abnormal, non-testosterone dependent overgrowth of prostate tissue 
itself. It can be this hypertrophy that obstructs the urinary duct (prostatic urethra) 
pushing against it, narrowing the urethra. The incidence of these problems generally 
increase with age1.
tCp®) The hypothalamus is a central area on the underside of the brain, controlling involuntary functions 
such as body temperature and the release of hormones.
ttCp6) The pituitary is a small oval gland at the base of the brain producing hormones that control other 
glands and influence growth of bone structure, sexual maturing, and general metabolism.
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1.1.5.1 Prostatitis
Prostatitis implies a prominent inflammatory lesion of the prostate gland that causes 
narrowing of the urethra and, consequently, urinary problems (21s mentioned above in 
1.1.5). Prostatitis is often associated with a specific infective cause (e.g. a bacterial 
infection)1. Prostatitis is usually split into four types, these are discussed in more detail 
below:
1.1.5.1.1 Acute suppurative prostatitis
This usually results from the spread of infection along the prostatic ducts secondary to 
urethritis or cystitis1. It is normally a bacterial infection that spreads, leading to acute 
inflammation of the prostate. Acute infection of both the bladder and the urethra 
usually follow. Common causative micro-organisms include coliforms (such as E. coE), 
staphylococci and gonococcil>2. Acute prostatitis may occasionally follow urethral 
catheterisation or endoscopy, although a more rare case is when the infection has gone 
blood-borne2. With inevitable urinary problems due to the enlarged prostate pushing 
against the urethra, the lesion can usually be characterised by difficulty in micturition 
(urination), or by its degree of rectal pain1. There may even be necrosis (from the 
damaged epithelial cells) with formation of an abscess, which may eventually discharge 
into the urethra1’2.
1.1.5.1.2 Chronic non-specific prostatits
Chronic non-specific prostatitis may develop from recurrent episodes of acute infective 
prostatitis1. The prostate is initially enlarged and tender but may eventually become 
fibrosed and shrunken2. Urethral obstruction, like that in acute prostatitis, may occur 
and the lesion may be mistaken clinically for prostatic carcinoma2. Tuberculosis of the 
prostate can also occur, showing characteristic caseating lesions that may involve the 
whole gland2.
1.1.5.1.3 Granulomatous prostatitis
Granulomatous prostatitis is a rare condition and consists of a heterogeneous group of 
lesions, all of which may cause enlargement of the prostate gland and urethral
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obstruction1. The inflammatory component and associated fibrosis produce a firm, 
indurated gland (rather than a soft/tender gland as in the acute prostatitis) on rectal 
examination, which, like the chronic prostatitis, may mimic a neoplasm clinically1*2. 
For this reason, the importance of the correct diagnosis for this type of prostatitis is 
critical.
1.1.5.1.4 Allergic (eosinophilic) prostatitis
This is probably the most rare of all benign prostatic diseases and most certainly of the 
different types of prostatitis that can occur. These types of lesions occur usually in men 
who are prone to allergic conditions, particularly bronchial asthma1. The gland 
contains granulomas (a small mass of granulation tissue caused by a chronic infection) 
with areas of fibroinoid necrosis, giant enlarged cells and numerous eosinophils1*2.
1.1.5.2 Benign nodular hyperplasia (BNH)
Benign nodular hyperplasia is a common non-neoplastic process. It represents an 
overgrowth of prostatic glandular tissue and smooth muscle and is comparable to 
conditions such as cystic hyperplasia of the breast2. The incidence of BNH certainly 
increases with age and, by the age of 75 years, over 75% of males are affected to some 
degree, although only 5% have significant symptoms1*2. The process normally starts in 
the peri-urethral prostatic glands and the growth occurs mainly on each side of the 
urethra (in the two lateral lobes of the prostate, see Figure 2). It is not unusual for the 
hyperplasia to project itself in the median lobe as well, by which these areas are 
susceptible to inflammation and can suffer abscesses2.
1.1.5.2.1 Aetiology o f BNH
Unlike with different forms of prostatitis, which are causally related to infections from 
bacteria, BNH is a different type of disease. Although the exact mechanism of the 
process towards BNH is uncertain, it is thought to be related to a hormonal imbalance. 
With increasing age, androgen levels fall, with a relative rise in oestrogens, which are 
notably responsible for an increase in prostatic tissue sensitivity, thus with the central
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(peri-urethral) group of prostatic glands being highly oestrogen-responsive, they 
undergo consequent hyperplasia1.
1.1.6 Malignant prostate disease {prosta te cancer)
Cancer of the prostate gland is a different problem to that of benign prostatic disease 
and is a common cause of death, accounting for about 2-3% of all male deaths5. It is 
one of the most common cancers of an internal organ in males in the developed 
countries, its mortality rate being exceeded only by carcinomas of the bronchus, 
stomach and large intestine2.
(S  Benign prostatic hyperplasia 1 ]  Carcinom a of prostate
Median groove 







Median groove obliterated 
by carcinoma arising in 
posterior subcapsular zone 
— invasion of capsule
Figure 2. A diagram that shows the difference between benign prostatic hyperplasia and malignant 
prostatic disease (carcinoma of the prostate)1
Once cancer of the prostate does occur, the cancerous cells are usually stimulated to 
more rapid growth by testosterone and are inhibited by removal of both testes 
(castration). This way, testosterone cannot be formed5. The aetiology of this disease is 
unknown, although it is probable that a hormonal imbalance, like that for BNH, may 
initiate such carcinomas. Since these lesions for prostatic carcinoma coexist with those
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for BNH, there is virtually no evidence that BNH is causally related to that in the 
development of malignancy2.
1 • 1.6.1 Epidem iology o f prostate cancer
With more and more men being diagnosed with prostate cancer worldwide, the 
knowledge and understanding of the disease is becoming increasingly more important. 
Prostate cancer is diagnosed in very few people younger than 50 years, < 0.1% of all 
patients in total. It is said that about 85% of patients are diagnosed after the age of 65 
years, with the mean age for the disorder being approximately 72-75 years8*9. As 
discussed in great detail by Henrik Gronberg in The Lancet9, the incidence of prostate 
cancer varies widely between ethnic populations and countries, and rates of the disease 
can vary as much as 90-fold between populations. The lowest rates tend to favour 
those in the far eastern countries, such as in Asia and especially Chinese people (1.9 
per 100,000 per year). The highest rates for this disease tend to prevail in more 
westernised populations, with the highest being in North America, Scandinavia and 
especially African-American people in the USA (137 per 100,000 per year)8*9. These 
global differences are poorly understood and its said that they may be caused by a 
combination of genetic susceptibility, exposure to unknown external risk factors, 
dietary components or artifactual reasons, such as cancer registration and differences 
in health care9*10. In 15 years time, prostate cancer is predicted to be the most 
common cancer in men12.
1.1.6.I.1 Genetic factors
Genetic susceptibility by the clustering of prostate cancer in families can be a large 
factor. This may be due to exposure to common environmental factors or simply by 
chance alone since prevalence of this cancer is so high9. It is stated that 10-15% of 
patients with prostate cancer (white, African or Asian) have at least one relative who is 
also affected13. It is also suggested that the disease is recessive or linked to the X- 
chromosome; it is believed that men who have a brother are more likely to obtain the 
disease than those who have a father who is affected9.
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1.1.6.1.2 Dietary factors
This is a controversial area, though results from ecological studies9 suggest that 
prostate cancer is associated with a western lifestyle. Despite many dietary studies 
being conflicting, some components are consistently associated with prostate cancer, 
e.g. high intakes of a-linolenic add (a polyunsaturated fatty acid found in vegetables 
and dairy products), fats, red meats and caldum9. Some studies have put forward that 
it may not be the intake of red meat that is causally related but the way it is cooked 
and prepared (e.g. cooking at high temperatures, charcoal grilling or frying which 
results in the formation of cardnogens such as heterocyclic amines)9. One area of 
interest towards reducing the risk of prostate cardnogenesis is that of the consumption 
of tomato products with a high lycopene content14. Lycopene is the principal 
carotenoid found in tomatoes and it is proposed that a high intake of this active 
lycopene component may reduce the risk of prostate cancer.
1.1.6.2 Clim copathological types o f prostatic carcinom a
There are currently two major dinicopathological types of prostatic carcinoma. There 
are the clinical carcinoma type, which are mainly symptomatic, and the latent 
carcinoma type, which are more inddental (Table 1).
Condition Incidence Location o f gland M orphology M etastasis
BNH 75% of men over 
70 years
Peri-urethral zone Nodular hyperplasia 



















80% of glands 
over 75 years
Any site Microscopic focus of 
adenocarcinoma
Rare
Table 1. Differences between the three most common types of prostatic pathology
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1.1.6.2.1 C linical (symptomatic) carcinom a
This type of tumour usually arises on the posterior part of the prostate and at the 
periphery of the gland (Figure 2), with a large majority being adenocarcinomas (a 
malignant tumour with cells arranged in patterns similar to those of the prostate 
gland)2. These types of adenocarcinoma are usually well differentiated and the 
convoluted outline of the gland is lost and neoplastic acini are formed from a single 
layer of cells, unlike the glands in BNH, which have a double-layered epithelium1. 
Clinical carcinomas are very much symptomatic with their symptoms being similar to 
that of BNH. As with BNH and most prostatic diseases, compression of the 
intraprostatic portion of the urethra due to enlargement of the prostate leads to 
impaired urine flow and an increased risk of urinary infections1. However, because 
these tumours arise from the periphery of the gland, they are extremely susceptible to 
spreading within the prostate gland, causing urethral obstruction. They soon can 
spread to adjacent tissues and may metastasise widely and silently before urinary 
symptoms appear2.
1.1.6.2.2 M ode o f spread
Spread via the lymphatic system
The lymphatic system provides an important route of dissemination of prostatic 
carcinoma, producing metastases in the iliac and para-aortic lymph nodes. These may 
result in lymphatic obstruction and oedemat of the legs1*2.
Spread via blood
Vascular invasion by the tumour results in blood-borne metastases, most commonly to 
bone, lungs and liver (Table 1). The most frequent sites of bone metastases are the 
pelvis, the lumbar spine and the proximal femur, less frequently the ribs and skull. 
Bone metastases are usually osteosclerotic2, with proliferation of osteoblasts and areas 
of new bone formation occurring in association with the neoplastic cells1.
t Oedema is an abnormal build-up of excess serous fluid between tissue cells and thus can lead to 
abnormal swelling
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1.1.6.2.3 Latent (incidental) carcinoma
Latent carcinoma is slightly different in comparison to clinical carcinoma (see Table 
1). Unlike clinical carcinomas which are symptomatic, latent carcinomas are generally 
found incidentally on histological examination of prostatectomy specimens removed 
for BNH, or in the prostate at autopsy1'2. These types of carcinoma are microscopic 
foci of carcinoma and the microscopical appearances are indistinguishable from those 
clinically overt well-differentiated prostatic carcinoma2. Like the clinical carcinoma, 
these tumours are generally adenocarcinomas and are thought not to produce clinical 
manifestations1.
The aetiology of these minute tumours is uncertain and the concept of the latent 
carcinoma has been questioned with the recognition that some of them eventually 
progress and metastasise1. However, these forms of carcinoma are much more 
common than the clinically active symptomatic form of the disease. As such, minute 
foci are found in about 30% of prostates over 50 years old, with the incidence rising to 
about 80% over the age of 75 years (Table l)1.
1.1.6.3 Diagnosis o f adenocarcinoma o f the prostate
Diagnosing prostate cancer in its early stages can be somewhat difficult. Not only 
being able to distinguish such carcinomas from other potential prostatic diseases that 
could be present (ie. BNH), but choosing the right technique in determining what type 
of carcinoma is present, and its stage of malignancy, is critical. There are various 
techniques that can be adopted in the investigation of prostate cancer. The preferred 
method is that of a biopsy (e.g,. transurethral resection, fine needle aspiration cytology 
and needle biopsy)15, with the latter being the most common technique. Normally, 
such techniques are used in combination with diagnostic imaging (ie. ultrasound and 
skeletal X-rays)1. This normally minimises false positives and negatives during 
diagnosis and aids selection of sites for such biopsies15. However, the difficulties with 
needle biopsy not only stem from the small amount of tissue available for histological 
examination but also arise because biopsies often identify only a few malignant glands 
among many benign glands15.
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Monitoring serum prostate specific antigen (PSA) is another way of diagnosing 
prostatic carcinoma. It is produced in prostatic epithelium and has a physiological role 
in the liquefaction of semen. It is also secreted in large amounts by malignant prostatic 
epithelial cells; thus makes it a very good diagnostic marker for the disease15. Also, 
patients with associated bone metastases have a raised level of serum acid 
phosphatase16, an enzyme produced by the neoplastic cells which is also a useful 
diagnostic marker of prostate cancers1’15.
1.1.6.4 Prognosis and the Gleason grading system
PROSTATIC ADEN0GARGI*0*A | 1
(Histologic Grades) ®  ©  ©
~  i ®  i t o i l
Figure 3. A modified illustration of Dr Gleason’s simplified drawing representing the five Gleason 
grades in determining the seventy of prostatic carcinomas17
Following the diagnosis, the next important clinical step is the prognosis and 
prognostic factors include stage of disease and grade of malignancy11. The degree of 
differentiation of the tumour is an important prognostic indicator. In the Gleason 
classification (Figure 3)17, tumours are graded on a scale of 1-5, with a grade 1 tumour 
being the most differentiated and grade 5 being the least differentiated, usually 
showing that tumours are anaplastic with a high mitotic rate2’15’17. More than one 
pattern of differentiation may be present in a surgical specimen and thus the two 
predominant ones are graded individually and then added together to give a final
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Gleason grade (e.g. 3 + 5 = 8). Gleason grades 2-6 are associated with better 
prognosis11’17.
1.1.6.5 Treatments
There are four main types of treatment with the aim of alleviating the prostatic 
disease. These treatments consist of: surgical methods (radical prostatectomy), 
radiation therapy (extemal-beam radiotherapy and brachytherapy), hormone therapy 
and chemotherapy.
1.1.6.5.1 Radical prostatectomy (surgery)
Radical prostatectomy is a surgical method for removal of all, or part of, the prostate 
gland18. If the cancer is localised within the gland and the prostate is completely 
removed, the likelihood of the cancer being cured is extremely high. This type of 
surgery has been the standard against which other local treatments are compared7. 
This procedure has been refined resulting in high cure rates with decreased 
morbidity8. Radical prostatectomy is a collective term for a family of procedures and 
can be separated into retropubic and transperineal approaches19. The retropubic 
approach has the advantage over the perineal method in that the lymph nodes can be 
dissected and the prostate gland removed in a single incision7. In contrast radical 
perineal prostatectomy requires separate incisions for the lymph-node dissection and 
prostatectomy7. The advantage of such surgery over radiation and hormone therapy 
(see sections 1.1.6.5.2 and 1.1.6.5.3, respectively) is that the biochemical follow-up is 
far less ambiguous with respect to the diagnostic marker, PSA. Prostate specific antigen 
is expected to be undetectable after prostatectomy; this contrasts with the 
radiation/hormone approaches in which the prostate remains in place and by which 
the prostate continues to secrete some PSA7>19.
1.1.6.5.2 Extemal-beam radiotherapy & brachytherapy (radiation)
Extemal-beam radiotherapy involves daily treatment for about 7-8 weeks. As with 
radical prostatectomy, this procedure has been refined and undergone a technological 
revolution with results leading to survival rates comparable to that of surgery7’8. Like
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general radiotherapy, it offers a reasonably precise delivery of an external beam to the 
prostate, allowing increased doses to the gland with minimal complications. Unlike 
surgery, this type of radiation therapy is non-invasive7 and has no anaesthetic risk 
(which could pose many problems in elderly patients). It can also be offered to patients 
that would not be able to tolerate either prostatectomy or brachytherapy7. However, 
one important disadvantage in extemal-beam radiotherapy is possible rectal 
complications (see Table 2 for a comparison in complication rates between the 
different treatments available). Since the prostate gland is close to the rectum, a 
therapeutic dose cannot be delivered to the prostate without some dose passing to the 







Rectal * * * * * * *
Sexual (impotence) * * * * * * * *
Urinary
incontinence
* * * * * *
Urinary
retention
* * * * * * * *
Increasing number o f (*s) indicates increasing complication rates.
Table 2. Relative complication ratesfrom local control treatmentsfor prostate cancer7
Brachytherapy is a very effective treatment for the early stages of prostate cancer. It is 
said to achieve disease-free survival rates comparable to those of both prostatectomy 
and extemal-beam radiotherapy but with a different side-effect profile (Table 2)7. 
Brachytherapy works by direct placement of radioactive sources in the area of interest. 
The advantage of using this technique is that it is a more precise, localised method of 
treatment that is less likely to affect surrounding structures (i.e. the rectum)7. However, 
dealing with radioactive sources and specifically in an area such as the prostate, this 
can lead to urinary toxic effects, like prostate oedema and urinary hesitancy. The latter 
may require to the need for a temporary catheter to alleviate such a problem.
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In addition to the follow-up uncertainties, it is well documented that brachytherapy 
leads to a PSA rebound effect (the cause of which is unknown); this takes place 1-2 
years after the procedure, also making follow-up PSAs difficult to interpret7.
1.1.6.5.3 Hormone therapy
The prostate gland is a hormone-responsive organ7 and the growth of most malignant 
prostatic cancer cells thrives on these male hormones, such as testosterone and other 
androgens. Hormonal therapy (or rather, hormone-suppression therapy) was 
previously accomplished mainly by the direct method of bilateral orchiectomy. 
Although the surgical removal of the testes eliminates the production of testosterone 
and is a relatively quick, painless and inexpensive process, the psychological side-effects 
can be highly significant, with the loss of the male libido. The latest method towards 
hormonal therapy is that of chemical castration7. Many hormonal agents are said to 
work along the hormone axis to inhibit and reduce the production of serum 
testosterone or to block the actions of this hormone altogether16*20. These methods are 
not just psychological and aesthetically more pleasing but they are said to be very 
effective in 75-80% of patients with prostate cancer9. Such chemical castration 
methods include the use of injectable drugs known as LHRH/GNRH agonists, the use 
of oral oestrogen drugs and the use of non-steroidal anti-androgen treatment.
1.1.6.5.3.1 LHRH (analogues/agonists) therapy & oestrogen therapy
Luteninizing Hormone-Releasing Hormone (LHRH) is responsible for the secretion of 
testosterone (see section 1.1.4.1.1). Thus the most common way to suppress the 
production of such male androgens is to use LHRH agonists (such as progestogens -  
see Appendix Figure 24)21. LHRH agonists stimulate and shut down signals from the 
pituitary gland in the brain, suppressing the release of the LH hormone and thus 
reducing the amounts of testosterone being produced. In conjunction with the LH 
hormone therapy, the use of Gonadotropin-Releasing Hormone (GnRH) agonists 
(which can also down-regulate the pituitary receptors) can also be used. This type of 
hormonal agonist type therapy is also known as steroidal anti-androgen therapy21. 
Oral oestrogen drugs (e.g. diethylstilbestrol -  see Appendix Figure 24) can be used as
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an alternative therapy and can also reduce testosterone to castrate levels by blocking 
and suppressing the hypothalamic production of GnRH and in turn, LH secretion. 
Since the availability of LHRH/GnRH agonists, oestrogen type drugs are used less 
frequently because of their potential fatal side effects (such as heart attacks and blood 
dots)21*22.
1.1.6.5.3.2 Non-steroidal anti-androgen therapy
This type of therapy is different to that of steroidal LHRH/GnRH therapy, in that 
these types of anti-androgens {e.g. flutamide -  see Appendix Figure 25), or androgen 
receptor antagonists, work by actually inhibiting and blocking testosterone from 
binding to its cellular target. These types of antagonists work without effecting the LH 
secretion, thus preserving the male sexual libido. Although this type of monotherapy is 
said to be less effective to that of steroidal hormonal therapy, a common regimen is the 
combination of a non-steroidal anti-androgen with an LHRH/GnRH analogue to 
provide total blockade of androgens7. Other successful combinations that have been 
shown to improve survival rates dramatically are the use of hormonal therapy 
combined with radiotherapy7*23. This is probably because of their different 
mechanisms of action and the fact that they can independently destroy prostate cancer 
and sensitise the tumour to radiation7.
In general, most hormonal therapies have common side effects, such as hot flushes, loss 
of libido, erectile dysfunction, weight gain, gynaecomastia, liver inflammation and 
osteoporosis20. These side-effects are usually short-lived and mild in short-course 
hormone therapy (typically used for early-stage prostate cancer) and the balance of 
such benefits against the possibility of having the opposing long-course hormonal 
treatment, need to be recognised early on and taken in to careful consideration7*20. 
Although, at first, hormonal ablation therapy seems like the easiest choice in treating 
prostate cancer, certainly in its early stages, problems can occur after a brief period of 
time when patients start to suffer from a relapse of the prostatic disease. Hormonal 
therapy starts to become limited when such relapses involve androgen-independent 
tumours24-25.
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In a number of experimental and clinical prostate cancers, MacNeal26 identified what 
is regarded as premalignant change in these cancers. These observations have led to 
the introduction of a new concept for the development of clinical prostate cancer that 
is significantly different to the established carcinogenic principles25. It is believed that 
prostatic cells do not die as normally and, although the proliferation of cells at this 
stage may not be faster than normal, the lack of cell death results in a greater number 
of cells and, thus, to an apparent new tumour growth26. It is said that these cells which 
do not age normally, escape the normal control mechanisms exerted by hormones and 
other growth factors and an increasing number of these cells at a given stage of growth 
will become relatively hormone-independent25-26.
Aiding these observations by MacNeal, Coffey and Isaacs27 have shown that there may 
be three different mechanisms for the development of hormone-independent cells:
1. The direct mutation of DNA.
2. Cells may adapt to a changing environment, in which, as androgens are suppressed 
by hormonal therapy, cells adapt to survive in a low-androgen environment.
3. Endogenous hormone-independent cells are present from the very start albeit in 
comparatively small numbers. They become prevalent only after the remainder of 
the initial cancerous tumour(s) has been controlled by hormone manipulation or 
some other therapeutic modality.
This third concept is said to fit well with the observed natural history of prostate 
cancer and certainly with the timing of apparent hormone relapse26.
Usually in the latter stages of the prostatic disease and almost always in relapse 
metastatic prostate cancer, the treatment of hormone-resistant cells may be 
accomplished only by immunotherapy and by chemotherapy. Since the number of 
these cells is then comparatively large, the former treatment is most unlikely to be 
successful and thus chemotherapy takes precedence26-27.
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1.1.6.5.4 Chemotherapy {of hormone-independent prosta te  cancer)
Chemotherapy refers to the use of cytotoxic drugs that inhibit or kill off rapidly 
dividing cells such as prostatic cancer cells. Since 1975, a number of chemotherapeutic 









Figure 4. A series of antimetabolites; procarbazine, hydroxyurea, 5-fuorouracil & methotrexate
Early examples, such as procarbazine (5), hydroxyurea (6) and methotrexate (8) (see 
Figure 4), failed to produce a significant response and were shown to be largely 
ineffective against relapsed prostate cancer, although, as a single-agent treatment, the 
antimetabolite, 5-fluorouracil (7) (Figure 4) appeared to offer some benefit25. Most 
antimetabolites such as those shown above have a similar mode of action, where they 
prevent the biosynthesis of cellular metabolites by acting as enzyme inhibitors28*29.
In contrast to these antimetabolites came the discovery of alkylating agents, such as 
melphalan (9) and cyclophosphamide (10). These types of alkylating agents, also 
known as nitrogen mustards30, are highly reactive N,N-bis(2-chloroethyl)amines and 
form covalent links with biomolecules containing SH, NH2 and OH nucleophiles, such
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as nucleic acids and proteins28. These types of interactions can be responsible for 
causing various types of DNA damage, such as the alkylation of a single base leading to 
loss of DNA functionality. Also, the alkylation of two bases that are cross linked 
together, can lead to faulty DNA transcription and, further more, it can lead to single 
or double strand breaks in highly alkylated and cross linked regions29. As single agents, 
nitrogen mustards have proved to be reasonably effective, though at higher doses in 
combination with the oestrogen estramustine, they have shown to be more effective. 
However, they almost always produce significant systemic toxicity leading to severe 
side-effects25.
Melphalan (9) Cyclophosphamide (10)
Figure 5. A series of nitrogen mustard alkylating agents; melphalan & cyclophosphamide
1.1.6.5.4.1 Anthracyclines & their derivatives
Antitumour cytotoxic agents such as anthracycline antibiotics are becoming of 
increasing intersest in the aid of tackling hormone-refractory prostate cancer31. 
Doxorubicin {Adriamycin (13))32 and other anthracyclines are amongst the most effective 
cytotoxic agents used in cancer chemotherapy. In particular, doxorubicin, 
daunorubicin (14) and epirubicin (12) (Figure 6) are amongst the more effective 
cytotoxic agents in advanced hormone-independent prostate cancer (Table 4)24.
1 At the cell membrane
2 DNA intercalation
3 DNA-protein link breakage
4 Topoisomerase inhibition
Table 3. Actions of anthracyclines
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At least one main reason suggested for the efficacy of anthracyclines, is the large 
number of mechanisms (Table 3) by which they can induce potentially lethal damage 
to dividing malignant cells25. As a single agent, doxorubicin is the most commonly and 
widely used anthracycline antibiotic in clinical therapy34. It has been reported to 
induce a 33% response rate against the disease when administered weekly, and has 
been incorporated in many active combination chemotherapy regimens32’33. Such 
combination regimens that have resulted in significant synergistic cytotoxic activity at 
subtoxic concentrations, are that of doxorubicin and a recent cytotoxic drug of 
interest, doxazosin (11) (a quinazoline compound that is a selective inhibitor of the 





Doxazosin (11) Epirubicin (12)
Figure 6. Structures of doxazosin & epirubicin
Anthracyclines are said to interfere with the topoisomerase II enzyme, which is 
fundamentally responsible for the regulation of DNA topology35. More so, these 
anthracyclines interrupt the functions of the enzyme by stabilizing a transient DNA- 
topoisomerase II complex, in which DNA strands are cut and covalently linked to 
tyrosine residues of the enzyme34-35. Furthermore, it is proposed that such 
anthracyclines have three distinct functional domains, which are responsible for their 
activity towards apoptosis (Figure 7)36. These have been defined from its ternary 
DNA—enzym e—drug complex, which consists of an amine-sugar moiety domain 
responsible for interactions with the phosphate backbone in nucleic acid, a planar ring 
system domain, which also is said to interact with DNA, and a substituted cyclohexane
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ring (A) domain, which is said to be responsible in interacting with the enzyme along 
with the OH functional group represented at position (C-9)36.
DNA-interacting domain 2 
(sugar moiety)
DNA-interacting domain 1 
(planar ring system)
Enzyme-interacting domain 
Figure 7. Putative Junctional domains of the anthracycline molecule
Although there are many types of chemotherapeutic drugs available for the treatment 
of hormonally resistant prostate cancer, treatments still remain palliative in patients, 
with the median survival duration being approximately 6 months37.
Compound R1 R2 R3 R4 R5 R6
13 Doxorubicin o c h 3 OH OH H n h 2 H
14 Daunorubicin o c h 3 H OH H n h 2 H
15 Idarubicin H H OH H n h 2 H
16 4-Demethoxy-3’-deamino-3’-
hydroxy-4’-epi-doxorubicin
H OH H OH OH H
17 3’-Deamino-4’-deoxy-4’-epi-
amino-idarubicin
H H H n h 2 H H
18 3’-Epi-daunorubicin o c h 3 H OH H H n h 2
19 3’-Deamino-3’-epi-hydroxy-4’-
deoxy-4’-amino-daunorubicin
o c h 3 H n h 2 H H OH
Table 4. Common anthracyclines & their potential cytotoxic derivatives (compare with Figure 7)
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The fundamental reason for this is that most patients with metastatic prostate cancer 
are elderly and with concurrent illnesses such as compromised bone marrow 
disfunctionality. Thus doses required to destroy and reduce significantly the effect of 
the disease are usually held to a minimum37. The effects of chemotherapy on tumour 
growth must therefore be balanced against the discomfort caused from normal tissue 
toxicity37. Therefore, with elderly patients unable to tolerate aggressive chemotherapy, 
such treatments can only be justified if there are significant improvements in the rate 
or quality of survival37. In this setting of the disease in which treatment is unlikely to 
affect survival, the primary aim for chemotherapeutic treatments have therefore 
become to mitigate the symptoms and improve the quality of life.
This has however, driven the need for symptomatic improvements, and the search for 
new cytotoxic chemotherapeutics with an improved therapeutic index, lower side 
effects and a higher activity against resistant cancer cells. This has stimulated ongoing 
research for new anthracycline analogues, such as halogenated versions of doxorubicin 
and daunorubicin34. Analogue development was originally limited by a lack of 
information on the cellular drug target. Nevertheless, with the mechanism of action of 
such cytotoxins such as doxorubicin and daunorubicin revealed and DNA 
topoisomerase II recognised as their main molecular target, many analogues have 
been synthesised and tested. Binaschi and Gapranico35-36 are amongst the leading 
developers in the research of analogues based on the most successful anthracyclines 
used in hormone-independent prostate cancer (Table 4 and Figure 7).
1.2 D ru g  ta rg e tin g
The concept of drug targeting is the ability to target pharmacologically active 
molecules to specific sites in the body. Upon administration of a drug, by either an oral 
route or by an intravenous injection, the drug substance will distribute throughout the 
body as a function of its molecular structural properties38. Furthermore, the final 
amount of drug actually reaching its target site may only be, and likely to be, only a 
small fraction of the dose originally administered and thus accumulation at non-target 
sites may lead to severe adverse reactions, leading to unwanted side-effects38. Though
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progress has been made in reducing the severity of cytotoxic-induced side-effects by 
methods of multiple administration schedules and dosage regimens based on 
pharmacokinetics principles39, the idea of applying the drug directly to its intended site 
of action seems to be of great advantage, as side effects would surely be reduced and it 
would open up many possibilities to the use of highly potent toxins39.
As mentioned in section (1.1.6.5.4), chemotherapy is an obvious example of the need 
for systemic drug targeting, where adverse reactions caused by cytotoxic agents are a 
major limiting factor38*39. The lack of antitumour specificity displayed by cytotoxic 
agents results from a low level of biochemical differentiation between normal cells and 
cancerous tumour cells, which together with the heterogeneous nature of tumour cell 
populations, limits the effectiveness and efficacy of current therapeutic approaches38. 
Systems that are currently available for achieving site-specific drug delivery range from 
the use of prodrugs (an inactive, metabolisable drug precursor) to the use of carriers 
such as macromolecules. Both systems will be discussed in more detail later in this 
section.
1.2.1 Target site specificity
There are three orders of classification towards the degree of specificity achieved by 
drug targeting, which accordingly relate to the level of selectivity of the delivery 
system40. The possibility of attaining each level of targeting can apply to various 
systems, though no single system exists that provides all three38.
• First-order delivery: This order of delivery is also known as ‘organ targeting,’ by 
which the aim of delivery is to target individual organs or tissues.
• Second-order delivery: This order of delivery refers to ‘cellular targeting,’ where the 
idea is to target a specific cell type(s) within a tissue.
\
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• Third-order delivery: This order of targeting involves the delivery to selected 
intracellular compartments within target cells, thus is referred to as ‘subcellular 
targeting.’
In cancer chemotherapy, the importance of having such orders of targeting can play a 
significant role when designing a specific delivery system and failures to meet these 
may explain the lack of success in other areas of cancer chemotherapy40. Thus, 
ultimately, the need for a targeting system that has the capability of accommodating 
an array of drug types and that can deliver its toxic agents to a range of tumour cell 
subpopulations will obviously have a significant general application. Furthermore, in 
view of the fact that it is known that cytotoxic drugs work at a variety of subcellular 
sites, a degree of third-order targeting maybe useful (see section 1.2.2.2.3 on the 
concept of GDEPT) to ensure maximum therapeutic efficiency if the survival of drug 
resistant cells remains a major cause of treatment failure38.
1.2.2 Modes o f drug targeting
Site-specific drug delivery systems can be classified according to their mechanisms of 
achieving target site localisation. Such methods are that of passive and active 
targeting38*40.
1.2.2.1 Passive targeting
Passive targeting is a function of the natural distribution pattern of the carrier in vivo. 
Factors affecting the biodistribution of such drug carrier systems can be determined 
largely on their physicochemical properties such as particle size and shape, and surface 
characteristics like hydrophobicity/hydrophilicity and particle surface charge38. It is, 
however, these properties that have been exploited41 in the attempt to improve 
targeting efficiency. Such examples are passive lung targeting42, where entrapment of 
large particles (>7 pm) in the capillary bed of the lungs has been exploited in 
radiodiagnostic imaging as well as for pulmonary delivery of anticancer agents. 
Another example is that of passive intra-arterial targeting38*43, where the injection of 
large particles results in mechanical entrapment by the first capillary bed. This
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entrapment effect could however be very useful upon the administration of cytotoxic 
agents into the arteries supplying a cancerous tumour site. This would probably result 
in drug accumulation at the tumour site before RES (reticuloendothelial system, 
known also as the mononuclear phagocytic system) clearance could take effect38.
The RES is a collective name for a group of highly phagocytic mononuclear cells 
derived from the bone marrow. These cells can be found throughout the body, either 
at fixed sites (like in the liver and spleen) or free in circulation42. Thus RES-mediated 
clearance can be a major factor in determining the biodistribution of colloidal systems. 
Based on the aforementioned, the RES can however be exploited in the distribution of 
drug targeting delivery systems, or clearance of tumour cell residues. Therefore, the 
RES presents itself for passive targeting as well44.
1.2.2.2 Active targeting
The term active targeting refers to a deliberate modification of a natural disposition 
pattern of a carrier in the aim to direct it to specific organs, tissues or cells38. A pot­
ential strategy in overcoming the limitations of chemotherapeutic agents where such 
modifications have been addressed is the introduction of the prodrug design (Figure 5).
1.2.2.2.1 The prodrug concept (the trigger-linker-ejfector concept)
The term prodrug maybe defined as a chemical which is non-toxic and pharmaco- 
dynamically inert but which can be transformed in vivo to a pharmacologically active 
drug45. Prodrugs have a variety of uses in cancer chemotherapy, as shown in (Table 5).




5 Optimal route of administration
6 Increased stability
Table 5. Uses of prodrugs in cancer chemotherapy
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There are two types of prodrugs to consider, the small-molecule prodrugs and the 
macromolecule (large) prodrugs. The latter will be discussed in more detail in section 
1 .2 .2 .2 .4 . However, both types of prodrugs follow the same concept and are 
considered to be comprised of two major domains46: a trigger unit, which acts as the 
substrate for an activating enzyme or system, and an e ffec to r  unit (active drug -  
cytotoxin) which is usually activated or released by a metabolic process46 and is 
sometimes joined by a definable linker group (Scheme 2)47>48.
1. B ipartite prodrug
Enzyme activation
T rigger D rue T rigger
(Inactive)
2. Tripartite prodrug









D rue J ^  J l in k e r  J D rue
(Inactive) (Active)
Schem e 2. A representative schematic view of enzymatic bipartite & tripartite prodrugs for their use 
towards site-specific drug targeting
Prodrugs can also be classified into being either bipartite or tripartite in design and 
functionality (Scheme 2). With regard to a bipartite prodrug, this consists of a carrier 
or linker moiety attached directly to the drug moiety. The trigger/carrier moiety 
generally serves to target the drug to a particular site, while a specific bond linking the 
trigger to the drug is hydrolysed, releasing free active drug in the body46*48.
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In certain cases, however, this basic prodrug strategy can fail. It is possible that the 
inherent nature of the bipartite prodrug bond connecting the trigger to the drug 
maybe sometimes be too unstable. Alternatively, it may have the opposite effect and 
the bond maybe present itself as being quite stable. Such stability could arise from 
electronic or steric features of the drug and thus hinder hydrolysis of the trigger—drug 
bond by the desired enzyme48. The idea of a tripartite drug can often circumvent this 
problem with the addition of a linker group (sometimes expressed as a se lf- 
im m o la tiv e  m o lecu la r  c /ip )49-51.
o l o am *
PSA cleavage












Schem e 3. A schematic representation of the release of vinblastine from a tripartite prodrug conjugate 
upon activation of PSA. for the complete structure of vinblastine - see Appendix Figure 26)
By spacing the drug away from the trigger moiety, this can allow a more viable route 
for enzymatic activation, where hydrolysis takes place at the trigger—linker bond
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rather than at the trigger—drug bond as with the bipartite prodrug concept. However, 
it is rather important that the linker moiety is designed such that, following enzymatic 
activation, the remaining bond connecting the linker to the drug moiety spontaneously 






















Schem e 4. The concept of elastase mediated splitting of doxorubicin-cephalosporin prodrug
An example of a tripartite prodrug is shown in (Scheme 3, p30). PSA-cleavage 
between a serine amino-acid and glutamine residue (which occupies the PI site)52'53 on 
a sensitive peptide (trigger domain), releases a linker-drug moiety. Furthermore, upon 
release of the linker-drug moiety, an intramolecular cyclisation52 between the exposed 
serine and proline residue leads to the spontaneous release of the drug, vinblastine (23) 

























+ H j A ^
COo
(30)
S ch em e 5. A schematic representation of the release o f doxorubicin from a tripartite prodrug 
conjugate upon activation of the proteose, cathepsin B.
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An example of a bipartite prodrug is shown in (Scheme 4, p 31). The strategy of using 
cephalosporin-drug conjugates by means of selective drug targeting is a relatively new 
idea and was firstly introduced by Veinberg et al54. In this instance, the cephalosporin- 
trigger domain acts more like a linker group and is directly attached to doxorubicin. 
Upon enzymic cleavage of the lactam ring, causing ring opening, free doxorubicin is 
released spontaneously. In the final example shown in (Scheme 5), the CbzPheLys is 
the trigger domain, the aminobenzyloxycarbonyl group is the linker and the 
doxorubicin (13) is the drug. In the presence of cathepsin B, this tripartite prodrug 
undergoes rapid 1,6-elimination, releasing doxorubicin. It is suggested that in this 
model, the linker group undergoes a 1,6-elimination49 process upon activation by the 
enzyme (ti/ 2  ~ 8 min at 25 °C)55.
1.2.2.2.2 Antibody-drug conjugates targeting
Antibody-drug conjugate targeting involves a number of potent antitumour cytotoxins 
being attached to an antibody moiety with the aim for a more specific and selective 
targeting approach56. Monoclonal antibodies (often abbreviated to MoAbs) are 
glycoproteins of the immune system capable of distinguishing malignant cells from 
their normal counterparts57 and typically have nanomolar affinities for their target56-58. 
The most commonly used chemotherapeutics towards constructing MoAb-drug 
conjugates are the anthracyclines doxorubicin and daunorubicin56 and, although 
monoclonal antibodies are typically tolerant to the conjugation of such 
chemotherapeutics, the agents themselves often lose potency in their conjugated form.
pH-selective hydrolysis
MoAb
fS  —NAc -  y -  calicheamicin
DrugBifunctional linker
(31)
Figure 8. Cleavable bifiinctional linkerfor the conjugation of calicheamicin to monoclonal antibodies
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A good example of this comes from the antitumour antibiotic calicheamicin58. When 
conjugated to a tumour-targeting MoAb through an amide linkage, the conjugate is 
accumulated in the tumour site, but has no appreciable cytotoxicity. In contrast, when 
conjugated by using a pH-sensitive bifunctional linker that permits the release of 
calicheamicin intracellulary (see Figure 8), the conjugate shows potent antitumour 
activity58. However, although this type of MoAb conjugate has shown reasonable 
potency in certain acute leukemias, immunogenicity and MoAb-drug conjugate 
potency towards prostate cancer still remains a problem57*58.
1.2.2.2.2.1 Antibody-directed enzyme prodrug therapy (ADEPT)
ADEPT is one method that has been investigated in an attempt to overcome the 
limitations with the MoAb-drug approach. ADEPT or antibody-directed catalysis is a 
strategy that achieves the local activation of prodrugs by the use of enzyme 
immunoconjugates59"61. An enzyme-antibody conjugate (which is recognised by a 
specific extracellular antigen) is administered and allowed sufficient time to bind to the 
tumour cells and to be cleared from the circulation. Subsequently, a prodrug is then 
administered and, upon recognition of the enzyme on the enzyme-antibody conjugate, 
the prodrug is activated selectively at the tumour site and free drug is released 
extracellularly and allowed to pass into the tumour cells59*62. A schematic 
representation of ADEPT is shown in (Figure 9).
However, certain problems can be raised with regards to ADEPT. The scarcity of 
tumour-selective antigens is still a limitation in the applicability of this type of therapy. 
Also, adverse immune effects may cause unwanted results59. Furthermore, the lack of 
effectiveness of ADEPT in humans so far is disappointing despite the high efficacy in 
rodent models59*60.
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1.2.2.2.3 GDEPT & VDEPT
Gene-directed enzyme prodrug therapy (GDEPT) and virally-directed enzyme 
prodrug therapy (VDEPT) are approaches that have been primarily designed to 
circumvent the limitations of ADEPT. Gene therapy may be broadly defined as a 
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Figure 9. A general schematic view for ADEPT, VDEPT and GDEPT strategies
There are two main types of gene therapy, the first being that of toxin gene therapy, 
whereby genes are introduced directly in to malignant cells and the respective protein 
produced directs the killing of tumour cells59-63. The second is GDEPT or virally- 
directed enzyme prodrug therapy (VDEPT). This is where a DNA constuct containing 
an enzyme-encoding gene is delivered to tumour cells using nonviral (GDEPT) or viral 
(VDEPT) vectors59. The gene is then transcribed and the mRNA is translated to yield 
the functional enzyme. The enzyme that is subsequently expressed activates 
intracellularly a non-toxic prodrug into a toxic drug that causes cell death63, (see
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Figure 9). In GDEPT, nonviral vectors that contain gene-delivery agents, such as 
cationic lipids, peptides, or naked DNA, are used for gene targeting. In VDEPT, gene 
targeting is accomplished using viral vectors, with retroviruses and adenoviruses being 
the most often used viruses59. The process by which these vectors are taken up by the 
cells and expressed, is known as transduction and it is this process that has become the 
limiting factor in the effectiveness of both GDEPT and VDEPT59.
An example of a recent self-immolative prodrug of interest for its use in suicide gene 
therapy (GDEPT) is shown below in Scheme 649. This prodrug has been designed to 
undergo a 1,6-elimination upon activation with the enzyme, carboxpeptidase G2 
(CPG2), in the delivery of nitrogen mustards.







Schem e 6. A novel nitrogen mustard tripartite prodrug used in GDEPT
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1.2.2.2.4 Polymeric prodrugs
In cancer therapy as a whole, macromolecular prodrugs are of increasing interest. The 
macromolecular prodrugs are thought to be selectively retained in solid tumours by 
the enhanced permeability and retention (EPR) effect64-66 and are taken up into cells 
via pinocytosis, a process described in detail below. The most integral part to a 
polymeric prodrug that is responsible towards its retention in the site-specific area, is 
the macromolecular carrier (Figure 10). This is the major determinant unit responsible 
for its pharmacokinetic property and all polymeric prodrugs contain a carrier unit 
(Table 6, p38). The ideal carrier should be easily synthesised, accessible to chemical 
modification, water soluble, non-toxic, biodegradable and non-immunogenic67. 
However, at present, no carrier unit has been found to fulfil all these criteria64.



















Tumour cell specific 
Organ specific
Figure 10. Modelfor macromolecule-drug conjugates
Above in Figure 10, is a general outlined model for the design of macromolecule-drug 
conjugates68. Almost all polymeric prodrugs follow this concept in the aim to help 
solubility and aid retention efficacy in the required area. The model carrier consists of 
3 major units of which can all be fine tuned for maximum effect. These units are 
represented as the, pharmacon unit, solubiliser unit and homing device. These are all
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attached to the carrier (polymer unit) of which a number of naturally occurring and 
synthetic soluble macromolecular carriers are represented below in (Table 6)69.
Soluble m acrom olecular carriers
Protein carriers Antibodies Albumin Glycoproteins Lipoprotein Lectins Hormones
Polysaccharides Dextran Pullulan
DNA -
Synthetic polym ers Poly HPMA Polyethylene glycol Pyran copolymer Polyamino acids
Table 6. The classification of soluble macromolecular carriers
1 .2 .2 .2 .4 .1  E nhanced  P erm ea b ility  and R eten tio n  E ffect (EPR)
Within solid tumours, the vasculature is thought to be fundamentally different to that 
in normal tissue, as they lack any organised system of lymphatic drainage. It is this 
poor lymphatic drainage which allows lipophilic materials and macromolecules to 
accumulate selectively and be retained in the tumours41-70. Shown below in (Figure 11) 
is a representation of extravasation and fluid drainage in normal tissue.
Movement of 
lymphatic fluid
Blood flow a Interstitium
Extravasation
Pathway fo llo w ed  





Pathway followed by 
water and small solutes
Figure 11. A schematic representation of extravasation andfluid drainage in normal tissue
38
As shown above, materials leave the bloodstream in the capillary bed by methods of 
diffusion, entering the interstitial space. Fluid and small solutes drain back into the 
bloodstream via postcapillary venules, while macromolecules drain into the lymphatic 
system, which is more freely permeable. However, in tumours, due to the absence of a 
lymphatic drainage system, macromolecules are denied an efficient drainage route41, 
thus the EPR effect applies.
1.2.2.2.4.2 Pinocytosis
Pinocytosis is the ingestion of fluid into a cell and can also be known as fluid phase 
endocytosis. The initial event in pinocytosis is when the extracellular fluid is 
encapsulated and the cell membrane folds inwards to form a sheath that is then 
pinched off forming a vesicle (a pinosome) that is released into the cytoplasm. These 
vesicles then fuse with lysosomes (vesicles from the Golgi apparatus), forming 
secondary lysosomes and it is within these where degradation of macromolecules 
occurs, releasing small molecules into the cytoplasm66*71.
Though macromolecule prodrugs generally follow this slow uptake process of 
pinocytosis, the idea of avoiding it and taking greater advantage of the EPR effect can 
be overcome by the interaction of an extracellular enzyme, namely Prostate Specific 
Antigen (PSA) (section 1.3.1.2).
1.2.2.2.4.3 Clinically active polymeric prodrugs
As mentioned in (section 1.1.6.5.4.1) doxorubicin (13) is one of the most effective 
cytotoxic agents used in cancer chemotherapy. With it being an amphipathic 
molecule, containing a hydrophobic anthraquinone moiety and a hydrophilic amino 
sugar moiety, it presents itself as being freely soluble in both organic and aqueous 
environments and thus can quite easily penetrate the cell membrane. However, it is 
known that chronic administration of high doses of doxorubicin can lead to severe 
systemic adverse effects, thus the idea of using macromolecular—doxorubicin 
conjugates could present a way of delivering doxorubicin more specifically and 
selectively to prostatic cancer cells41.
39
Kopecek et al.n  have reported that a water soluble polymer, PK1 (polyacrylate, namely 
poly(HPMA) [HPMA= (±)-N-(2-hydroxypropyl)methacrylamide]) bearing doxorub­
icin, is showing activity in clinical trials. It is proposed the cytotoxic drug is released 
intracellularly by the cleavage of the tetrapeptide linkage (GlyPheLeuGly) between the 
poly acrylate polymer backbone and drug by lysosomal enzymes64’73’74, such as 
cathepsin B. However, this is limited by two important factors:
• The sole basis of tumour-selectivity of delivery is concentration of the prodrug by the 
EPR effect. Also, the (GlyPheLeuGly) sequence poses a problem because normal cells 
are also capable of cleaving this tetrapeptide sequence.
• The actual enzyme that is responsible in cleaving the (GlyPheLeuGly) sequence is a 
lysosomal enzyme, thus the whole mechanism is essentially intracellular.
This poses a problem for conventional macromolecular prodrugs, as they enter the 
cells via pinocytosis, which is a relatively slow process, thus, the release of the active 
drug becomes limited. An attractive way of overcoming the problem would be to find 
a polymeric prodrug system (see Figure 10, p37)68 from which the active drug could be 
released by the action of an endogenous enzyme that is catalytically active solely in the 
tumour and is located either on the outer surface of the cells or in the extracellular 
space. The tumour-selectivity of the drug delivery would then be binary involving:
• The EPR effect.
• Tumour-localisation of the enzyme.
Furthermore, the rate of site-selective drug release would be much greater. As 
mentioned previously, prostate specific antigen (PSA) satisfies these criteria for an 
endogenous activating enzyme (see section 1.3.1.2).
Other examples of clinically active polymeric prodrugs that have been developed are 
those that incorporate the drug, 5-fluorouracil (7)75'78, but in most cases, the
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antitumour activity has resulted from non-specific chemical hydrolysis between the 
active drug and the polymer backbone79. Another example of a polymeric prodrug 









Figure 12. A general structure of mitomycin C (MMC)-dextran conjugates
In this polymeric prodrug, mitomycin C (drug) is attached to the dextran 
(macromolecule carrier) via the aziridine nitrogen linkage. In this case, the linker 
group is derived from 6-aminohexanoic acid (the length of the chain is believed to 
directly effect the rate of conjugate cleavage in this case). Studies on the mitomycin 
C-dextran conjugate (37)41 of MW 70,000 Da, has shown in certain murine models 
(in vivo) to have high anti-tumour activity when compared to free mitomycin C. 
Furthermore, the activity of this prodrug is thought to be mediated by extracellular 
hydrolytic release of the drug80.
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1.3 T u m o u r  b io m a rk e rs  fo r  p ro s ta te  c a n c e r
In recent years, considerable effort has been made to identify enzyme or antigen 
markers for various types of cancers with the view towards developing specific 
diagnostic reagents81. The ideal tumour marker would exhibit, amoung other 
characteristics, organ site or cell-type specificity and would be released into circulation 
or other biological milieu which is easily obtained by individuals81. Serum acid 
phosphatase enzyme (refer to section 1.1.6.3) has been considered to be the standard 
diagnostic biomarker for adenocarcinoma of the prostate during the past years and has 
been used for the screening and staging of the disease as well as towards the 
monitoring of patients in response to therapy82. Unfortunately, as a biomarker serum 
acid phosphatase constitutes one major difficulty in its usage, that being its inability to 
report serum concentration of the woenzyme produced by prostatic tissue without 
interference from other isoenzymes generated by other organs within the body83. This 
as led to the use of prostate-specific proteins as biomarkers for prostatic disease.
1.3.1 Prostate-specific proteins
Amid several prostate-specific proteins, the expression of prostate-specific membrane 
antigen (PSMA) and prostate-specific antigen (PSA) are sensitive biomarker proteins 
for prostate cancer screening, diagnosis and progression84. Both are well characterised 
and remain highly active in the hormone refractory stage of the disease.
1.3.1.1 Prostate-specific membrane antigen (PSMA)
Prostate-specific membrane antigen was discovered as a membrane antigen reactive to 
a monoclonal antibody (mAb), namely 7E11-C584. PSMA is a putative class II 
transmembranoust(P43) glycoprotein of molecular weight (94 KDa) and is exclusively 
expressed in metastatic prostatic carcinoma85. PSMA in known to progressively cleave 
terminal y-linked glutamate residues from poly-y-glutamated folates by its 
carboxypeptidase activity, it is this process that is essential for y-glutamate transport 
into cells86. Based on this, an approach to target prostate cells that over express PSMA 
has led to the design of a prodrug bearing the active pore-forming synthetic peptide 
H3 toxin (Helix-3). H3 is a 25-amino acid peptide that is capable of penetrating into
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lipid bilayers by adopting a membrane pore-forming mode of action, which in turn 
can lead to a significant leakage of essential intracellular macromolecules or 
furthermore, can cause an electrolyte imbalance, resulting in cell death87. 
Unfortunately the H3-prodrug has only shown activity in vitro88 and, furthermore, 
PMSA is also expressed in normal brain and salivary gland tissue88 (thus PSMA is not 
completely prostate-specific). As a result, it is unclear whether or not it could be used 
for targeting therapy in vivo89.
1.3.1.2 Prostate-specific antigen (PSA)
Human prostate-specific antigen (PSA)90*95 is a glycoprotein that contains 93% amino 
acids and 7% carbohydrates. It is a monomer96 with 240 amino acid residues, four 
carbohydrate side chains and a M r of 33-34 kDa91*92. Subsequent studies have shown 
that one carbohydrate side chain exists at the N-side chain of amino acid 45 
(asparagine) while the other remaining three exist at the O-side chain of amino acids 
69 (serine), 70 (threonine) and 71 (serine) respectively. The N-terminal amino acid of 
the sequence is (woleucine) and the C-terminal residue is (proline)96. PSA is synthesised 
in malignant prostatic epithelial cells and secreted in large amounts (0.5-2.0 gL_1). It is 
also found at much lower levels in normal epithelial cells lining the acini and the ducts 
of the prostate gland96*97. PSA is a (chymo)trypsin-family serine protease and functions 
to cleave the high molecular weight proteins (semenogelins I and II) responsible for the 
seminal coagulum into smaller polypeptides leading to liquefaction of the coagulum. It 
can also be detected in the systemic serum of men with prostatic cancer, thus making it 
a diagnostic serological marker for the disease98. However, in systemic circulation, its 
catalytic activity is completely inhibited by complexation with inhibitory proteins, 
namely, ai-antichymotrypsin and a 2-macroglobulin">100.
t(P42) The functionality of class II membrane proteins are to serve as transport or binding proteins, or 
possess hydrolytic activity86. Contrary to this, it is known that a portion of PSMA exhibits modest 
homology with regards to the transferrin-receptor, however, common amino acids responsible for the 
internalisation sequence of the receptor are absent. This suggests that PSMA does not actually operate 
as a transport, but rather as a binding protein or pro tease85.
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Thus, it is proteolytically active exclusively in the prostate96, th e  ta rg e t tis su e  fo r  
a n ti-p ro sta te  cancer therapy, and is an ideal catalytically active enzyme for the 
release of drugs from polymeric prodrugs.
1.3.1.2.1 S u b stra te -sp ec ific ity  o f  PSA.
Based on the PSA cleavage maps for semenogelins I and II, small peptides have been 
synthesised containing amino acid sequences proximal to the PSA proteolytic sites101. 
Coombs et al.102 are amongst those who have studied the substrate specificity of PSA in 
great detail. Shown in (Figure 13) is the peptide sequence that is cleaved most 
efficiently by PSA.
Substrate
 NHCHC NHCHC NHCHC — NHCHC NHCHC -  -NHCHC NHCHC NHCHC NHCHC-----
SerLys Ser Ser Gly Ala Gly
C lea v a g e b e tw een  Pi and PPProtease
Figure 13. Peptide sequence most efficiently cleaved by PSA.
The consensus from this study is that the SS pair be situated at sites P3 and P4 
respectively, and the (F/Y)Y pair at sites Pi and P2 respectively with Y next to the 
cleavage site. However, the literature suggests that these sequences have also been 
cleaved efficiently by chymotrypsin102.
Based on the peptide sequence shown in (Figure 13), Denmeade et al.m  have 
optimised this substrate sequence for better PSA selectivity, such that it is unaffected 
by catalytically active enzymes in normal cells, (such as chymotrypsin). It has been 
shown that the substrate sequence of (HisSerSerLysLeuGln 1), where 1 is the cleavage 
point of the PSA, was identified to be the most selective for PSA cleavage and proved
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to be unaffected by chymotrysin, trypsin, elastase and six other pro teases (see Table 7). 
Denmeade et al.m  also showed that, in a head-to-head study, this sequence was only 
cleaved some 10-20 fold less efficiently than similar sequences with Y at Pi. It has also 
been identified that the length of the amino acid sequence required for PSA-activation 
has to be at least a te trapeptide, thus analogous to the sequence 
(HisSerSerLysLeuGlnJ), the tetrapeptide sequence (SerLysLeuGln j) also gave a high 
degree of selectivity for cleavage by PSA.




seq u en ce
P S A C hym o­
trypsin
E lastase T rypsin P lasm in H k l Hk2
K G IS S Q Y 5 1 0 4 2 9 0 3 0 6 8 6 5 8 N D N D U D
1 SRKSQQY 234 3630 2788 260 0.4 2.0 UD
GQKGQHY 49.6 4274 922 122 UD ND UD
EHSSKLQ 31.6 UD UD UD UD UD UD
QNKISYQ. 16.8 9.0 9.0 UD UD ND UD
ENKISYQ, 14.4 3.6 2.6 1.8 0.6 UD ND
ATKSKQH 16 38.8 UD UD UD UD ND
2 H SSK L Q , 6 2 .7 U D U D U D U D U D U D
SKLQ , 2 9 .6 U D U D U D U D U D N D
K L Q UD 10.6 0.4 UD ND UD ND
LQ. UD UD UD UD UD ND ND
Q. UD UD 0.7 UD UD ND ND
3 KGLSSQC 13.6 12.2 950 UD UD UD ND
LGGSQQL 6.0 314 94 UD UD ND ND
q n k g h y q . 1.8 0.2 0.6 UD UD UD ND
4 TEERQLH 1.2 48.8 1.0 UD 3.8 UD UD
GSFSIQH UD 3.6 0.4 0.4 0.2 ND ND
Table 7. A comparison of peptide substrates relative to their corresponding PSA activity respectively. 
(UD -  undetectable <0.1 pmol of substrate hydrolysis/min/100 pmol ofprotease; ND  -  not done; 
H kl -  human plasma kallikrein; Hk2 -  human glandular kallikrein; all substrates are at a 
concentration o f 0.2 mM in PSA assay buffer103
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1.3.1.2.2 PSA-activated prodrugs
In a small-molecule study, Denmeade and co-workers103 developed a bipartite 
prodrug system that contained the PSA-sensitive peptide sequence, HSSKLQ and 
the aromatic amine drug, 7-amino-4-methyl-coumarin (AMG). The coumarin was 
attached to the peptide linker via an amide bond to the C-terminal carboxyl group 
on the glutamine. Interestingly, PSA had shown to cleave the Gin—AMG bond 
from this construct HisSerSerLysLeuGln—AMC, releasing free coumarin from the 
peptide linker. Notably, this construct was not hydrolysed by a series of other 













Scheme 7. PSA-triggered release of doxorubicin from the prodrug HSSKLQL-dox.
With the success of the HisSerSerLysLeuGln—AMC construct towards PSA 
activity, further studies by Denmeade and coworkers103 showed a similar strategy 
but by incorporating an aliphatic amine drug (namely, doxorubicin) to the PSA- 
sensitive peptide linker. However, the consensus from these studies, showed that no 
cleavage by PSA had occured. What some studies had indicated though, was to 
achieve PSA cleavage, the construct HisSerSerLysLeuGlnLeu—doxorubicin was 
needed. Moreover, it was noticed that PSA-cleavage did occur, but rather than the 
free cytotoxin (doxorubicin) being expelled, Leu—doxorubicin (40) was released 
(Scheme 7). In conclusion to these studies, PSA is only capable of hydrolysing an 
amide bond directly adjacent to an aromatic ring moiety or aminoacyl group98*104.
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The specificity regarding the cytotoxic response of this prodrug had been 
recognised when 70 nM of the prodrug killed 50% of PSA-producing LNCaP cells, 
whereas no (in vitro) cytotoxic effect on PSA-non-producing TSU human prostate 
cancer cells was seen. Furthermore, based on these results, in vivo studies on the 












Sch em e 8. PSA-triggered release of Leu 12ADTfrom the prodrug HSSKLQjLeu 12ADT.
With the success of the HSSKLQL-doxorubicin prodrug (38) showing selective 
proteolytic activity towards PSA, other cytotoxic agents bearing this PSA-sensitive
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linker (HSSKLQL) are currently in development (Scheme 8). For example: 
Thapsigargin is a potent inhibitor of the Ca2+ dependent ATPase pump107. With this 
inhibition, the Ca2+ concentration rises and causes cell death108. Given the mechanism 
of action of thapsigargin, it is however, unlikely to be prostate specific (or cell-type 
specific for that matter) and cannot be administered systemically as a therapeutic agent 
without causing host toxicity. The aim of targeting thapsigargin selectively to prostatic 
cancer cells avoiding toxicity to normal cells, has led to the development of 
HisSerSerLysLeuGlnLeu-thapsigargin (Scheme 8). This prodrug (in vitro) was 
efficiently hydrolysed by PSA and selectively toxic to PSA-producing cancer cells109. 
Furthermore, it has been shown to cause complete growth inhibition (in vivo) of 
established PSA-producing prostate cancer xenograft tumours and, has been shown to 
have no effect on renal xenograft tumours (that do not produce PSA). Therefore, the 




2.1 A im  & o b jectiv es  o f  th e  resea rch
The overali aim of this research is to develop a novel polymeric prodrug that will 
release free doxorubicin selectively and specifically in prostate tumours via an 
innovative system.
The main objectives of the research are: 1. to develop, compare and evaluate two self- 
immolative molecular clips, which after release from the polymer by action of a 
protease, will expel free doxorubicin. 2. to synthesise and evaluate an advanced 
monomeric model comprising a peptide (which is cleavable by prostate specific antigen 
(PSA)) joined to doxorubicin by the molecular clip.
2.2 R e se a rc h  p lan
2.2.1 Design of a PSA-activated polymeric prodrug system
The general features of the design for the PSA-activated polymeric prodrug system are 







molecular clip D R U G
solubilising group
Figure 14. Proposed structure of a polymeric prodrug for prostate-specific drug release
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The first fundamental part of the polymeric prodrug will consist of a polymer 
backbone which will be a polyacrylate, similar to poly(HPMA) to that of PK1 
[HPMA = (±)-N-(2-hydroxypropyl)methacrylamide]72>74. One other reason for bas­
ing the design of the prodrug on the polyacrylate backbone similar to that of PK1, 
is that PK1 and the homopolymer (poly(HPMA)) have both been demonstrated to 
be non-immunogenic72. Also, as in PK1, many solubilising groups are going to 
occupy many of the sites on the polyacrylate backbone to aid aqueous solubility.
The next key figure in the polymeric prodrug model is that of the PSA-cleavable 
peptide linker. Based on further work carried out by Denmeade et al.103 on small- 
molecule prodrug studies, drugs containing amines will be conjugated to selected 
sites on the PSA-cleavable peptide linker. In the prodrug studies of Denmeade and 
co-workers103, 7-amino-4-methyl-coumarin (AMC) was shown to have been 
released from the peptide linker of amino add sequence, (HisSerSerLysLeuGln— 
AMC). However, in studies using the same peptide sequence, but with doxorubicin 
instead of (AMC), no sign of cleavage by PSA was shown. What some studies had 
shown though, was to achieve PSA cleavage, the construct of (HisSer 
SerLysLeuGlnLeu—doxorubicin) was needed. It was noticed that PSA cleavage 
did occur, but rather than the free drug (doxorubicin) being expelled, (Leu—  
doxorubicin) was released (refer to Chapter 1, sections 1.3.1.2.1 & 1.3.1.2.2).
These data strongly suggest and encourage the need for the innovative design and 
development of a “se lf-im m o la tive  m o lecu lar c l ip /3 which has peptide-like 
character to replace that of the Leucine (Leu). The molecular clip(s) as shown in 
(Figures 15 and 16) respectively, will lie between the peptide linker and the drug. It 
will be designed, so when the (clip—drug) moiety is released from the polymer by 
PSA-catalysed cleavage, the clip will undergo a 1,6-elimination process in becoming 
detached from the drug spontaneously, releasing free drug and no interfering 
pendant amino acid(s) or short peptide fragments. The drug for this study is, 
‘doxorubicin,’ but this innovative design could be applied to other drugs that 
contain amines (e.g. doxazosin, a very recent drug of interest in prostate cancer31).
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2.2.2 Design and evaluation of the self-immoladve molecular clip 1
Both clips must contain a secondary amide linkage between the peptide linker and 
the molecular clip. The peptide-like structure of the molecular clip will strongly 
encourage the binding to the PSA active site, allowing PSA to cleave as shown in 
(Figures 15 and 16), releasing the clip-drug moiety, followed by the rapid release of 
free drug, see (Scheme 9, p53). The same system and idea also applies to the novel 






Figure 15. Design of the tripartite prodrug, utilising molecular clip 1 and peptide sequences, 
HSSKLQ SSKLQand SKLQrespectively








Figure 16. A tripartite prodrug utilising molecular clip 2 and peptide sequences, HSSKLQ SSKLQ 
and SKLQrespectively
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With doxorubicin being extremely expensive and toxic to work with, it is very 
important to establish a model for the initial stages in the synthesis and evaluation of 
our primary targets. 2-(4-Nitrophenyl)ethylamine (NPEA) presents itself as an excellent 
alternative, as it will allow us to mimic the primary aliphatic amine nature to that of 
doxorubicin. Not only is it significantly less toxic and less expensive than doxorubicin, 
it easy to work with, and it also has a signature UV chromophore, serving as a 
spectroscopic window for its detection during synthesis, and more importantly, its 
release detection in future HPLC studies.
2.2.4 Synthesis and evaluation o f a m onomeric m odel for PSA-triggered 
release o f doxorubicin
Construct 45 (Scheme 9) is designed as the complete monomeric model for studies of 
PSA-triggered release of doxorubicin from a polymeric prodrug. The first part toward 
this advanced prodrug model is the polymeric backbone. This will be represented by a 
fluorescent marker, namely dansyl, which is linked via a spacer group, to the N- 
terminus of the PSA sensitive peptide sequence. As with the NPEA (drug), its 
fluorophore will act as a tag and thus will be easily detected from the peptide cleavage 
products after the clip-drug moiety is released from the linker, (e.g. dansyl- 
HN(CH2)5CO-HSSKLQ^ will be detectable via the dansyl, and the NPEA + peptide- 
NPEA will be detectable through the NPEA).
Constructs containing three peptide sequences (the linker group), HSSKLQ, SSKLQ 
and SKLQ, will be targeted. HSSKLQ was used by Denmeade et al.103 in their 
monomeric prodrug model, but an earlier study104 of PSA substrate specificity showed 
that the histidine (His) is probably unnecessary. It may be that the synthetic difficulties 
occasioned by the presence of the His in the sequence, outweigh its usefulness in 
promoting selectivity. Therefore, based on the aforementioned, peptides SSKLQ- 
CZ/P-NPEA and SKLQ-CZ/P-NPEA will be prepared. Since these only differ in their 
N-termini, the synthesis will be made more efficient by the synthesis of the late 
common intermediate, protectedKLQ-CZ/P-DRUG. A careful approach will be 
adopted in synthesising the peptide linkers, as side chain protections will have to be
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orthogonal to the respected N-termini of the exposed amino acid (this will be discussed 
further in Chapter 3). In the future, each of the advanced models will be evaluated for 
cleavage with PSA90. This could be achieved by incubating the advanced models with 
PSA and performing HPLC analysis to show the release of drug from the peptide 
linker and from clip-drug moiety respectively.
M olecu lar  c lip
n Peptide
(45)
peptide = HSSKLQ, SSKLQ, SKLQ
Me
Me












3.1  S y n th esis  o f  the P SA -cleavable p e p tid e  lin k er
3.1.1 Negative control sequence
The key intermediate for the synthesis of the initial clip-free target is SerSerLys- 
LeuGlnNHCH2CH2Ph-/>-N02 (47). This is also a critical intermediate for the synthesis 
of the negative control compound, SerSerLeuLysGlnNHCH2CH2Ph-/>-N02 (48). In 
this latter compound the L e u  and the L y s  amino acids are transposed in the 
sequence, so that it should not be reco g n ised  by PSA, thus the aim of comparing 
these two constructs was to investigate whether the former would be cleaved by PSA 
and the latter would not. (NB: the NHCEECE^Ph-jfr-NCh moiety can sometimes be 
expressed as NPEA and is often used throughout the text).
X = Fluorophore
Target intermediate (47): R = Lys, R1 = Leu 
(48): R = Leu, R1 = Lys
Figure 17. The structures of target intermediates (47) and (48)
In the preparation of larger peptide sequences, there are two synthetic approaches that 
can be used. A convergent synthesis were units of a few amino acids are condensed in
a final step, or a linear stepwise synthesis where each amino acid is added in turn to
the growing peptide. Though convergent syntheses of peptides are generally more 
attractive, with yields being much higher than that of a linear approach, the risk of
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racemisation in the final condensation step could present a major problem (Scheme 
I O ) " o . A  convergent synthetic approach is inappropriate in these syntheses.
loss of 
stereochemistry
R = alkoxy --------^ O x a z o l i d i n o n e  Oxazole
Schem e 10. Peptide racemisation via the formation of oxazolidinones
In developing these sequences (47) and (48), it was important to use an orthogonal 
protecting group strategy such that the main chain amines (alpha amines) in the 
growing main chain of the peptide are masked by protecting groups which can be 
removed efficiently while retaining the protection of amino acid side-chain functional 
groups, such as the e-amine side chain of Lys. Fully orthogonal protecting groups can 
be defined in that protecting group A can be removed under one set of conditions 
leaving protecting group B untouched. And another set of conditions will remove 
protecting group B selectively while group A remains unscathed. When A and B are 
semi-orthogonal protecting groups, group A can be removed in the presence of group 
B, but removal of B may adversely affect group A.
In the two target sequences (47) and (48) respectively, the requirements for the 
protecting groups were such that the integrity of the nitro-aryl group (NPEA) of the 
model drug, also needs to be maintained. Thus for example, hydrogenolytic removal 
of Cbz would be inappropriate as nitro groups are reduced rapidly under these 
conditions. The Cbz (benzyloxycarbonyl) and Boc (tert-butoxycarbonyl) moieties are 
two commonly used protecting groups for primary amines, and are fully orthogonal. 
Thus these were the two protecting groups for these syntheses.
The Cbz group, first reported by Bergman and Zervas111 in 1932, can be easily 
introduced to amino acids and other amino compounds using benzyl chloroformate
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under Schotten-Baumann conditions. The Cbz protecting group is stable to mild 
acidic and basic conditions and can be removed on treatment with catalytic 
hydrogenolysis or with hydrogen bromide (HBr) in glacial acetic acid. In contrast to 
the Cbz group, the Boc group (^-butoxycarbonyl) is unaffected by catalytic treatment 
with hydrogen and can be easily removed in the presence of acid, commonly HC1 and 
trifluoroacetic acid (TFA). The Boc group can be introduced with di-fer£-butyl 
dicarbonate (B0 C2O) 112 in generally fast and high yielding reactions, the byproducts 
being carbon dioxide and 2-methylpropene. Alternatively, 2-(ter^-butoxycarbony 1- 
oxyimino)-2-phenylacetonitrile (BOC-ON)113 can also be used, though it has been 
shown to be less reactive than B0 C2O.
Glutamine (49) was converted to the N“-Cbz derivative, CbzGlnOH (50) by treatment 
with benzyl chloroformate (under Schotten-Baumann conditions) in moderate yield 
(45%) (Scheme 12, p58). The side chain primary amide is not nucleophilic under these 
conditions. At this point the carboxylic acid needed to be activated as an electrophile, 
through conversion of the OH to a good leaving group.
The use of acid chlorides to achieve couplings of amino acids to peptides or other 
amino acids, is an attractive technique110 as reactions via this method proceed very 
rapidly. However, the conditions required to synthesise acid chlorides are harsh and it 
is well known that these are prone to racemisation. For example, as shown in Scheme 
11 (p57), an amino acid in the presence of a tertiary base can result in the formation of 
a ketene by removal of the a-proton. It is believed that going from an sp3 chiral centre 
to an sp2 centre under these conditions is more favourable. Furthermore, a nucleophile 
(e.g. another amino add) is able to attack the highly electrophilic carbonyl of the ketene 
from above or below the plane, thus in turn, can give rise to a mixture of epimers upon 
reformation of chirality.
Although acid fluorides can be used in peptide synthesis114, their synthesis can be 
difficult and yields are often modest, thus both the aforementioned and acid chlorides 
are inappropriate in these syntheses.
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B = tertiary base X  RgNHg
(e.g. triethylamine) B /
x  (nucleophile)
+ R1> j - t  NHR< 
H fl
Schem e 11. Racemisation ofpeptides via the use of acid chlorides
More common is to convert the carboxylic acid into an active ester. These active esters 
are derived from alcohols with low pKa values (i.e. the conjugate base, the alkoxide or 
aryloxide anions) and are stabilised either by a neighbouring electron withdrawing 
group or by delocalisation.
Two active esters of CbzGln were prepared for their comparison in their coupling with 
4-nitrophenylethylamine (NPEA) (67). Firstly the hydroxysuccinimide active ester 
(ONSu) was prepared by treatment of CbzGlnOH (50) with N-hydroxysuccinimide 
and dicyclohexylcarbodiimide (DGC) in ethyl acetate (EtOAc) under the usual 
conditions. DCG is a dehydrating agent, initially the proton is transferred from the 
carboxylic acid to the carbodiimide; this generates the nucleophilic carboxylate anion, 
which attacks the electrophilic carbodiimide carbon to generate an O-acyl iso-urea. 
This intermediate has electrophilic activity comparable with that of an acid anhydride, 
which it closely resembles in structure. The hydroxysuccinimide, which is relatively 
nucleophilic, then attacks the carbonyl of the intermediate expelling the iso-urea. The 
latter rapidly tautomerises to N,N’-dicyclohexylurea (DCU); thus the driving force for 
the formation of the active ONSu ester, is the formation of the low energy urea. This 
active ester was then treated with the 4-nitrophenylethylamine (NPEA) in the presence
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of triethylamine as a tertiary amine base which captures the acidic N ,N ’- 
hydroxysuccinimide formed. This coupling gave the required CbzGlnNHCH2CH 2Ph- 
j^ N 0 2 (53) in moderate yield (44%) (Scheme 12). In an attempt to improve the yield 



















Schem e 12. A schematic representation to the formation o f compound CbzGlnNPEA (53) via 
various active ester-coupling methods
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Esters of phenols carrying electron-withdrawing substituents are often used as active 
esters in peptide-coupling, for example, the /wra-nitrophenyl esters were used 
frequently in the earlier days of solution phase peptide synthesis110, as were 2,4,5- 
trichlorophenyl esters110.
However, fluorinated phenols are now used widely in this context. Pentafluorophenyl 
esters (PFP-esters) are amongst the most reactive of the active esters115, although 
2,3,5,6-tetrafluorophenyl esters (TFP-esters) have found favour more recently. 
Although PFP-esters are considerably cheaper than TFP-esters, it has been claimed 
that the TFP-esters are more useful as the phenol moiety carries a proton. This proton 
can be observed in standard NMR spectroscopy to confirm the formation and 
structure of the active ester. Since 19F NMR spectroscopy is readily available at the 
University of Bath, it was decided to use PFP-esters for couplings and monitor their 
formation by this means.
Given the limited solubility of CbzGlnOH (50) in EtOAc the alternative solvent 
mixture THF and DMF (9/1) was used for the coupling with pentafluorophenol in the 
presence of DCC.
The GbzGlnOPFP active ester reacted smoothly with NPEA in a 50/50 THF/DMF 
mixture to give the 4-nitrophenylethylamide (53) in a satisfactory 44% yield. This was 
the optimum solvent system for this coupling, a range of other single solvents and 
mixtures have been investigated. The need for a relatively polar solvent mixture 
reflects the polarity and insolubility of constructs containing glutamine (Gin) and a 
portent of solubility difficulties to come. This amide (53) was the first novel compound 
synthesised in this project and was fully characterised by *H NMR spectroscopy, 13C 
spectroscopy, IR-spectroscopy, micro-analysis, mass spectrometry and polarimetry.
In the *H NMR spectrum the diastereotopic p-protons resonated as discrete multiplets 
centred at 6 1.66 ppm and 6 1.78 ppm. The y-protons although also diastereotopic, 
are more remote from the chiral centre and resonate as overlapping multiplets around
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6 2.00 ppm. The chirality of the molecule is also reflected in the signals for the other 
CH2CH2 system adjacent to the 4-nitrophenyl group. The inequivalence of the CH2 
protons adjacent to the amide nitrogen is evident as they resonate as a complex 
multiplet at 6 3.28-3.40 ppm, where as the signal for the more remote CH2 attached to 
the benzene ring is a straightforward triplet. Moreover, the methylene protons of the 
Cbz group are magnetically inequivalent in this compound and resonate as a pair of 
doublets at 6 5.00 ppm and 6 5.03 ppm. The coupling constant, 2J  (coupling through 2 
bonds) equals 12.5 Hz, which is typical for geminal coupling116. Also magnetically 
inequivalent, but for a different reason, were the 2 protons of the side chain primary 
amide, the C-N bond in amides has partial double bond character since the nitrogen is 
sp2 hybridised and its p-orbital, containing the lone pair, overlaps sideways with the 
carbonyl Ji-orbital. Thus one of the NH protons is held cis to the carbonyl oxygen and 
the other is held trans, placing them in different environments on the NMR time scale.
The signal for one of these protons appeared at 6 6.76 ppm and the other at 6 7.24 
ppm. The other two NH protons in the molecule were also readily assigned though 
their multiplicity, the a-NH resonating as a doublet at 6 7.39 ppm and the NHCH2 
proton appearing as a triplet at 6 7.99 ppm. As expected the aromatic protons ortho to 
the powerfully electron-withdrawing nitro group, resonated nearly 1 ppm downfield 
from the usual chemical shift of benzene (6 8.12 ppm vs. 6 7.27 ppm). In the solid 
phase IR-spectrum, bands for the primary and secondary amides were observed. For 
example, the band at Vmax 1690 corresponds to the amide I band of the secondary 
amide whereas the broad band centred at vmax 1648 represents the overlapping amide 
I and amide II bands of the primary amide. The nitro group gave its characteristic 
symmetric and anti-symmetric stretch bands at Vmax 1518 and 1344 cm-1.
The removal of the Cbz protecting group was achieved almost quantitatively with HBr 
in glacial acetic acid to give GlnNHCH2CH2Ph-/>-N02.HBr salt (54) (Scheme 13, 
p61). Characterisation of this novel compound was achieved by !H NMR 
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Schem e 13. The synthetic route to theformation of tripeptide BocLeuLys(Cbz) GlnNPEA (57)
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The assignment of the !H NMR spectrum of (54) was aided by a 2D COSY 
(correlation spectroscopy) experiment. Notably the a-proton resonated at 6 3.72 ppm, 
which is significantly up-field from the corresponding signal for the Gbz precursor and 
reflects the removal of the electron withdrawing carbonyl from the nitrogen.
The reaction of this amine salt with commercially available Na-(Boc)-Ne-(Gbz)Lys N- 
hydroxysuccinimide ester in the presence of triethylamine afforded the dipeptide 
derivative BocLys(Cbz)GlnNPEA (55) in satisfactory 47% yield. In this case 4- 
dimethylaminopyridine (DMAP) was added as a nucleophilic catalyst110.
With the orthogonality of the Cbz and Boc protecting groups proving its usefulness, 
treatment of the di-protected peptide derivative (55) with hydrogen chloride in MeOH 
removed only the Boc group to give a quantitative yield of the N“-unmasked peptide 
derivative (56). The Gbz was not removed owing to the lesser nucleophilicity of 
chloride over bromide. The protecting group strategy from this point thus involved 
Cbz as the side chain protection and Boc as the main chain. This dipeptide was then 
coupled in modest yield (37%) with commercial BocLeuONSu to give the tripeptide 
derivative BocLeuLys(Cbz)GlnNPEA (57). Again, the rather complex JH NMR 
spectrum was assigned with the aid of a 2D COSY spectrum. A notable feature was 
the multiplet (actually overlaying doublets) at 6 0.77-0.90 ppm, which relate to the Leu 
methyl groups. This shows that these methyls are also diastereotopic in nature and 
thus magnetically inequivalent (resonate at different frequencies).
Unfortunately, this tripeptide proved to be too insoluble in compatible organic solvents 
for elaboration and further progress towards the target tetra- and penta-peptide 
derivatives. Further synthesis was not possible.
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3.1.2 Positive control sequence
In the approach towards the putative positive control sequence SerSerLysLeuGln- 
NHCH2CH2Ph-/>-N02 (47) the GlnNHCH2CH2Ph-/>-N02 (54) was coupled with 
BocLeuONSu to provide BocLeuGlnNHCH2CH2Ph-/>-N02 (60) in satisfactory yield 
(Scheme 15, p64). In this sequence the removal of the Boc protecting group was with 
the strong organic acid TFA rather than the hydrogen chloride that had been used 
earlier. At this point, the observation of solubility problems from the previous sequence 







S ch em e 14. The synthesis of FmocGlu(OBit)NPEA as a test for the stability o f the Fmoc 
protecting group in the presence of base
As a model reaction to establish the stability of Fmoc-protected amino acids in peptide 
coupling, FmocGh^OBu^OPFP active ester was treated with a primary amine (NPEA) 
under basic conditions (which in turn, may have affected the base labile Fmoc group). 
However, FmocGlufOBu^NPEA (59) was given in excellent yield (65%) without 
disruption of the protecting groups (Scheme 14).
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Schem e 15. The synthesis of tripeptide Lys(Boc)LeuGlnNPEA
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Backed by the confidence of this successful model, the dipeptide derivative salt 
LeuGlnNHCH2CH2Fh-/>-N02.TFA salt (61) was coupled with FmocLys(Boc)ONSu to 
afford the required tripeptide derivative FmocLys(Boc)LeuGlnNHCH2CH2Ph-/?-N02 
(62) in a modest yield (41%) (Scheme 15, p64). The Fmoc and Boc protecting groups 
are fully orthogonal to one another, Boc being removed with acid and Fmoc, primary 
and secondary amines. Treatment of the tripeptide derivative (62) with piperidine53 
failed to affect the required cleavage of Fmoc. A convenient modification to this 
process was the replacement of piperidine with diethylamine, which removed the 
Fmoc efficiently allowing precipitation of the free amine of Lys(Boc)LeuGln 
NHCH2CH2Ph-/>-N02 (63) (85%) from the reaction mixture (Scheme 15). Regrettably 
this tripeptide was too insoluble for further couplings.
3.2 Synthesis o f  the am inobenzyloxycarbonyl clip
Where as the previous control model compounds omitted the self-immolative 
molecular clip, the attention was now turned to the synthesis of peptide derivatives 
where the PSA-sensitive peptide sequence was linked to the model drug (NPEA) 
through an aminobenzyloxycarbonyl linker49*117 (self-immolative molecular clip) 
(Scheme 16).
The idea of having a self-immolative clip linking the drug to the peptide has become 
apparent in our aims and objectives (see section 2.2, p49). It has been stressed that 
having an aromatic ring directly adjacent to the PSA-sensitive amide bond shown in 
the monomeric model (64) (Scheme 16), is essential for the cleavage of PSA. 
Moreover, Denmeade et a/.103 have shown this in their small molecule prodrug studies, 
where the release of 7-amino-4-methyl-coumarin (AMC) directly from the peptide 
constructs HisSerSerLysLeuGln, SerSerLysLeuGln and SerLysLeuGln occurred by 
action of the serine protease.
During cleavage of the sensitive amide bond (shown in Scheme 16) by the action of the 
enzyme, the primary aromatic nitrogen on the self-immolative molecular clip is 
exposed. This amine has a higher electron density at the nitrogen compared with its
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corresponding amide. The newly available electron pair on the exposed nitrogen can 
feed into the electron rich 7C-system of the adjacent aromatic ring and can cause 1,6- 
elimination of the carbamate (66) (very good leaving group) at the reactive para- 
benzylic position. Notably, if the amine were ortho to the carbamate functionality, a 
similar elimination would occur, but with the ortho being synthetically less favourable, 
the para was the obvious choice. The 1,6-elimination process could not be triggered if 
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Schem e 16. The mechanism of the PSA-triggered release of the model drug (NPEA)
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Naylor et a/.118 have shown the rates of a variety of leaving groups from a series of 
indolequinones for the use of bioreductively-activated prodrugs under both chemical 
and radiolytic conditions. The rate of release in the elimination step from a range of 
function groups, consisting of, carboxylate, phenol and thiol groups, where related to 
their leaving group ability. Furthermore, it is important to note that elimination would 
not occur if the aliphatic amine on the model drug were directly attached to the benzyl 
CH 2 on the anilide moiety, this is due to the amine being a poor leaving group118.
A critical intermediate in this part of the project was BocGln-linker-NPEA (68). In 
this target, the use of Boc protection for the Gin is critical as the Cbz used in earlier 
studies would have been too similar to the amidobenzyloxycarbonyl linker unit 
(Scheme 17): no conditions could be envisaged for selective removal of Cbz in the 





(68)t Route not viable
0*S^NH2
♦ X X - .
Similar to Cbz 
functionality
X = leaving group
(e.g. active ester/mixed anhydride)
(69) (66)
Schem e 17. A non-viable route to the amidobenzyloxycarbonyl linker unit
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RetrosyntheticaUy, two bonds are available in this structure for disconnection: the 
amide bond between the Gin and the linker and the carbonyl to oxygen bond of the 
carbamate joining the model drug to the linker (see Scheme 17). Of these, the former 
would be more convergent in the long term but would require the synthesis of the very 
primary amine («6), which would be released by PSA-cleavage and would self- 
immolate. Therefore, the BocGln has to be joined to the linker (se lf-im m o la tive  
m olecular clip) before the linker is joined to the model drug (NPEA).
3.2.1 Synthesis o f  the target isocyanate intermediate (75)
In the first series of experiments on this, our primary aim was to synthesise the target 
intermediate, isocyanate (75). There are two distinct strategies available for the 
synthesis of isocyanates. Because isocyanates are highly electrophilic and sensitive to 
the presence of nucleophiles, they need to be generated under appropriate conditions. 
One strategy involves treating primary amines with electrophilic carbonyls carrying 
two leaving groups, thus the reaction of primary amines in phosgene has been used to 
make isocyanates, but this reagent is highly toxic and volatile and has been replaced 
with safer reagents such as N,N-carbonyldiimidazole (GDI), di-phosgene and tri­
phosgene.
Alternatively, rearrangement reactions of acyl nitrenes or their equivalents can be 
used. For example, the Hoffman rearrangement in which a primary amide is treated 
with bromine and NaOH to give a primary amine with one less carbon, this proceeds 
via an isocyanate119. The Lossen rearrangement of hydroxamic acids under strongly 
acidic conditions is similar. In contrast, the Schmidt and Curtius rearrangements are 
driven by loss of molecular nitrogen, an excellent leaving group, from acyl azides. In 
the former, the acyl azide is generated in situ from the carboxylic acid and sodium 
azide in the presence of concentrated H 2SO4 . In the latter however, the acyl azide is 
synthesised under mild conditions, either by treatment of an acid chloride with sodium 
azide or with trimethylsilyl azide120, or by nitrosation121 of a hydrazide.
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The initial objective was to convert phenylpropanoic acid (71) to its corresponding 4- 
nitro analogue (72). The first attempted nitration122 employed concentrated H 2SO4 
and H N O 3 at room temperature for 48 h (Scheme 18). Unfortunately, the sole 
isolatable product from this reaction was the di-nitro compound (70), which was 
clearly identified by !H NMR by a typical 1,2,4-tri-substituted benzene pattern that 







F igure 18. Proton couplingsfor 3-(2,4-dimtrophenyl)propanoic acid (70)
Based on the strategy adopted by Strazzolini et al.123 in which more mild conditions 
were used (reaction time 2h at 0°G), the para-nitro analogue (72) was furnished in 
modest yield (34%). The next step was to convert (72) in to its respective target 


















S ch em e 18. Synthesis to the formation o f isocyanate (75)
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3-(4-Nitrophenyl)propanoic acid (72) reacted with thionyl chloride in the presence of 
catalytic DMF to afford the required acid chloride (73), which upon treatment of 
sodium azide in acetone for 2 h at RT, yielded the isocyanate precursor (74). 
Confirmation by infra-red spectroscopy clearly showed the expected N3 peak at Vmax 
2139 with its adjacent carbonyl peak, appearing at Vmax 1700. Notably, the carbonyl of 
the acid azide is further up-field from that of the carbonyl on the acid chloride (73), 
this is due to the available lone pair of electrons on the nitrogen of the azide shielding 
the carbonyl. Finally, the target isocyanate (75) was achieved by thermolysis of the add 
azide (74) in toluene for approximately 2 h. Further characterisation by infra-red 
spectroscopy, indicated the appearance of a peak at Vmax 2272 which is typical for 
N =C =0 stretching.
3.2.2 Synthesis o f  the target primary alcohol intermediate (83)
In the second series of experiments, the primary alcohol of the 4-aminobenzylalcohol 
linker was to be masked either by protection as a silyl-ether or at a higher oxidation 
level as the corresponding carboxylic acid and methyl ester. Taking the latter 
approach first, attempts were made to couple active esters of BocGln with methyl-4- 
aminobenzoate (81), however the hydroxysuccinimide and pentafluoro- phenyl esters 
both proved insufficiently electrophilic for a successful reaction with this weakly 
nudeophilic aniline which carries an electron withdrawing group para to the amine (see 
Scheme 19, p71).
Senokuchi et al,124 have reported the use of mixed aminoacyl-pivaloyl anhydrides for 
difficult couplings of anilines. Following this approach, BocGln was treated with 
triethylamine and pivaloyl chloride in a THF/DMF mixture at low temp. Attack of 
the Gin carboxylate on the add chloride gave the required mixed anhydride (79), 
which was coupled in situ with methyl-4-aminobenzoate (81). The regioselective 
reaction of the nucleophile with the aminoacyl carbonyl is driven by steric factors (the 
bulk of the tertAmtyX unit of the pivaloyl) and by electronic factors (the electronegative 


















Schem e 19. Routes to the synthesis of GlnNHPhC02Me (80)
From here it was intended to carry out the selective reduction of the ester to the 
corresponding benzyl alcohol with LiBFU (Scheme 19, p72). This reagent is selective 
for reduction of esters in the presence of amides110. However, it is incapable with 
hydroxylic solvents, and a suitable non-hydroxy lie solvent could not be found which 
would dissolve (80), including, 1,2-dimethoxyethane and hot diglyme. The ester also 
could not be hydrolysed to the corresponding carboxylic acid under a variety of
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conditions, due to poor solubility. Selective reduction of the carboxylic acid (82) with 
















Schem e 20. Routes to the synthesis of BocGlnCLIPNPEA (84)
In an attempt to alleviate these problems of poor solubility, the use of a more lipophilic 
protecting group for the N“ of the Gin was investigated. Since insolubility was driven 
by the side chain primary amide, this was replaced by the corresponding tert-butyl ester
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(85), which could later be converted to the amide. FmocGlu(0-fe7t-butyl)OH was 
converted to its pivaloyl mixed anhydride which reacted in situ with methyl-4- 
aminobenzoate to give the required 4-methoxycarbonylanilide (87) (Scheme 21). 
Although this compound contained two esters, it was anticipated that the methyl-ester 
could be selectively reduced by LiBH4 as the fer£-butyl ester is considerably more bulky. 
This predicted selectivity could not be put to the test, as compound (87) was again too 
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Schem e 21. The attempted synthesis of FmocGluKHPhCH20H (88)
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Another strategy would be to build part, or all of the peptide before reduction of the 
methyl ester to the benzyl alcohol of the linker. To this end, an attempt was made to 
remove the Na Boc protection from compound (80), however, treatment of (80) with 
TFA under very mild conditions followed by evaporation of the reagents, gave a 
material which was clearly not the deprotected Gin derivative (Scheme 22). JH NMR 
analysis of the product mixture suggested that the deprotected Gin had cyclised under 
the reaction conditions to give Pyg-4-methoxycarboanilide (90) (Scheme 22). Also 
evident in the NMR spectrum was a 1-1-1 triplet at 6 7.28 ppm integrating for 4 
protons and with the very large coupling constant of J  = 51.5 Hz. The 1-1-1 ratio of 
peak heights of this triplet which is different to the normal 1-2-1 ratio observed when a 
proton is observed to couple to 2 other protons, indicates coupling to a spin I = 1 
nucleus (2 halves). 14N has this spin value, although couplings to 14N are usually not 
observed owing to rapid proton exchange and the quadrupolar nature of this nucleus, 
however, proton exchange is suppressed for salts in DMSO solution. Moreover, the 
high symmetry of the ammonium cation allows 14N-1H coupling to be observed despite 
the quadrupolar nature of the nitrogen, thus this signal is assigned to ammonium 








Schem e 22. The attempted deprotection of BocGlnNHPhC02Me (80) with TFA.
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In view of the lack of success regarding the strategy incorporating the benzyl alcohol as 
the methyl ester for later reduction, a series of experiments were conducted to study 
the possibility of attaching 4-aminobenzyl alcohol to glutamine derivatives, either with 
the primary alcohol protected or unprotected.
Firstly, 4-aminobenzyl alcohol (30) had to synthesised by reduction of 4-nitrobenzyl 
alcohol in ethanol, in the presence of palladium on activated carbon under hydrogen. 
Interestingly, during the purification of 4-aminobenzyl alcohol, a minor fraction was 
isolated and identified to be /><zra-toluidine (102). This had showed that under these 
conditions above, a small amount of the amino-product (30) had further reduced to its 
arylmethyl derivative (102) (Scheme 27, p80). Alternatively, other methods can be 
used for the reduction of nitro groups, for example, the addition of NaBH4  in aqueous 
MeOH in the presence of palladium. This method has been claimed to be selective for 
reduction of nitro groups in the presence of all other functionalities, although this 
selectivity has recently been called into doubt126. 4-Aminobenzyl alcohol is 
commercially available but the quality of sample obtained from several sources was 
poor.
Studies on the coupling of BocGln to 4-aminobenzyl alcohol through a range of active 
esters (ONSu/ONP/OPFP) (Scheme 23, p76) failed to give usable yields of the target 
amide (83). Although the pivaloyl mixed anhydride approach had been effective for 
the coupling of other anilines, it failed completely in this case. Similarly, the use of 
wobutyl chloroformate in the aim to alleviate steric compression of the mixed 
anhydride, failed also to be effective in this case. Furthermore, the direct coupling with 
the use of carbodiimide reagents (DCC/EDC115) failed to attach the arylamine to the 
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All of the glutamine derivatives shown above were reacted 
with 4-aminobenzyl alcohol ± DMAP (unless otherwise stated)
S ch em e 23. Attempted syntheses towards the formation ofBocGln-anilide (83)
Moreover, in the case of the ED C/H O Bt method, a major product was isolated upon 
purification and characterised by *H NMR and mass spectrometry as the cyclised 
glutamine analogue, 2,6-piperidinedione (96)127 (Scheme 24, p77). Thus, direct 
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S ch em e 24. The attempted synthesis of BocGln-anilide (83) leading to the formation of 2,6- 
piperidinedione (96)
Finally, Dubowchik et al.m  have shown in their peptide coupling strategies, that 4- 
aminobenzyl alcohol can be conjugated to small peptides in the presence of EED Q  in 
high yields. To confirm the use of E ED Q  in peptide coupling, a model run was 
attempted by reacting FmocLeuOH (97) with EEDQ, followed by the addition of 4- 
aminobenzyl alcohol at RT. This reaction worked smoothly and yielded the anilide 





Schem e 25. Synthesis of compound anilide (99)
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Based on the success of this model reaction, many attempts of coupling 4-aminobenzyl 
alcohol to BocGlnOH (76) with the newer peptide-coupling reagent EEDQwere 
unsuccessful. Furthermore, studies on the coupling of the more freely soluble 
FmocGlu(O-fer^-butyl) (85) to 4-aminobenzyl alcohol via the EEDQand isobutyl mixed 
anhydrides129, all failed also to give the required anilide (83) (compare with Scheme 
23). The !H NMR spectra of some of the crude product mixtures suggested the 
presence of only a trace of the desired anilide (83), although its presence could not be 
confirmed by mass spectrometry.
With regard to the active esters of BocGln, they had been prepared in the usual way 
from the corresponding ONSu or phenol (PFP) with DCG. As noted above (Scheme 
19, P71), the successful synthesis of the PFP-ester130 could be demonstrated by 19F 
spectroscopy. Whereas the 19F NMR signal for pentafluorophenol occurred in the 
region of 6 -164-180 ppm, the additional electron-withdrawing carbonyl in the ester 
moves these signals downfield. Interestingly, two sets of signals were observed in an 
integral ratio of approximately 9:1, the or^o-fluorines in the major set of signals 
resonate as a doublet at 6 -153.27 ppm, the mota-fluorines resonate as a double doublet 
at 6 -162.21 ppm and the para-fluorine gives rise to a signal at 6 157.61 ppm. The 
corresponding signals for the minor component have similar multiplicity and appear at 
similar chemical shifts, 6 -153.57, 6 -157.38 and 6 -162.04 ppm, respectively. Since 
this compound was shown by TLC to be homogenous, the presence of the two sets of 
signals in the fluorine NMR spectrum can be ascribed to rotamers about the 
carbamate carbonyl to nitrogen bond. The greater dispersion of the signals in 19F 
NMR spectroscopy allows these rotamers to be observed as separate signals. In 
contrast, most of the signals of the two rotamers overlap fully in the !H NMR 
spectrum. The exception is the signal for the carbamate NH for which the signal from 
the major rotamer is at 6 7.72 ppm, and that for the minor rotamer is some 2 ppm up- 
field from this position at 6 5.57 ppm. Returning to the fluorine spectrum, it was also 
noted that the 3J  ortho coupling between the 2F and 3F were greater at 17.6 Hz than 
the corresponding SJ  between 3F and 4F which was 16.3 Hz.
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These failures in the couplings may have been due to the possibility that the primary 
benzylic alcohol was more nucleophilic than the aromatic amine. Amines are usually 
much more nucleophilic than alcohols but in this case, the amine is aromatic and the 
alcohol is primary and unhindered. To test this, 4-aminobenzyl alcohol was treated 
with di-tert-butyl dicarbonate in the presence of base (Scheme 26)131. The sole product 
of this reaction was the N-Boc compound (100) with no evidence for the formation of 
the carbonate at the primary alcohol.
Dioxane
Di-tert-butyl pyrocarbonate
OHHKX T" ^A X T '
M2N 0° C 1 JL. H
(30) J ^ Y ^ °  (100)
(101)
S ch em e 26. A synthetic route to 4-[N-(1, l-Dimethylethosycarbonyl)amino]benzyl alcohol (100)
The NMR spectrum of the product (100) confirmed that acylation had taken place 
at the nitrogen. Firstly, separate signals were seen for the OH and NH, whereas the 
alternative ter/-butyl-(4-aminobenzyl) carbonate (101) would have shown the 2- 
equivalent N H 2 protons as a broad singlet. Secondly, the chemical shift of the benzylic 
CH 2 protons was 4.56 ppm, whereas the corresponding signal for benzyl esters comes 
in the region of 6 5.0-5.5 ppm. Thirdly, the protons ortho to the nitrogen function 
resonate at 6 7.22 ppm, whereas the signal of the corresponding protons in the starting 
material (30) appears up-field at 6 6.64 ppm, owing to the mesomeric electron- 
donating character of the primary amine.
Although this experiment on the regioselectivity of the introduction of the Boc group 
confirmed that the amine was significantly the most nucleophilic site in 4- 
aminobenzyl alcohol, masking of the hydroxyl function may avoid side reactions 
during coupling. A series of experiments was then conducted to prepare O-protected 
analogues of 4-aminobenzyl alcohol. The choice of protecting groups was critical. 
Esters would simply undergo acyl-migration from the corresponding 4-hydroxymethyl
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anilides. Benzyl type protecting groups are clearly inappropriate, given the benzylic 
nature of the substrate (Scheme 17, p67). O-fert-Butyl protection would have led to 
difficulties in orthogonality of the protecting groups late on in the synthetic sequence. 
Thus tert-butyldimethylsilyl ether (TBDMS ether) was selected as this group should not 
migrate from O to N. 4-Nitrobenzyl alcohol in dry DMF was treated with TBDMS 
chloride in the presence of imidazole under nitrogen, to give the silyl ether (104) 
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S ch em e 27. The attempted syntheses o f BocGln-protected anilide (107) & FmocGlu(0-tert- 
butyl)-protected anilide (108)
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Now a selective reduction was required to expose the required aromatic amine (106) 
from its masked state as the nitro group. As mentioned previously, NaBH4  in aqueous 
MeOH in the presence of palladium-on-charcoal was studied for this selective 
reduction. Surprisingly, use of 4 molar equivalents of NaBHt, gave high yield (77%) of 
a very non-polar material (Rf = 0.8, 25 : 75 hexane : toluene) (105).
The *H NMR spectrum of this material indicated that it contained two inequivalent 
/wra-disubstituted rings, two inequivalent methylenes and two inequivalent TBDMS 
units. The observation of M+H ion at m /z 487 in the FAB+ mass spectrum pointed to 
the compound being an unsymmetrical dimer. Moreover, since the molecular weight is 
shown to be an even number, the compound must have an even number of nitrogen 
atoms (probably two). The aromatic portion of the JH NMR spectrum comprised 4 
doublets, each integrating for 2 protons, these doublets were centred at 6 6.64, 6 7.11, 
6 7.48 and at 6 8.19 ppm respectively. The coupling constant for each was 
approximately 8 Hz. A ^ ^ H  COSY spectrum (Figure 20, p83) showed that the signal 
at 6 6.64 ppm was coupled to the signal at 7.11 ppm and that 7.48 ppm correlated 
with that at 8.19 ppm. Since the other signals in the spectrum are singlets, a 2D 
NOESY (Figure 19, p82) spectrum was also required to establish through space 
connectivity and thus which TBDMS group was adjacent to which methylene and 
which methylene was adjacent to which aromatic system. This spectrum (Figure 19) 
showed that the doublet at 6 7.48 ppm had through space connectivity to the 
methylene signal at 6 4.83 ppm. This methylene signal also showed a cross peak to the 
fert-butyl signal at 6 0.94 ppm and the SiMe2 signal at 6 0.14 ppm. Similarly, the 
aromatic doublet at 6 7.11 ppm showed a NOE cross peak to the methylene signal at 6 
4.63 ppm. In turn this methylene was shown to be close in space to the tert-butyl 
resonating at 6 0.94 ppm and to SiMe2 resonating at 6 0.09 ppm. Since the chemical 
shifts of the methylenes correspond well with the environment of a benzyl alcohol or 
benzyl silyl ether, the unexpected product, therefore contains two inequivalent Ar- 
CH2-OTBDMS units. The question now is what is the nature of the group linking 
these two units? The protons ortho to this linker resonate at the very different chemical 
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Figure 19. NOEST expansions for azoxy compound (105) (All scales are in ppm represented as 6)
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Figure 20. A 2D COSTfor azoxy compound (105)
A high resolution FAB mass spectrum gave the molecular formula as C26H42N203Si2, 
thus the linker contains only two nitrogens and one oxygen and the compound can be 
characterised as having the azoxy structure shown in (Scheme 27, p80) (see Appendix 
Figure 27 for a 3D representation of azoxy compound (105)). The difference in the lH 
NMR chemical shifts of the 2 sets of protons ortho to the azoxy link is remarkable since 
the difference between the chemical shift of the corresponding signals for 
azoxybenzene is only 0.15 ppm132*133.
Whereas the use of 4 molar equivalents of NaBFU gave the azoxy compound (105), 
reaction of the reduction with 10 molar equivalents of the reagent effected full 
reduction to the desired aromatic amine (106) (Scheme 27). Reduction of nitro to
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amino is a six-electron process; each molar equivalent of NaBH4  is, in principle, an 
eight-electron reductant; thus it is surprising that the use of thirty two electron 
equivalents of reductant only reduced the nitro compound (104) by the equivalent of 
three electrons per molecule in making the azoxy compound (105). As a quick check to 
see if the TBDMS could be removed efficiently from compounds of this type, the 4-tert- 
butyi-dimethylsilyoxymethylaniline was treated with TBAF134 in THF at 0°C to give 
4-aminobenzyl alcohol (30) in excellent yield (65%). Unfortunately, no coupling of the 
OTBDMS (106) with BocGln derivatives could be achieved under a variety of 
conditions.
3.3 Synthesis o f  the am inophenylpropargyloxycarbonyl clip
In view of the difficulties in synthesising the aminobenzyloxycarbonyl clip derivatives, 
a modified aminophenylpropargyloxycarbonyl clip was designed. This latter dip is also 
triggered by cleavage of the amide bond, releasing electron density in the amine 
nitrogen to expel the (model) drug through a 1,8-elimination. Two versions of this dip 
were planned, the straightforward aminophenylpropargyloxycarbonyl unit and a 
derivative in which the propargyl CH2 is replaced by CMe2 . It was postulated that, in 
the latter, expulsion of the leaving group would be speeded by relief of the steric 
compression between these geminal methyls as the central carbon moves from sp3 to 
sp2 hybridisation following triggering. Of course these two new clips introduce 
restrictions to the synthetic planning, particularly in the choice of protecting groups. 
The aminophenylpropargyloxycarbonyl unit will be incompatible with allyl, benzyl 
and Cbz-type protection, owing to the similarities in structure (Figure 21, p86). 
Additionally, the aminophenyl(dimethyl)propargyloxycarbonyl unit will preclude the 
use of Boc and other acid-sensitive protection as it contains a tertiary carbamate. 
These aminophenylpropargyloxycarbonyl clips are novel and untested; therefore, a 
series of model compounds was designed to allow investigation of the action of the 
clips before incorporation into a peptide system. These models comprised simple N- 
protected clip-model drug systems where the protection was e.g. trifluoroacetyl 
(removed with ammonia) or Boc (removed rapidly with add but incompatible with the 
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Sch em e 28. The mechanism of the PSA-triggered release of the model drug (NPEA)
Retrosynthetic analysis of the structures of the model compounds required for testing 
the clip indicated several possible points of disconnection (Figure 21, p86), firstly 
disconnection between the carbamate carbonyl and the nitrophenylethylamine 
nitrogen would require the corresponding chloroformate or equivalent to react with 4- 
nitrophenylethyl amine, secondly, disconnection between the carbamate carbonyl and 
carbamate oxygen pointed to synthesis through reaction of the aryl propargyl alcohol
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with nitrophenylethyl isocyanate (75). Thirdly, a Sonogashira coupling of a propargyl 
carbamate with an iodoarene was conceivable.
(Points of disconnection)
Labile to Cbz/Fmoc deprotectionsPG,
H
(113): Protecting group = Boc
(114): Protecting group = CF3CO
PG,
Similar to Boc protecting group
(115): Protecting group = Boc
(116): Protecting group = CF3CO
Figure 21. Protecting group strategies for compounds (113-116)
Sonogashira cross-coupling135 reactions are derived from the Gastro-Stephens “non­
palladium” coupling methods136, where it has previously been demonstrated that a 
variety of aryl alkynes may be obtained by a copper-promoted cross-coupling reaction 
of aryl halides and copper(I) acetylides137. The more recent organometallic coupling 
strategies in aryl-alkyne coupling, are the alkyne versions of the palladium-mediated 
Heck reaction138 and the (tin/zinc) metallated Negishi alkynylation139. Sonogashira 
coupling however, is considered to be more advantageous over other methods due to 
its versatility and high tolerance for nearly all types of functional groups. This is 
extremely important in our syntheses, as all of the synthetic targets contain nitro and 
carbonyl functional groups.
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The Sonogashira reaction is responsible for cross-coupling an aryl (or vinyl) halide 
(electrophile) with a terminal alkyne (nucleophile) in the presence of an aliphatic amine 
(base), a catalytic amount of a palladium-phosphine complex and copper(I) iodide in 
dry conditions. As presented by Sonogashira140, the general order of reactivity of the 
organic halide is similar to the reactivity of the leaving group. Thus, an iodoarene 
generally affords quicker reaction times and higher yields compared to other halides, 
such as bromo and chloro. In Sonogashira reactions, there are many catalysts that can 
be used. It is however, more common to use Pd(II) derivatives, such as, 
bis(triphenylphosphine)palladium(II) chloride [(PPh^PdCk], palladium(II) acetate 
[Pd(OAc)2] and the new catalyst of interest, tetrakis(diphenylphosphinomethyl)- 
cyclopentane (Tedicyp)141, although the palladium(O) catalysts are coordinatively 
unsaturated and are the catalytically active species. Moreover, Pd(II) catalysts (or 
rather pre-catalysts) are usually more stable and less sensitive to air and generally 
soluble in organic solvents. Copper(I) iodide is the co-catalyst in these types of 
reactions and is responsible for facilitating the substitution reaction in the catalytic 
cycle (see Scheme 29 and 30). Di-i'jopropylamine acts as a base during the 
transmetallation rate-determining step, although other bases, such as triethylamine 




Schem e 29. Formation of the al/ynyl copper conjugate (123) from a reaction between 2-methyl-3 - 
butyn-2-ol and copper(I) iodide in the presence of triethylamine
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The first model compound required was based on the trifluoroacetyl-protected type. 4- 
Iodoaniline (130) was converted to its trifluoroacetyl anilide (129) by treatment with 
the reactive ester ethyl trifluoroacetate142 (Scheme 31). A Sonogashira reaction of this 
iodo trifluoroacetyl anilide with 2-methyl-3-butyn-2-ol (dimethylpropargyl alcohol) in 
the presence of [(PPhs^PdCk] and copper(I) iodide under nitrogen, gave the coupled 









Schem e 30. A representation of the Sonogashira catalytic cyclefor compound (126)
The catalyst used in the reaction was prepared separately by heating palladium(II) 
chloride with two equivalents of triphenylphosphine in DMF at 80°C for 24 h. 
Furthermore, triethylamine was the base used in this instance, as the more commonly 
used secondary alkyl amine (ditsopropylamine (DIPA)) can be responsible for the 
removed of trifluoroacetyl-type protecting groups. In an attempt to improve the 
efficiency of the Sonogashira coupling reaction, effort in varying the following 
experimental conditions [reaction temperature, reaction time, Ar (argon) atmosphere, 
palladium catalyst used: tetrakis(triphenylphosphine)palladium(0) and palladium(II) 
acetate] were unsuccessful.
The exact detailed mechanism for Sonogashira reactions is yet to be established, 
though it has been proposed by Sonogashira135’140, that the required substitution 
occurs via a catalytic cycle consisting of three stages (Scheme 30, p88). Above is an 
example of these stages for formation of the required intermediate (126).
At this point, it was necessary to convert the tertiary alcohol of (126) to its 
corresponding chloroformate or its equivalent for reaction with 4-nitrophenylethyl 
amine to form the required carbamate143’144.
Chloroformates are normally synthesised by treatment with excess phosgene, however 
this reagent is highly toxic and its use can be avoided by using 4-nitrophenyl 
chloroformate. Reaction of alcohols with 4-nitrophenyl chloroformate normally gives 
the corresponding 4-nitrophenyl carbonates, which are synthetic equivalents of 
chloroformates. The advantages of using these carbonates are the use of a solid and 
less toxic reagent and the opportunity to characterise and sometimes isolate the 4- 
nitrophenyl carbonate before the reaction with an amine. Unfortunately, the tertiary 
alcohol (126) could not be converted to its corresponding carbonate under a variety of 
conditions, this failure maybe attributed to the presence of a highly acidic NH in the 
trifluoroacetamide moiety, which is removed preferentially by the triethylamine base.
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Attention was then turned to the Boc protected model in which the corresponding NH 
proton would be expected to be much less acidic. 4-Iodoaniline was treated with di-tert- 
butyl carbonate under the usual conditions to give the Boc protected compound (131) 
in good yield (Scheme 31). Sonogashira coupling of 2-methyl-3-butyn-2-ol to give the 
Boc protected compound (131), was very effective in proving useful quantities of the 
arylalkyne alcohol to give the Boc protected compound (132). In this case it was 
possible to use DIPA as the co-solvent and base, very dry conditions was essential for 





















Schem e 31. A schematic representation shouting the attempted syntheses of compounds (135, 136)
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The tertiary alcohol (132) was taken forward for treatment with 4-nitrophenyl 
chloroformate in an attempt to obtain the mixed carbonate (Scheme 31, p90). It was 
anticipated that characterisation of the product carbonate by *H NMR would be 
challenging since it would be expected that there would be no significant change in the 
chemical shifts of the proton signals from the alkyne containing unit and possibly little 
change in the chemical shift of the nitrophenyl protons when compared to the starting 
materials. Since the tertiary alcohol oxygen is becoming acylated one would expect a 
significant downfield shift of the signal for the quaternary carbon to which this oxygen 
is attached. Thus, it was important to assign rigorously the 13C NMR spectrum of the 
tertiary alcohol and, in particular to identify the signal from this quaternary carbon. 
The signals due to the methyl groups appear at 6 28.35 and 6 31.56 ppm, as shown by 
135 DEPT spectrum. This spectrum also showed GH signals at 6 117.99 and 6 132.08 
ppm. Quaternary carbon signals were observed at, 6 65.64, at 6 80.86, at 6 81.96, at 6 
92.96, at 6 116.93, at 6 138.47 and 6 152.52 ppm. An HMQC (Figure 22, p92), which 
shows cross peaks between directly bonded carbons and proton, showed that the up- 
field methyl signal at 6 28.35 ppm correlated with the Boc protons, confirming that 
this signal could be assigned to the Boc methyl carbons. Similarly, a cross peak linking 
the signals for the geminal Me2 protons with the downfield methyl carbon signal at 6 
31.56 ppm, confirmed the latter as being due to geminal Me2 carbons. Assignment of 
GH tertiary carbons however was not possible by using HMQC (Figure 22, p92), since 
the signals for all the aromatic protons were accidentally coincident, appearing as a 4- 
proton singlet at 6 7.34 ppm. The calculations of the predicted chemical shifts were 
made based on the formula given by Williams and Fleming116 (6C = 128.50 + Z1 + Z° + 
Zm +Zp); these calculations predict 6 110.40 ppm for the carbons ortho to the nitrogen 
and 6 131.80 ppm for the carbons ortho to the alkyne. These values are sufficiently 
different from each other to assign the observed signal at 6 117.99 ppm to the carbons 
ortho to the nitrogen and 6 132.08 ppm to the carbons ortho to the alkyne. Similar 
calculations confirmed that the aromatic carbon carrying the nitrogen resonated at 6 
138.47 ppm and the carbon carrying the alkyne resonated at 6 116.93 ppm. Clearly, 
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Figure 22. HMQC & HMBC spectra for compound (132) (axis x = 6c and axisy -  6 h)
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None of these methods allowed the confident assignment of the remaining 4- 
quartemary carbon signals. For this purpose, an HMBC was obtained. This 2D 
spectrum shows cross peaks between carbon and proton signals where the protons and 
carbons are coupled through 2 or 3 bonds. Firstly, observation of an HMBC (Figure 
22, p92) cross peak between the proton signal at 6 7.34 ppm and the carbon signal at 6 
80.86 ppm confirmed the latter as being the alkyne carbon attach to the benzene ring. 
The Boc methyl proton signal correlated with the carbon signal at 6 81.96 ppm, thus 
the latter arises from the quaternary Boc carbon. However, since the geminal Me2 
proton signal gave cross peaks to both the remaining carbon signals, these could not be 
differentiated by HMBC spectroscopy since the alkyne carbon lies 3 bonds from these 
protons and the sp3 quaternary carbon lies 2 bonds from these protons. Therefore, 
predicted calculations for the chemical shift were made which allowed assignment of 
the signal at 6 65.64 ppm to the COH carbon and of the signal at 6 92.96 ppm to the 
adjacent alkyne carbon (Figure 22).
Unfortunately the reaction of the tertiary alcohol (132) with 4-nitrophenyl 
chloroformate gave materials that appeared to be a mixture of the starting alcohol and 
4-nitrophenol. It maybe that the tertiary alcohol was just too sterically hindered to 
react effectively as a nucleophile.
In a further experiment, the reaction mixture of the tertiary alcohol and the 4- 
nitrophenyl chloroformate was treated in situ with triethylamine to test whether any 
mixed carbonate had been formed in the reaction. The isolation of a substantial yield 
of the bis(nitrophenylethyl)urea (137) however, demonstrated that the 4-nitrophenyl 
chloroformate had not reacted with the tertiary alcohol (132) and had therefore been 
available for reaction with the stronger nucleophile NPEA (67) (Scheme 31).
The alternative disconnection at the arene-alkyne bond was then studied. In view of 
the poor nuclophilic reactivity of the tertiary alkyne alcohol noted above, this strategy 
was investigated using the propargyl analogue lacking the methyl substituents Scheme 
32). The critical intermediate in this sequence is the propargyl-NPEA-carbamate
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(140), which is required for Sonogashira coupling to peptidyl iodoanilides as the final 
step in the assembly of the prodrugs. Sonogashira couplings are tolerant to a wide 
variety of functional groups including those found in anticancer drugs such as 
doxorubicin (13) and daunorubidn (14) (refer to Chapter 1, section 1.1.6.5.4). Thus, 
this reaction is apposite for the final step in the construction of the final prodrug 
system. To this end, propargyl alcohol (138) was acylated with an equimolar amount 














Cu(l)l /  (PPh3>2 PdCI2 
DIPA or Et3N 
Protected aniline 
No
Target (141): R = CF3CO 
(142): R = Boc
(139)
Schem e 32. Attempted syntheses towards carbamates (141 <2? 142)
The mild conditions were necessary to avoid nuclophilic displacement of 
nitrophenoxide from the product. The mixed carbonate is a good electrophile and is 
the synthetic equivalent of the corresponding chloroformate. Reaction with 4-
94
nitrophenylethylamine gave the target carbamate (140) in very good yield. There was 
no evidence for displacement of the propargyloxy group. This can be rationalised, as
4-nitrophenoxide is a much better leaving group than propargyloxide (pKa of 4- 
nitrophenol is 7.15 and the pKa of a typical aliphatic primary alcohol is approximately 
15).
With this important carbamate (140) readily available, attention was turned to 
optimising the Sonogashira coupling of this alkyne with 4-iodoanilides. Initial 
experiments with model iodoanilides were discouraging in that the reaction of 4- 
iodotrifluoroacetyl anilide (129) and tert-huty\ N-4-iodophenyl carbamate (131) with 
the alkyne (140) under Sonogashira conditions with a variety of palladium catalysts (as 
mentioned previously), failed to give significant yields of the coupled products (141) 
and (142) respectively.
Undaunted by these results of these model compounds, studies were initiated on 
Sonogashira couplings of propargyl carbamate (140) with amino acids and peptide 4- 
iodoanilides. As discussed above, formation of anilides from BocGln and 4-substitued 
anilines, especially those carrying electron-withdrawing groups in the 4-position, is 
difficult. In this case BocGlnOPFP (78) failed to react with 4-iodoaniline, but use of the 
pivaloyl mixed anhydride method, which had proven good results with other anilines, 
allowed the synthesis of the BocGln-iodoanilide (145) in 10-15% yield after 
optimisation. Much of the difficulty in achieving high isolated yields can be attributed 
to the very poor solubility of the product in most solvents. Contrary to the 
BocGlnOPFP (78) failing to react with 4-iodoaniline, a similar coupling with 
FmocGlu(0-ter£-butyl)OPFP (143) gave the corresponding anilide (144) (Scheme 33, 
p96) in 11% yield; this coupling was an attempt to avoid the sparingly soluble 
intermediate BocGln-iodoanilide (145), as the side chain ester could be later converted 
to a primary amide. However, the low coupling yields obviated this potential 
advantage. Since this iodoanilide was critical to this synthetic sequence, an alternative 





Schem e 33. The synthesis of anilide (144) from its OPFP-ester
Pyroglutamic acid (Pyg) (146) is an analogue of glutamic acid (Glu) where the side 
chain carboxylic acid has formed an amide with the alpha amine. Although ring 
opening of pyroglutamic acid with nucleophiles is very difficult and requires forcing 
conditions, as it is a gamma lactam, acylation of the nitrogen converts it to a much 
more electrophilic imide. Thus BocPyg (146) can be considered as a potential synthon 
for Gin and is much more lipophilic than the latter.
Pyroglutamic acid (146) was converted efficiently to its benzyl ester (147) by alkylation 
of the carboxylate with benzyl chloride145 (Scheme 34, p97). This esterification serves 
to mask the carboxylate nucleophile during the introduction of the N-Boc group. 
Treatm ent of the PygOBn (147) with an excess of di-ter*-butyl carbonate and 
triethylamine, furnished BocPygOBn (148) in good yield. This acylation of a lactam 
nitrogen proceeded well despite amides normally having much lower nucleophilic 
reactivity than amines. The carboxylic acid was then revealed by hydrogenolysis of the 
benzyl ester146 (148). The carboxylate was activated as its OPFP ester in the usual way. 
This active ester reacted slowly with the weakly nucleophilic 4-iodoaniline to give 
BocPyg-iodoanilide (151) (Scheme 34, p97) in modest yield. It is noteworthy, that the 
reaction of BocPygOPFP with 4-iodoaniline was significantly more efficient than the 
corresponding reaction of BocGlnOPFP with this nucleophile. Also, the pivaloyl mixed 
anhydride coupling of BocPygOH with iodoaniline, gave BocPyg-iodoanilide (151) in 
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Schem e 34. A schematic representation of multiple synthetic ways to target intermediate (145)
The BocPyg-iodoanilide (151), lacking the primary amide of glutamine derivatives, 
was reasonably soluble in organic solvents and could be readily purified by column 
chromatography. At this point, simple treatment of ammonia in THF, gave the
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BocGln-iodoanilide (145) in high yield. Clearly the nitrogen nucleophile has attacked 
the less sterically crowded of the two carbonyls of the imide, as there was no evidence 
of the formation of BocPyg-iodoanilide (151). Thus, BocPyg is shown to be a 
potentially useful synthetic equivalent of Gin in building peptide constructs, although 
its use in this context has been scarcely reported previously. Comparing the three 
approaches to BocGln-iodoanilide (145), the overall yields are similar, but the 
apparent advantage with solubility of the Pyg route, is balanced by the fact that is a 
long six-step linear sequence.
Given the success of the coupling of the BocPygOPFP (150) with iodoaniline, it was 
conjectured that this active ester may react with the amino group of 4-aminobenzyl 
alcohol (refer to Scheme 35 below) to give, after ring opening with ammonia, BocGln- 
benzyl alcohol (83). However, no useful coupled material was obtained. Similarly, 
couplings of BocPygOH (146) with this aniline using pivaloyl mixed anhydride 
couplings and EED Q /D CC 147 also failed (Scheme 35).
*3 !n&








(All of the active intermediates were reacted with 4-aminobenzyl alcohol) 
(Base = triethylamine)
NH3 (35% soln.)
Schem e 35. Attempted syntheses to target compound (83)
At this point, there were two possible alternatives for approaching the target peptide 
prodrug construct (109). Either the required peptide could be built onto Gln-
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iodoanilide (146), followed by Sonogashira coupling with the propargyl carbamate
(140), or the Sonogashira coupling could precede the peptide synthesis. Clearly the 
former would be more synthetically efficient, particularly when doxorubicin and other 
anticancer drugs are used, as it is more convergent.
Removal of the Boc protecting group148 of the BocGln-iodoanilide (145) was needed 
for coupling with amino-acid derivatives to develop the peptide. BocGln-iodoanilide 
was treated under mild conditions with HC1 (gas) in methanol to give Gln- 
iodoanilide.HCl salt (158), which was coupled in situ with BocLeuONSu to give the 
protected dipeptide anilide (159). Isolation of the Gln-iodoanilide.HCl salt was not 
possible owing to its instability. Indeed, deprotection by dissolution of BocGln- 
iodoanilide in TFA149 did remove the Boc group but also triggered cydisation with loss 
of ammonia to give Pyg-iodoanilide (156) (Scheme 36, plOO). This material was 
readily purified as it was non-basic and readily soluble in organic media. Its structure 
was firmly characterised by TO NMR and mass spectrometry. The feature in the TO 
NMR spectrum, which most markedly identified the compound as the gamma lactam, 
was the signal for the a-proton at 6 4.14 ppm which comprised a double doublet with 
coupling constants, J  — 4.4 and J  = 8.2 Hz. These values are different from the 
coupling constants for open-chain Gin derivatives, but are typical for the coupling to 
the two p-protons in the 5-membered ring of Pyg. Interestingly, no coupling was 
observed between the a-proton and the lactam NH. In open-chain Gin peptides, the 
a-proton to NH is typically in the range of 4-8 Hz, but a chemical 3D model suggests 
that the dihedral angle between the a-proton and lactam NH is close to 90 degrees 
(see Appendix Figure 28), suggesting a coupling constant of zero according to the 
Karplus relationship. From one run using trifluoroacetic acid (TFA) as the 
deprotecting agent for a very short contact time, the Gln-iodoaniliide.TFA salt (157) 
was obtained. Examination of the FAB+ mass spectrum of this salt and of Pyg- 
iodoanilide (156) (formed in most runs with TFA), revealed some interesting features. 
The base peak in the spectrum of the Pyg compound was the M+H ion of m /z at 331 
with no abundant fragment ions. Peaks were also seen for clusters of M+H + 3- 

































Schem e 36. A synthetic route to the tetrapeptide target intermediate (163)
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The spectrum of the Gln-iodoanilide.TFA salt (157), showed a strong molecular ion at 
m /z 348 with a M+H + 3-nitrobenzyl alcohol at m /z 501. Interestingly, each spectrum 
obtained from the Gln-iodoanilide.TFA salt and the analogous HG1 salt (158), showed 
a significant fragment ion at m /z 331. This indicated loss of ammonia from the parent 
ion and reflects the propensity of this type of salt to undergo cyclisation to the Pyg 
derivative.
Having observed this novel cyclisation of BocGln-iodoanilide (145) and BocGln- 
methoxycarbonylanilide (90) to the Pyg anilides with acids under mild conditions, one 
experiment was conducted to investigate whether this reaction could be extend to N- 
alkyl glutamine amides (Scheme 37). BocGlnNPEA (164) was dissolved in TFA; the 
!H NMR spectrum obtained after a few minutes, revealed the characteristic signals for 
the Pyg-nitrophenylethylamide (165) (where it has been assumed that the 
stereochemistry has not altered) and the 1-1-1 triplet for ammonium trifluoroacetate. 
Pyg-NPEA (165) was isolated in high yield from this mixture. Thus, this cyclisation is 
potentially a significant problem in the deprotection of BocGln derivatives.
(20 min)
Schem e 37, A cyclisation to compomd(165) from the Boc deprotection of compound (164)
In contrast, the removal of the Cbz group from CbzGln-nitroanilide (166), formed 
from a pivaloyl mixed anhydride coupling of CbzGlnOH (50) with 4-nitroaniline 
under highly acidic conditions (HBr (30% in acetic acid)), gave no trace of the Pyg 
cyclisation product (Scheme 38, p i02). Gln-nitrophenylanilide.HBr salt (167) was 
obtained in a quantitative yield and was coupled efficiently with BocLeuONSu to give 


















H’N n X X(167) ^ ^ N 0 2
Schem e 38. A schematic route to dipeptide (168)
Returning to the main reaction sequence towards the target peptide iodoanilide 
reaction of Gln-iodoanilide.HCl (158) with BocLeuONSu, efficiently gave the 
protected BocLeuGln dipeptide iodoanilide (159) (Scheme 36, p i00). From here, the 
Boc protection was removed under acidic conditions, giving LeuGln-iodoanilide (160) 
to which FmocLys(Boc) was introduced using FmocLys(Boc)ONSu (Scheme 36). As 
noted above, the Fmoc and Boc protecting groups are fully orthogonal and treatment 
of the protected tripeptide (161) with diethylamine, afforded Lys(Boc)LeuGln- 
iodoanilide (162). This material was sufficiently soluble in the dipolar aprotic solvent 
DMSO to allow a proton NMR spectrum to be attained, but it was too insoluble in 
solvents suitable for peptide coupling to permit further chain extension.
Since it was not possible to assemble the tetrapeptide iodoanilide (163) (Scheme 36), 
the next series of experiments investigated Sonogashira couplings onto BocGln- 
iodoanilide (Scheme 39, p i03). Although propargyl alcohol has been reported to give 
very poor yields150 for Sonogashira couplings, treatment of the BocGln-iodoanilide 
(145) with propargyl alcohol in DIPA and DM F in the presence of 
bis(triphenylphosphine) palladium(II) chloride and copper(I) iodide under very dry 
conditions, did give a moderate yield of the arylpropargyl alcohol (169).
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Dry DMF
Cu(l)l /(PPh3)2 PdCI2 
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Schem e 39. The synthesis of the target alkyne molecular clip derivative (172)
However, this could not be elaborated to the carbamate (170) via the 4-nitrophenyl 
carbonate. In contrast, the Sonogashira coupling of the pre-assembled propargyl 
carbamate (140) with BocGln-iodoanilide (145) was successful in furnishing a useful 
quantity of the target intermediate BocGln-CL/P-model drug (170) (see NMR in 
Figure 22). Removal of the Boc deprotection with HG1 in M eOH for a very short 
contact time (to avoid Pyg formation), followed by coupling with BocLeuONSu in the 
presence of DMAP, afforded the dipeptide-CZ,/P-model drug target (172) in a good 
yield (Scheme 39, p i03). This has the potential for elongation of the peptide sequence 
to give the advanced target containing the PSA-sensitive sequence, a self-immolative 
molecular clip and the model drug.
6
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Figure 23. A JH N M R spectrum for compound (170) (scales in ppm)
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3.4 S y n th es is  o f  a m o n o m er ic  m o d e l fo r  ch y m o try p sin -  
triggered  re lease  o f  m odel drug (NPEA)
In parallel with the above synthetic approaches to PSA-triggered prodrug systems, 
which required tetra-peptides and penta-peptides containing “difficult” amino acids, 
an approach towards a simpler construct designed for triggering by chymotrypsin was 
initiated.
Chymotrypsin is a serine protease related to PSA but with a different sequence 
selectivity. It normally cuts peptides at the C-terminal side of aromatic amino acids, 
especially phenylaniline103. Thus the construct AlaPhe-CL/P-model drug (180) 
(Scheme 40, p i06) was devised as a system in which the function of this new (alkyne) 
self-immolative molecular clip could be tested under enzymic conditions. The 
chymotrypsin, a cheap and readily available enzyme should cleave between the Phe 
and the aniline releasing the aminophenylpropargyl carbamate (111) (refer to Scheme 
28, p85).
BocPheOH (173) was converted to its pivaloyl mixed anhydride which reacted in situ 
with 4-iodoaniline (130) to give the BocPhe-iodoanilide (175) in modest yield. 
Acidolytic removal of Boc furnished Phe-iodoanilide (176) quantitatively for coupling 
with BocAlaOPFP (which was prepared in the usual way from BocAlaOH with PFP 
and DCG, Scheme 40). The required protected dipeptide iodoanilide (179) was 
























Schem e 40. The synthesis of the chymotrypsin-sensitive monomeric model
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3 .5  S y n th esis  o f  th e  N -term in a l flu o r e sc e n t m a rk er
In the overall design of the advance model prodrug system, it was planned to 
incorporate a fluorescent marker at the PSA-sensitive peptide to mimic the eventual 
polymer backbone and to report on the fate of the peptide sequence during the 
enzymatic reaction with PSA (see below in Scheme 41 and refer also to Chapter 2).
F,udrescentmM er
(45)
p e p t i d e  =  H S S K L Q ,  S S K L Q ,  S K L Q
a S n u A c
(46)







S ch em e 41. The use o f the fluorescent marker in the PSA-triggered release of doxorubicin from the 
monomeric model (this fluorophore would be viable for either molecular clip system)
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Dansyl (5-dimethylaminonaphthalene-l-sulfonyl) is a convenient biocompatible 
fluorophore. To avoid any possible steric encumbrance of the dansyl group with the 
enzyme active site, it was proposed to link the dansyl to the N-terminals of the peptides 
through a simple 6- carbon linker.
6-Aminohexanoic acid was converted quantitatively to its methyl ester151 with thionyl 
chloride in MeOH. This protection stops the 6-aminohexanoyl unit being zwitterionic 
and aids its solubility in organic solvents, correspondingly, the amine (182) was treated 
with dansyl chloride152*153 in a TH F/D M F mixture in the presence of triethylamine to 


















Schem e 42. The synthetic steps to the formation of thefluorophore-hydra i^de (184)
Since it was necessary to activate the carbonyl as the electrophile for later coupling 
with the N-terminals of the peptides, the ester in dry M eOH was treated with 
hydrazine hydrate to afford the hydrazide (184) in one step. Hydrazides are readily 
converted110 to the corresponding acyl azides with tert-butyl nitrite and HC1 at very low 
temperatures. The low temperature is necessary to avoid accidental Curtius
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rearrangements. Acyl azides such as the one derived from this azide are effective acyl 




The aim of the project was to develop an advanced model for a PSA-triggered 
polymeric prodrug system. The specific objectives included synthesis of the PSA- 
sensitive peptide sequence and development of self-immolative molecular clips to link 
this sequence to a model drug NPEA (67). This molecular clip was expected to be 
required, as studies by other workers had shown that the aliphatic amine of 
doxorubicin (13) is not cleaved from the sequence HisSerSerLysLeuGln-dox but Leu- 
dox is released from HisSerSerLysLeuGlnLeu-dox. Aromatic amines are also released 
by PSA-mediated cleavage of HisSerSerLysLeuGlnNHAr. Thus, PSA can release 
aromatic amines and amino adds, but not, apparently, conventional aliphatic amines. 
Synthetic approaches to peptide-CZJP-model drug constructs were investigated, where 
the clip is either a 4-aminobenzyl moiety or the extended 4-aminophenylethynyl 
methyl unit.
Early experiments focused on assembling peptide-model drug constructs omitting the 
molecular dip to test whether such a dip was indeed necessary. Active-ester peptide 
couplings, together with appropriate use of the orthogonal Boc, Cbz and Fmoc 
protecting groups led to the successful synthesis of LysBocLeuGlnNPEA (55) and 
BocLeuLys(Cbz)GlnNPEA (57). The latter, with the Leu and Lys reversed in the 
sequence, would have provided an womeric construct, which should not be 
recognisable by PSA. Unfortunately, the very low solubility of these tripeptide 
derivatives in appropriate organic solvents precluded further elaboration to the target 
pentapeptides.
Two synthetic units were required for assembly of the full peptide-CZJP-model drug 
construct, the 4-hydroxymethyl anilide of the pentapeptide and 2-(4- 
nitrophenylethyl)isocyanate (75). The latter was conveniently prepared by Curtius 
rearrangement of 3-(4-nitrophenyl)propanoyl azide (74). However, a large number of
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coupling reagents all failed to link 4-aminobenzyl alcohol to protected glutamine 
derivatives. Although methyl-4-aminobenzoate could be coupled to Bocglutamine, the 
product anilide (80) was too insoluble for selective reduction of the ester.
In developing suitably O-protected versions of 4-aminobenzyl alcohol, reduction of the 
TBDMS-ether of 4-nitrobenzyl alcohol with a large excess of NaBHU in aqueous 
methanol in the presence of Pd/C, gave the O-TBDMS-4-aminobenzyl alcohol (106) 
in good yield. In contrast, the use of 4 molar equivalents gave the 3-electron reduction 
product 4,4’-bis(TBDMSOCH2)azoxybenzene (105), the structure of which was 
proven by COSY and NOESY 2D NMR spectra.
Synthetic approaches to a modified peptide-CZ/P-model drug construct were more 
successful. In this, the molecular clip is a 4-aminophenylethynylmethyl unit. The 
presence of this new clip, allows a new point of retrosynthetic disconnection to be 
identified as a potential Sonogashira coupling of a terminal alkyne with an iodoanilide. 
In model experimental sequences to study viability of such Sonogashira couplings, 
propargyl N-nitrophenylethyl carbamate (140) was assembled from propargyl 4- 
nitrophenyl carbonate and 2-(4-nitrophenyl)ethylamine (NPEA). However, this 
terminal alkyne failed to couple with the model anilides 4,-iodotrifluoroacetanilide
(141) and tert-butyl N-4-iodophenyl carbamate (142). Undaunted by the disappointing 
results of these model experiments, the coupling of this propargyl carbamate (140) 
with BocGln-iodo anilide (145) was attempted. This anilide was prepared by two 
distinct routes. Firstly, BocGln (76) was coupled directly with 4-iodoaniline in modest 
yield through a pivaloyl mixed anhydride. Again, solubility constraints limited the 
effectiveness of this procedure. To avoid these, a longer synthetic sequence was 
investigated in which the troublesome primary amide side chain of glutamine was 
masked by cyclisation as pyrogluatamine. BocPygOPFP (150), prepared in 4 steps 
from PygOH (146), reacted with 4-iodoaniline to give BocPyg 4-iodoanilide (151) in 
satisfactory yield. In an innovative approach, simple ring opening of this lactam with 
ammonia gave the BocGln iodoanilide (145).
I l l
Encouragingly, this iodoanilide did undergo Sonogashira coupling with propargyl N- 
nitrophenylethyl carbamate (140) to give a good yield of the phenylalkyne (170). 
Demonstration of the potential of this construct for elaboration into the target 
pentapeptide prodrug construct was made by removal of the Boc protection and 
coupling with BocLeuONSu in the usual way.
In summary, despite the major difficulties occasioned by the low solubility of the 
critical glutamine residue, a route has been discovered which has strong potential for 
synthetic access to the target pentapeptide-CZ/P-model drug construct for biological 




5.1 M a te r ia ls
Chemicals were purchased from Aldrich, Acros, Lancaster, Nova Biochem, Sigma 
chemical companies and used without further purification. All anhydrous solvents 
were purchased in anhydrous form, except THF which was freshly distilled from 
Na/benzophenone and triethylamine (Et3N) and diethylamine (DEA) which were 
freshly distilled and dried from sodium hydride (NaH). All chiral amino acids are (L), 
unless otherwise stated.
5.2 G e n e ra l an a ly tic a l p ro c e d u re s
All and I3C NMR spectra were acquired on Jeol EX400 or Jeol GX270 
spectrometers. All 19F NMR, COSY 2D, NOESY, HMBC and HMQC spectra were 
recorded on a Jeol EX400 spectrometer. Chemical shifts are reported in ppm (parts 
per million) relative to the protons of tetramethylsilane (TMS), which was the internal 
standard for samples dissolved in CDCI3. TMS or DMSO for samples in (CD3)2SO 
and deuterated methanol for samples in CD3OD. Multiplicities are indicated as 
follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), dt (doublet of 
triplets), q (quartet), m (multiplet) and br (broad singlet). IR spectra were recorded on a 
Perkin Elmer RX 1 FT1R spectrometer in two forms, all liquid and oils were recorded 
as liquid films between NaCl plates and all solid materials as potassium bromide (KBr) 
disks. Vmax Values are given in cm-1. Mass spectra were obtained by chemical 
ionisation (Cl), by electrospray (ES) or by fast atom bombardment (FAB) (with m- 
nitrobenzyl alcohol as the matrix) using a Fisons VG mass spectrometer. Thin layer 
chromatography (TLC) was carried out on Merck Kieselgel 6 OF2 5 4 pre-coated 
aluminium plates. Purifications of all crude compounds were performed using flash 
chromatography on Merck Silica Gel 60 flash silica. Components were visualised using 
ninhydrin (for detection of amines) (ninhydrin 1.5g/100mL propan-2-ol), iodine or
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UV light. Melting points were acquired on a Reichert Jung Thermo Galen Kofler 
block and are uncorrected. Elemental analyses were carried out by the University of 
Bath microanalysis service. All [<x ] d  values were measured at 24°G (in DMF) at 
wavelength (X 589 nm) using sodium light. All specific rotation values were acquired 
on a AA-10 polarimeter (Optical Activity Ltd).
5.3 G e n e ra l la b o ra to ry  p ro c e d u re s
Unless otherwise stated, after solvent extractions, all solutions were dried using 
magnesium sulfate (MgS0 4 ) and all solvents were evaporated under reduced pressure. 
Solutions of aqueous citric acid and copper(II) sulfate were of 5% w/v concentration; 
brine was a saturated solution. Gaseous HG1 was generated by addition of 
concentrated sulfuric acid to NaCl. Experiments were conducted at ambient 
temperature, unless otherwise stated.
Sonogashira reactions: Unless otherwise stated, the Pd catalyst, (PPh3)2PdCl2 used 
in the Sonogashira reactions was prepared as follows: A mixture of PPI13 (375 mg, 1.4 
mmol) and PdCb (130 mg, 0.7 mmol) in DMF (20 mL) was heated at 80°G for 24 h. 
Filtration and drying yielded (PPh3)2PdCl2 as a bright yellow powder (469 mg, 93%).




A solution of 4-nitrobenzyl alcohol (2.27 g, 15 mmol) and palladium (10% wt on 
activated carbon) (502 mg, 10 mmol) in ethanol (25 mL) was stirred for 24 h at RT 
under hydrogen atmosphere. The reaction mixture was filtered (Celite®) and 
concentrated under vacuum. Purification by column chromatography (300 : 10 : 1
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DCM : MeOH : NH4OH) yielded two main fractions, 4-methylaniline (270 mg, 17%) 
and 4-aminobenzyl alcohol (1.22 g, 6 6 %) as a dark brown solid: mp 59-61°C; 1H 
NMR (CDCI3) 6 1.65 (brs, 1H, NH or OH), 2.15 (brs, 1H, NH or OH), 3.67 (brs, 1H, 
NH), 4.51 (s, 2H, GH2), 6.64 (d, J  = 8.4 Hz, 2H, Ar 2,6-H2), 7.12 (d, J  = 8.4 Hz, 2H, 
Ar 3,5-H2); NMR (GDGI3) 6 65.11 (GH2), 115.12 (CH), 128.70 (CH), 131.04 (Cq),
145.90 (Cq). MS (FAB+) m/z  123 (M+).
Side product: 4-methylaniline (para-toliddine) 102
Rf = 0.65 (100 : 10 : 1 DGM : MeOH : NH4OH); JH NMR (GDGI3) 6 2.31 (s, 3H, 
CH3), 3.59 (brs, 2H, NH2), 6.63 (d, J  = 8.1 Hz, 2H, Ar 2,6-H2), 7.03 (d, J  = 8.1 Hz, 
2H, Ar 3,5-H2); 13G NMR (GDCI3) 6 21.10 (GH3), 115.44 (CH), 128.51 (Cq), 129.98 
(CH), 145.12 (Cq). MS (El) m /Z 165.0790 (M+) (C7H 9N requires 165.0789).
ProcedureB
4-(fer^Butyldimethylsilyloxy)aniline (500 mg, 2.1 mmol) in THF (5 mL) was stirred at 
0°C for 30 min. TBAF (1.2 mL, 4.2 mmol) was then added and the whole mixture was 
allowed to stir for 30 min at RT. Evaporation and purification by column 
chromatography (10 : 1 CHCI3 : MeOH) yielded 4-aminobenzyl alcohol (167 mg, 
65%) as a dark brown solid: Rf = 0.5 (10:1 CHCI3 : MeOH). Data as above.
Na-(Benzyloxycarbonyl)glutamine 50
Benzyl chloroformate (95%, 11.08 g, 65 mmol) was added to L-glutamine (7.30 g, 50 
mmol) and NaOH (6.0 g, 150 mmol in H20  (100 mL)) at 0°C. The mixture was 
stirred for 24 h. The mixture was washed with Et20  (4x) and the aqueous layer was
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acidified to pH 2-3. The product was extracted into EtOAc (4x 25 mL) and dried. 
Evaporation gave Na-(benzyloxycarbonyl)glutamine (6.31 g, 45%) as a fine white 
powder: mp 138-140°G (Lit.154mp 134-136.5°C): Rf = 0.2 (10 : 1 CHC13: MeOH);1H 
NMR (CDCI3) 6 1.86-2.00 (m, 1H} P-H), 2.12-2.24 (m, 1H, p-H), 2.28-2.38 (m, 2H, y- 
H2), 4.16 (q, J  = 4.7 Hz, 1H, a-H), 5.10 (s, 2H, PhCH2), 7.27-7.33 (m, 3H, 6-CONH2, 
a-NH), 7.33-7.39 (m, 5H, Ph-H5). MS (FAB+) m /Z 281 (M + H). [a]D = - 6.8° (Lit.154 
[a]D = - 6.9°).
N^-fBenzyloxycarbonyl) glutam ine N-hydroxysuccinim ide ester 51
Na-(Benzyloxycarbonyl)glutamine (2.39 g, 10 mmol) in EtOAc (20 mL) was cooled to 
0°C. N-Hydroxysuccinimide (1.15 g, 10 mmol) in EtOAc (10 mL) was added at 0°C 
and the mixture were stirred for 30 min. DGG (2.16 g, 10 mmol) in EtOAc (20 mL) 
was added and the mixture was stirred for 2 h. The suspension was filtered (Celite®) 
and the filtrate was kept at 0°G for 24 h. Filtration and evaporation yielded N“- 
(benzyloxycarbonyl)glutamine hydroxysucdnimide ester (3.91 g, quantitative) as a buff 
coloured gum. This was used without further purification: *H NMR ((CD3)2SO) 6 2.2-
2.5 (m, 4H, Gin p, y-H2), 2.86 (s, 4H, succ-H4), 4.78 (m, 1H, Gin a-H), 5.12 (br, 1H, 
a-NH), 5.49 (s, 1H, 6-CONH), 5.85 (s, 1H, 6-CONH), 5.91 (m, 2H, PhCH2), 7.36 (s, 
1H, Ph-Hs). MS (FAB+) m /z 378 (M + H).
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Na- (Benzyloxycarbony 1) g lu tam ine  pen ta flu o ro p h en y l e s te r  52
F
Na-(Benzyloxycarbonyl)glutamine (1.12 g, 4.0 mmol) in dry THF (8 mL) and dry DMF 
(2 mL) was cooled to 0°C. Pentafluorophenol (0.81 g, 4.4 mmol) in dry THF (6 mL) 
was added at 0°G and the mixture were stirred for 25 min under N2 . DCG (0.91 g, 4.4 
mmol) in dry THF (3 mL) was added and the mixture was stirred for 90 min. The 
suspension was filtered (Celite®) and the filtrate was kept at 0°C for 24 h. Filtration and 
evaporation yielded Na-(benzyloxycarbonyl)glutamine pentafluorophenyl ester (2.29, 
quantitative) as an off-white gum. This was used without further purification. MS 
(FAB+) m /z 437 (M + H).
Na- (Benzyloxy carbonyl)glutam ine N-(2-(4-nitrophenyl)ethyl)am ide 53
2-(4-Nitrophenyl)ethylamine hydrochloride (1.03 g, 5.1 mmol), Et3N (2.1 mL, 15 
mmol) and DMAP (5 mg) were stirred with Na-(benzyloxycarbonyl)glutamine 
pentafluorophenyl ester (2.29 g, 5.1 mmol) in THF (10 mL) and DMF (10 mL) for 6 h. 
The evaporation residue, in EtOAc, was washed with H 2O (3x). Drying, evaporation 
and chromatography (10:1 CHCI3 : MeOH) gave Na-(benzyloxycarbonyl)glutamine 
N-(2-(4-nitrophenyl)ethyl)amide (992 mg, 44%) as a light yellow powder: mp 162-
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164°C. R, = 0.4 (10: 1 CHCls: MeOH); 'H  NMR ((CD3)2SO) 5 1.58-1.70 (m, 1H, P- 
H), 1.70-1.85 (m, 1H, P-H), 1.95-2.12 (m, 2H, y-H2), 2.85 (t, J  = 7.0 Hz, 2H, ArCtfc 
CH2), 3.28-3.40 (m, 2H, ArCH2CH2), 3.83-3.92 (m, 1H, a-H), 5.00 (d, J  = 12.8 Hz, 
1H, PhCHO), 5.03 (d, J  = 12.5 Hz, 1H, PhCHO), 6.76 (brs, 1H, 6-CONH), 7.24 (brs, 
1H, 6-CONH), 7.28-7.62 (m, 5H, Ph-Hj), 7.39 (d, J  = 8.2 Hz, 1H, a-NH), 7.48 (d, J  
= 8.6 Hz, 2H, Ar 2,6-H2), 7.99 (t, J  = 5.7 Hz, 1H, CONHCH2), 8.12 (d, J  = 8.6 Hz, 
2H, Ar 3,5-H2); i3C NMR ((CD3)2SO) 6 27.72 (ArCH2£ H 2), 31.52 (P-C), 34.80 
(ArCH2CH2), 54.61 (a-C), 65.48 (PhCH2), 65.56 (y-C), 123.32 (3-Ph, 5-Ph), 127.71 (4- 
Ph), 127.81 (2-Ar, 6-Ar), 128.37 (3-Ar, 5-Ar), 130.24 (2-Ph, 6-Ph), 137.00 (1-Ar),
146.02 (1-Ph), 147.93 (4-Ar), 155.99 (6-C), 171.62 (CONH), 173.60 (OCONH). MS 
(FAB+) m /z 429.1729 (M + H) (C2iH25N406 requires 429.1772). IR (KBr) 1690 
(Il-amide C =0), 1648 (I-amide C =0), 1605 (Ar), 1518, 1344 (N 02). Anal. 
(C2iH24N4Os) Calc’d C 58.88% H 5.61% N 13.08% Found C 58.70% H 5.69% N 
13.01%. [a]D = - 2.3°.
Glutamine N-(2>(4-mtrophenyl)ethyl)amide hydrobrom ide 54
Ck. ^NH2
Br
Na-(Benzyloxycarbonyl)glutamine N-(2-(4-nitrophenyl)ethyl)amide (120 mg, 0.3 mmol) 
was stirred with AcOH (1.5 mL) and HBr (30% in AcOH) (1.5 mL) for 25 min and 
then concentrated. Et20 (8 mL) was added and the suspension was stirred for 5 min. 
The ether layer was then decanted off and the process repeated 10 times. This solid 
was dried to yield glutamine N-(2-(4-nitrophenyl)ethyl)amide hydrobromide (103 mg, 
96%) as a pale orange powder: mp 148-150°C. Rf = 0.2 (10:1 CHCI3 : MeOH); 
NMR ((CD3)2SO) (COSY 2D) 6 1.80-1.90 (m, 2H, P-H2), 2.00-2.18 (m, 2H, y-H2), 
2.90 (t, J  = 6.6 Hz, 2H, ArC£bCH2), 3.26-3.46 (m, 1H, ArCH2CH2), 3.46-3.58 (m, 1
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H, ArCH2C a ) , 3.72 (q, J  = 5.6 Hz, 1H, a-H), 6.96 (s, 1H, 6-CONH), 7.42 (s, 1H, 6- 
CONH), 7.53 (d ,J =  8.6 Hz, 2H, Ar 2,6-H2), 8.11 (brs, 3H, +NHs), 8.16 (d ,J =  8.6 
Hz, 2H, Ar 3,5-H2), 8.54 (t, J  = 5.5 Hz, 1H, CONHCH2). MS (FAB+) m /z 295 (M + 
H). Anal. (Ci3Hi9BrN4 0 4 .2 H 20 ) Calc’d C 38.00% H 4.62% N 13.60% Found C 
38.20% H 4.68% N 13.40%.
N°-(N“- (1,1 -D imethylethoxycarbonyl) -Ne- (phenylmethoxycarbonyl) lysyl) 
glutam ine N-(2- (4-nitroplienyl)etliyl) am ide 55
o J f i  ^
N“-( 1,1 -Dimethylethoxycarbonyl)-Ne-(phenylmethoxycarbonyl)lysine N-hydroxysucci- 
nimide ester (62 mg, 0.13 mmol), Et3N (50 pL, 0.4 mmol), DMAP (5 mg) and 
glutamine N-(2-(4-nitrophenyl)ethyl)amide hydrobromide (50 mg, 0.13 mmol) were 
stirred in THF (3 mL) and DMF (2 mL) for 16 h. The evaporation residue, in EtOAc, 
was washed with H 2O (3x). Drying, evaporation and recrystallisation (EtOAc /  
hexane) gave N“-(Na-( 1,1 -dimethylethoxycarbonyl)-N8-(benzyloxycarbonyl)lysyl)glut- 
amine N-(2-(4-nitrophenyl)ethyl)amide (40 mg, 47%) as a light yellow powder: mp 
148-150°C. Rf = 0.4 (10 : 1 CHCI3 : MeOH); »H NMR ((GD3)2SO) 6 1.10-1.60 (m, 
8H, Lys p-H2, Lys y-H2j Lys 6-H2), 1.35 (s, 9H, OG(CH3)3), 1.60-1.85 (m, 2H, Gin p- 
H2), 2.00 (t, J  = 7.8 Hz, 2H, Gin y-H2), 2.85 (t, J  = 7.0 Hz, 2H, ArCH^GH2), 2.95 (q, 
J  = 6.0 Hz, 2H, Lys e-H2), 3.20-3.42 (m, 2H, ArCH2CH2), 3.75-3.90 (m, 1H, Lys a- 
H), 4.15 (q, J  = 7.8 Hz, 1H, Gin a-H), 5.00 (s, 2H, PhCH2), 6.76 (s, 1H, Gin 6- 
CONH), 6.94 (d, J  = 7.4 Hz, 1H, Gin a-NH), 7.21 (s, 1H, Gin 6-CONH), 7.24 (t, J  =
5.5 Hz, 1H, PhCH2OCONH), 7.26-7.39 (m, 5H, Ph-H5), 7.48 (d, J  = 8.6 Hz, 2H, Ar
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2,6-H2), 7.82 (d, J  = 7.8 Hz, 1H, Lys a-NH), 8.00 (t, J  = 5.4 Hz, 1H, CONHCH2), 
8.13 (d, J  = 8.6 Hz, 2H, Ar 3,5-H2). MS (FAB+) m /z 657 (M + H). [a]D = - 13.3°..
Na-(N8-(Benzyloxycarbonyl)lysy 1) g lu tam ine N - (2-(4-nitrophenyl) ethyl) 
am ide hydrochloride 56
HC1 was passed through a solution of Na-(Na-(l,l-dimethylethoxycarbonyl)-Ne- 
(benzyloxycarbonyl)lysyl)glutamine N-(2-(4-nitrophenyl)ethyl)amide (40 mg, 0.06 
mmol) in MeOH (10 mL) for 25 min and then concentrated to yield Na-(NE- 
(benzyloxycarbonyl)lysyl)glutamine N-(2-(4-nitrophenyl)ethyl)amide hydrochloride as a 
buff oil (32 mg, quantitative). This was used in the next step without further 
purification: »H NMR ((GD3)2SO) 6 1.20-1.45 (m, 2H, Gin 0-H2), 1.60-2.10 (m, 6H, 
Lys P-H2, Lys y-H2, Lys 6-H2), 2.05 (t, J  = 7.8 Hz, 2H, Gin y-H2) 2.85 (t, J  = 7.0 Hz, 
2H, ArCIfcCH2), 2.95 (q, J  = 6.2 Hz, 2H, Lys e-H2), 3.09 (dt, J  = 7.0 Hz, ArCH2CH£ 
), 3.70-3.80 (m, 1H, Lys a-H), 4.20 (q, J  = 6.0 Hz, 1H, Gin a-H), 5.00 (s, 2H, FhCH2),
6.80 (s, 1H, Gin 6-CONH), 6.90 (d, J  = 7.2 Hz, 1H, CONHCH2), 7.22 (t, J  = 4.3 Hz, 
1H, PhCH2OCONH), 7.26-7.38 (m, 6H, Ph-H5, Gin 6-CONH), 7.48 (d, J  = 8.6 Hz, 
2H, Ar 2.6-H2), 8.12 (d, J  = 8.6 Hz, 2H, Ar 3,5-H2), 8.14-8.23 (m, 3H, +NH3), 8.60 (d, 
J  = 7.8 Hz, 1H, Gin a-NH). MS (FAB+) m /Z 558.2751 (M + H) (C26H37N607 
requires 558.2757).
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Na-(Na- (Na-( 1,1 -D im ethylethoxy carbonyl) leucyl) -N8- (benzyloxy carbonyl)
lysyl) g lu tam ine N -(2-(4-nitrophenyl)ethyl)am ide 57
,NH.
N“-(l,l-Dimethylethoxycarbonyl)leucine N-hydroxysuccinimide ester (30 mg, 0.09 
mmol), Et3N (0.04 mL, 0.27 mmol), DMAP (5 mg) N-(Ne-(benzyloxycarbonyl) 
lysyl)glutamine N-(2-(4-nitrophenyl)ethyl)amide hydrochloride (50 mg, 0.09 mmol) 
were stirred in THF (4 mL) and DMF (1.5 mL) for 16 h. The evaporation residue, in 
EtOAc, was washed with H 2O (3x). Drying, evaporation and recrystallisation (EtOAc 
/  hexane) gave Na-(Na-(Na-(l, 1 -dimethylethoxycarbonyl)leucyl)-NE-(benzyloxycarbon 
yl)lysyl)glutamine N-(2-(4-nitrophenyl)ethyl)amide (25 mg, 37%) as an off-white 
powder: mp 156-158°C; lH NMR ((GD3)2SO) (COSY 2D) 6 0.77-0.90 (m, 6H, Leu y- 
(CH3)2), 1.35 (s, 9H, OC(CH3)3), 1.18-1.82 (m, 10H, Lys P-H2,Lys y-H2, Lys 6-H2,Leu 
P-H2, Leu y-H, Gin P-H2), 1.94-2.00 (m, 2H, Gin y-H2) 2.82 (t, J  = 6.6 Hz, 2H, 
ArCIfcCHz), 2.93 (q, J  = 6.6 Hz, 2H, Lys e-H2), 3.20-3.38 (m, 2H, ArCH 2CH2), 3.92 
(q, J  = 6.2 Hz, 1H, Lys a-H), 4.04-4.12 (m, 1H, Glu a-H), 4.15-4.24 (m, 1H, Leu a- 
H), 4.98 (s, 2H, PhCH2), 6.74 (brs, 1H, Gin 6-CONH), 6.96 (d, J  = 7.4 Hz, 1H, 
CONHCH2), 7.20 (brs, 1H, FhCH2OCONH, Gin 6-CONH), 7.25-7.37 (m, 5H, Ph- 
Hs), 7.46 (d, J  = 8.6 Hz, 2H, Ar 2,6-H2), 7.78 (d, J  = 7.8 Hz, 1H, Lys a-NH), 7.88- 
7.98 (m, 1H, Leu a-NH), 8.01 (m, 1H, Gin a-NH), 8.11 (d, J  = 8.6 Hz, 2H, Ar 3,5- 
H2). MS (FAB+) m /Z 770 (M + H).
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Na-(Fluoren-9-yIm ethoxycarbonyl) glutam ic acid  N -(2-(4-nitrophenyl) 
ethyl) am ide 6-(l,l-d im ethylethyl)ester 59
2-(4-Nitrophenyl)ethylamine hydrochloride (103 mg, 0.51 mmol) was stirred with Na- 
(fluoren-9-ylmethoxycarbonyl)glutamic acid 6-(l,l-dim ethylethyl) ester a- 
pentafluorophenyl ester (300 mg, 0.51 mmol) and Et3N (0.21 mL, 1.5 mmol) in 
CH2CI2 (5.0 mL) for 16 h. The evaporation residue, in EtOAc, was washed with H 2O 
(3x). Drying, evaporation and recrystallisation (EtOAc /  hexanes) gave N“-(fluoren-9- 
ylmethoxycarbonyl)glutamic acid N-(2-(4-nitrophenyl)ethyl)amide 6-(l,l-dimethyl 
ethyl)ester (190 mg, 65%) as a fine off-white powder: mp 138-140°C. R f = 0.9 (10:1 
CHCls: MeOH); !H NMR (GDCI3) 6 1.40 (s, 9H, OC(CH3)3), 1.78-2.08 (m, 4H, 0- 
H2, Y-H2), 2.90 (t, J  = 6.6 Hz, 2H, ArCHsCHa), 3.55 (q, J  = 6.2 Hz, 2H, ArCH2CIfc), 
4.02-4.12 (m, 1H, a-H), 4.19 (t, J  = 7 Hz, 1H, Flu 9-H), 4.30-4.42 (m, 2H, FluCH2), 
5.70 (d, J  = 6.2 Hz, 1H, a-NH), 6.44 (br, 1H, CONHCH2), 7.29 (t, J  = 7.3 Hz, 2H, 
Flu 3,6-H2), 7.32 (d, J  = 8.4 FFz, 2H, Ar 2,6-H2), 7.38 (t, J  = 7.3 Hz, 2H, Flu 2,7-H2), 
7.55 (d, J  = 7.3 Hz, 2H, Flu 1,8-H2), 7.75 (d, J  = 7.7 Hz, 2H, Flu 4,5-H2), 8.12 (d, J  = 
8.4 Hz, 2H, Ar 3,5-H2); 13C NMR (CDCI3) 6 27.91 (OC(CH3)3)} 27.98 (OC(CH3)3), 
31.51 (ArGH2GH2), 35.57 (P-C), 40.12 (ArGH2GH2), 41.14 (FluCH2), 47.00 (a-G), 54. 
46 (9-Flu), 67.12 (y-C), 81.22 (GONHCH2), 119.92 (3-Ar, 5-Ar), 123.78 (2-Ar, 6-Ar),
124.90 (4-Flu, 5-Flu), 127.01 (2-Flu, 7-Flu), 127.72 (1-Flu, 8-Flu), 129.65 (3-Flu, 6-Flu), 
141.24 (1-Ar), 143.60 (4-Ar), 146.44 (2x quat.-Flu), 146.74 (2x quat.-Flu), 171.40 (6-C),
173.80 (OGONFF). MS (FAB+) m /z 574 (M + FF).
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N°-(N°-(1 ,l-D im e th y le th o x y c a rb o n y l) le u c y l)g lu ta m in e  N -(2 -(4 -n itro
phenyl) ethyl) am id e  60
N“-(l,l-Dimethylethoxycarbonyl)leucine N-hydroxysuccinimide ester (290 mg, 0.89 
mmol), Et3N (0.37 mL, 2.66 mmol) and DMAP (1 mg) were stirred with glutamine N- 
(2-(4-nitrophenyl)ethyl)amide hydrobromide (332 mg, 0.89 mmol) in THF (2 mL) and 
DMF (3 mL) for 16 h. The evaporation residue, in EtOAc, was washed with H 2O (3x). 
Drying, evaporation and recrystallisation (EtOAc /  hexane) gave N“-(N“-(1,1- 
dimethylethoxycarbonyl)leucyl)glutamine N-(2-(4-nitrophenyl)ethyl)amide (225 mg, 
50%) as a light brown powder: Rf = 0.4 (10:1 CHCI3 : MeOH); *H NMR ((GD3)2SO) 
6 0.82 (d, J  = 5.9 Hz, 3H, Leu y-CHs), 0.84 (d, J  = 5.9 Hz, 3H, Leu y-CH3), 1.35 (s, 
9H, OC(CH3)3), 1.38 (m, 2H, Leu P-H2), 1.60 (m, 1H, Leu y-H), 1.66-1.80 (m, 2H, 
Gin P-H2), 1.97 (t, J  = 7.2 Hz, 2H, Gin y-H2), 2.83 (t, J  = 6.9 Hz, 2H, ArCH2), 3.24-
3.40 (m, 2H, ArCH2CH2), 3.90 (m, 1H, Leu a-H), 4.12 (m, 1H, Gin a-H), 6.73 (br, 1 
H, 6-CONH), 6.97 (d, J  = 7.9 Hz, 1H, a-NH), 7.20 (br, 1H, 6-CONH), 7.46 (d, J  = 
8.7 Hz, 2H, Ar 2,6-H2), 7.76 (d, J  = 8.0 Hz, 1H, a-NH), 7.98 (t, J  = 5.7 Hz, 1H, 
NHCH2), 8.12 (d, J  = 8.9 Hz, 2H, Ar 3,5-H2). MS (FAB+) m /z 508.2773 (M + H) 
(C24H 38N5O 7 requires 508.2771).
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N°-(N °-(Leucyl)glutam ine N -(2 -(4-n itrophenyl)ethy l)am ide trif lu o ro a ce d c
ac id  s a lt  61
c f3c o 2
H3N: 4 U x v ,y H* XX,
Na-(Na-( 1 , 1  -Dimethylethoxycarbonyl)leucyl)glutamine N-(2-(4-nitrophenyl)ethyl) 
amide (221 mg, 0.44 mmol) was stirred with TFA (1 mL) in DCM (2 mL) at RT for 30 
min. Evaporation gave ^-(N^-fleucylJglutamine N-(2-(4-nitrophenyl)ethyl)amide 
trifluoroacedc acid salt (352 mg, 65%) as a brown oil: NMR ((CD3)2SO) 6  0.84 (d, J
= 5.9 Hz, 3H, Leu y-CHs), 0.87 (d, J  = 6.2 Hz, 3H, Leu y-CH3), 1.45-1.83 (m, 5H, 
Leu p, Y-H3 + Gin P-H2), 1.95-2.07 (m, 2H, Gin Y-H2), 2.85 (brt, J  = 5.8 Hz, 2H, Ar 
GH2), 3.35 (m, 2H, ArCH2GH2), 3.76 (m, 1H, Leu a-H), 4.72 (m, 1H, Gin a-H), 6.78 
(m, 1H, 6-CONH), 7.24 (br, 1H, 6-CONH), 7.47 (d, J  = 8.9 Hz, 2H, Ar 2,6-H2), 8.07 
(m, 1H, NHCH2), 8.12 (d, J  = 8.7 Hz, 2H, Ar 3,5-H2), 8.61 (d, J  = 7.9 Hz, 1H, Gin a- 
NH). MS (FAB+) m/z  409 (M).
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Na- (Na-(N8- (1,1 -Dimethylethoxycarbonyl) -N°- (fluoren-9-ylmethoxy- 
carbonyl)lysyl)leucyl)glutam ine N-(2-(4-nitrophenyl)ethyl)am ide 62
T
Ne-( 1,1 -Dimethylethoxycarbonyl)-Na-(fluoren-9-ylmethoxycarbonyl)lysine N-hydroxy 
succinimide ester (382 mg, 0.68 mmol), EtsN (0.28 mL, 205 mg, 2.03 mmol) and 
DMAP (1 mg) were stirred with IST-^Leucyl)glutamine N-(2-(4-nitrophenyl)ethyl)amide 
trifluoroacetic acid salt (352 mg, 0.68 mmol) in THF (2 mL) and DMF (3 mL) for 14 h. 
The evaporation residue, in EtOAc, was washed with H 2O (3x). Drying, evaporation 
and recrystallisation (EtOAc /  hexane) gave Nct-(Na-(Ne-(l, 1 -dimethylethoxycarbonyl)- 
N°-(fluoren-9-ylmethoxycarbonyl)lysyl)leucyl)glutamine N-(2-(4-nitrophenyl)ethyl) 
amide (243 mg, 41%) as a light brown solid: Rf = 0.5 (10 : 1 CHCI3 : MeOH); *H 
NMR ((CD3)2SO) 6 0.83 (m, 6H, 2x Leu y-GHs), 1.34 (s, 9H, OC(CH3)3), 1.20-1.80 
(m, 11H, Lys p, y, 5-H6 + Leu P, y-H3 + Gin P-H2), 1.97 (t, J  = 7.2 Hz, 2H, Gin y-H2), 
2.48 (t, J  = 6.9 Hz, 2H, ArCH2), 2.84 (m, 4H, 2x GH2N), 3.72 (m, 1H, Leu a-H), 3.94 
(m, 1H, Lys a-H), 4.06-4.30 (m, 4H, Gin a-H  + Flu 9-H + FluCH2), 6.75 (m, 3H, 2x 
NH + Gin 6-CONH), 7.20 (br, 1H, Gin 6-CONH), 7.30 (t, J  = 7.4 Hz, 2H, Flu 2,7- 
H2), 7.40 (t, J  = 7.2 Hz, 2H, Flu 3,6-H2), 7.45 (d, J  = 8.7 Hz, 2H, Ar 2,6-H2), 7.70 (d, 
J  = 8.0 Hz, 1H, a-NH), 7.72 (d, J  = 7.2 Hz, 2H, Flu 1,8-H2), 7.87 (d, J  = 7.2 Hz, 2H, 
Flu 4,5-H2), 7.95 (m, 1H, NHCH2), 8.02 (m, 1H, NH), 8.13 (d, J  = 8.7 Hz, 2H, Ar 
3,5-H2).
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3-(2,4-D initrophenyl) p ro p an o ic  ac id  70
“OH
NO.
3-Phenylpropanoic acid (2.00 g, 13.3 mmol) was added at 0°C to an ice-cold stirred 
mixture of conc. H 2SO4 (15 mL) and conc. HNO 3 (5 mL). The solution was stirred for 
a further 2 d, extracted in to EtOAc and washed with H 2O (3x). The organic layer was 
then dried, concentrated and purified by chromatography (9 : 1 CHCI3 : MeOH). 
Recrystallisation (EtOAc /  hexane) yielded 3-(2,4-dinitrophenyl)propanoic add (1.95 
g, 61%) as fine yellow needles: mp 126-128°C. (Lit.122 mp 125.5-126.5°C). Rf= 0.35 (9 
: 1 CHCls : MeOH); NMR ((GD3)2SO) 6 2.65 (t, J  = 7.4 Hz, 2H, ArCH2Gifc),
3.15 (t, J  = 7.4 Hz, 2H, ArCHa), 7.86 (d, J  = 8.4 Hz, 1H, 6’-H), 8.45 (dd, J  = 8.4, 2.2 
Hz, 1H, 5VH), 8.69 (d, J  = 2.4 Hz, 1H, 3’-H), 12.37 (brs, 1H, OH); 13C NMR 
((CD3)2SO) 6 27.11 (ArCH2), 33.72 (ArCH2GH2), 119.82 (6-Ar), 127.20 (5-Ar), 133.50 
(3-Ar), 142.51 (1-Ar), 146.16 (2-Ar), 149.18 (4-Ar), 173.12 (CO2H). MS (FAB+) m/z 
240 (M).
3-(4-Nitrophenyl) propanoic acid 72
“OH
3-Phenylpropanoic acid (2.00 g, 13.3 mmol) was added at 0°C to an ice-cold stirred 
mixture of conc. H 2SO4  (15 mL) and HNO3 (5 mL). The solution was stirred for 2 h, 
extracted in to EtOAc and washed with H 2O (3x). The organic layer was then dried, 
concentrated and purified by chromatography (10 : 1 CHCI3 : MeOH). Re­
crystallisation (EtOAc /  hexane) yielded 3-(4-nitrophenyl)propanoic acid (894 mg, 
34%) as fine white needles: mp 165-167°G. (Lit.123 mp 165°C). Rf = 0.38 (10 : 1
126
CHCh : MeOH); »H NMR ((CD3)2SO) 6 2.64 (t, J  = 7.4 Hz, 2H, ArCH2CH2), 2.96 (t, 
J  = 7.4 Hz, 2H, ArCHg), 7.54 (d, J  = 7.0 Hz, 2H, 2’,6>-H2), 8.17 (d, J  = 7.0 Hz, 2H, 
3’,5’-H2), 12.30 (brs, 1H, OH); NMR ((GD3)2SO) 6 30.12 (ArCH2), 34.40 
(AtCHjjGH^, 123.46 (2-Ar, 6-Ar), 129.64 (3-Ar, 5-Ar), 145.91 (1-Ar), 149.32 (4-Ar),
173.40 (G02H). MS (FAB+) m/Z 196 (M + H).
2-(4-Nitrophenyl) ethyl isocyanate 75
3-(4-Nitrophenyl)propanoic acid (200 mg, 1.0 mmol) was stirred with thionyl chloride 
(2 mL) and DMF (2 drops) at 85°G for 14 h. Evaporation gave crude 3-(4- 
nitrophenyl)propanoyl chloride as a yellow solid: IR (KBr) vm» 1793 (C=0), 1607 
(Ar), 1519, 1346 (N 02). This material was dissolved in acetone (3 mL) and added to 
sodium azide (200 mg, 3 mmol) in H20  (2 mL) and the mixture was stirred at RT for 3 
h. Evaporation at 25°G gave a solid which was extracted with CH2C12 (3x 10 mL) and 
washed with H20  (3x). The combined organic extracts were dried and the solvent was 
evaporated to give 3-(4-nitrophenyl)propanoyl azide. IR (film) Vmax 2139 (N3), 1700 
(C=0), 1653 (C=0), 1518, 1346 (N 02). This material, in dry toluene (10 mL) was 
heated under reflux for 100 min. Evaporation afforded 2-(4-nitrophenyl)ethyl 
isocyanate (120 mg crude) as orange needles: mp 140-142°C. The isocyanate was used 
without further purification. IR (KBr) Vmax 2272 (N=C=0), 1518, 1346 (N 02).
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N a- (1,1 -D im ethyloxycarbonyl) g lu tam ine  p en ta flu o ro p h en y l e s te r  78
,NH.
Na-(l,l-Dimethyloxycarbonyl)glutamine (2.05 g, 10 mmol) in EtOAc (50 mL) was 
cooled to 0°G. Pentafluorophenol (0.81 g, 4.4 mmol) in EtOAc (10 mL) was added at 
0°G and the mixture were stirred for 30 min. DGG (2.16 g, 10 mmol) was added and 
the mixture was stirred for 2 h. The suspension was filtered (Celite®) and the filtrate 
was kept at 0°G for 24 h. Filtration and evaporation yielded Na-(1,1- 
dimethyloxycarbonyl)glutamine pentafluorophenyl ester (2.95 g, quantitative) as a 
colourless gum. This was used without further purification: TO NMR ((CD3)2SO) 6
1.40 (s, 9H, OC(CH3)3), 1.92 (m, 1H, Gin P-H), 2.09 (m, 1H, Gin p-H), 2.26 (t, J  = 7.4 
Hz, 2H, Gin y-H2), 4.32 (m, 1H, Gin a-H), 5.57 (d, J  = 7.8 Hz, 0.1H, a-NH), 6.86 (s, 
1H, 6-CONH), 7.35 (s, 1H, 6-CONH), 7.72 (d, J  = 7.0 Hz, 0.9H, a-NH); 19F NMR 
(DMSO) 6 -162.21 (dd, J  = 22.3, 18.4 Hz, 1.8F, 3,5-F2), -162.04 (t, J  = 19 Hz, 0.2F,
3,5-F2), -157.61 (t, J  = 18.0 Hz, 0.9F, 4-F), -157.38 (t, J  = 17.4 Hz, 0.1F, 4-F), -153.57 
(d, J  = 20.3 Hz, 0.2F, 2,6-F2), -153.27 (d, J  = 21.6 Hz, 1.8F, 2,6-F2). MS (FAB+) m/z 
413 (M + H).
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Na-(1 ,1 -D im e  th y  le th o x y  c a rb o n y l)  g lu ta m in e  N -(4-m e  th o x y  c a rb o n y l
phenyl) am id e  80
N“-( 1,1 -Dimethylethoxycarbonyl)glutamine (0.99 g, 4.0 mmol) was stirred in dry THF 
(12 mL) at 0°C with pivaloyl chloride (603 mg, 5.0 mmol) and EtsN (0.56 mL, 4.0 
mmol) for 30 min. Methyl 4-aminobenzoate (760 mg, 5.0 mmol) was added and the 
mixture was brought to RT and stirred for 2 h. The evaporation residue, in EtOAc, 
was washed with H 2O (3x). Drying, evaporation and chromatography (9 : 0.5 CHCI3 : 
MeOH) gave Na-(l,l-dimethylethoxycarbonyl)glutamine N-(4-methoxycarbonyl- 
phenyl)amide (820 mg, 54%) as a white powder: mp 190-192°G. Rf = 0.35 (10:1  
CHCI3 : MeOH); JH NMR ((CD3)2SO) 6 1.30 (s, 9H, OC(CH3)3), 1.70-1.95 (m, 2H, 0-
13C NMR ((CD3)2SO) 6 27.21 (OC(GH3)3), 28.21 (OC(CH3)3), 31.46 (0-C), 51.94 (CH3
143.41 (4-Ar), 155.47 (6-C), 165.82 (GONHAr), 171.70 (OCONH), 173.69 (ArGO). 
MS (FAB+) m/z 380 (M + H). [a]D = + 5.2°.
O
H2), 2.05-2.22 (m, 2H, y-H2), 3.80 (s, 3H, GH3) 4.05 (q, J  = 7.0 Hz, 1H, a-H), 6.78 (s, 
1H, 6-CONH), 7.14 (d, J  = 7.0 Hz, 1H, a-NH), 7.28 (s, 1H, 6-GONH), 7.73 (d, J  =
7.4 Hz, 2H, Ar 2,6-H2), 7.91 (d, J  = 7.4 Hz, 2H, Ar 3,5-H2), 10.28 (s, 1H, CONHAr);
), 54.90 (a-G), 78.20 (y-C), 118.68 (2-Ar, 6-Ar), 123.94 (1-Ar), 130.33 (3-Ar, 5-Ar),
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Na-(FIuoren-9-ylmethoxycarbonyl)-Oy-(1 , 1-dim e thyle thy 1)glutam ic acid N- 
(4-methoxycarbonylphenyl) am ide 87
.OMe
N“-(Fluoren-9-ylmethoxycarbonyl)-0Y-(l, 1 -dimethylethyl)glutamic acid (1.70 g, 4.0 
mmol) was stirred in dry THF (12 mL) at 0°C with pivaloyl chloride (603 mg, 5.0 
mmol) and Et3N (0.56 mL, 4.0 mmol) for 30 min. Methyl 4-aminobenzoate (760 mg,
5.0 mmol) was added and the mixture was brought to RT and stirred for 2 h. The 
evaporation residue, in EtOAc, was washed with H 2O (3x). Drying, evaporation and 
chromatography (9 : 0.5 CHCI3 : MeOH) gave N“-(fluoren-9-ylmethoxycarbonyl)-0Y- 
(l,l-dimethylethyl)glutamic acid N-(4-methoxycarbonylphenyl)amide (1.42 g, 63%) as 
a white powder: Rf = 0.5 (9 : 0.5 CHCI3 : MeOH); *H NMR ((CD3)2SO) 6 1.44 (s, 9H, 
OC(CH3)3), 2.04 (m, 1H, Glu P-H), 2.13 (m, 1H, Glu P-H), 2.40 (dt, J  = 16.6, 6.5 Hz, 
1H, Glu v-H), 2.55 (dt, J  = 16.6, 6.4 Hz, 1H, Glu y-H), 3.88 (s, 3H, OMe), 4.17 (t, J  =
6.9 H, 1H, Flu 9-H), 4.36 (m, 1H, Glu a-H), 4.39 (d, J  = 6.9 Hz, 2H, FluCH2), 5.98 
(d, J  = 7.7 Hz, 1H, Glu a-NH), 7.25 (t, J  = 7.4 Hz, 2H, Flu 2,7-H2), 7.36 (t, J  = 7.4 
Hz, 2H, Flu 3,6-H2), 7.52-7.60 (m, 4H, Ar 2,6-H2 + Flu 1,8-H2), 7.73 (d, J  = 7.6 Hz, 
2H, Flu 4,5-H2), 7.95 (d, J  = 8.7 Hz, 2H, Ar 3,5-H2), 8.99 (br, 1H, NH). MS (FAB+) 
m/z 559.2432 (M + H) (C32H35N20 7 requires 559.2444), 503 (M -  Me2C=CH2).
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P yrog lu tam ic  ac id  N -(4-m ethoxycarbonyl) am id e  90
N°-(l ,l-Dimethylethoxycarbonyl)glutamine N-(4-methoxycarbonylphenyl)amide (25 
mg, 0.06 mmol) was stirred in TFA (1.0 mL) for 20 min. Evaporation gave a mixture 
of pyroglutamic acid N-(4-methoxycarbonyl)amide and ammonium trifluoroacetate: 
m  NMR ((CD3)2SO) 6 1.80-2.20 (m, 4H, Pyg p, y-H4), 3.80 (s, 3H, OMe), 4.42 (m, 
1H, Pyg a-H), 7.28 (t, J  = 51.2 Hz, 4H, +NH4), 7.78 (m, 2H, Ar 2,6-H2), 7.91 (m, 2H, 
Ar 3,5-H2), 8.61 (br, 1H, PygNH), 11.43 (s, 1H, ArNH).
S'-3-(l, 1-Dim ethylethoxycarbonylam ino)piperidine-2,6-dione 96
N“-(l,l-Dimethyloxycarbonyl)glutamine (2.00 g, 8.12 mmol) in dry THF (15 mL) was 
stirred with EDC (1.71 g, 8.93 mmol) and HOBt (1.20 g, 8.93 mmol) at 0°G for 30 
mins. 4-Aminobenzyl alcohol (1.00 g, 8.12 mmol) and Et3N (1.24 mL, 904 mg, 8.12 
mmol) in dry THF (10 mL) was added and the mixture was allowed to stir at RT for a 
further 16 h. The suspension was filtered (Celite®) and the filtrate evaporated. The 
evaporation residue, in EtOAc, was washed with H 20  (3x), dried and concentrated to 
yield S-3-(l, 1 -dimethylethoxycarbonylarnino)piperidine-2,6-dione (950 mg, 51%) as a 
brown oil: Rf = 0.5 (EtOAc); *H NMR (CDCls) 6 1.44 (s, 9H, OG(CH3)3), 1.86 (m, 
1H, 4-H), 2.47 (m, 1H, 4-H), 2.65 (ddd, J  = 18.0, 10.3, 5.2 Hz, 1H, 5-H), 2.76 (ddd, J  
= 18.0, 5.7, 2.3 Hz, 1H, 5-H), 4.31 (m, 1H, 3-H), 5.40 (d, J  = 6.0 Hz, 1H, BocNH), 
8.55 (br, 1H, NH). MS (FAB-) m/Z 227 (M - H).
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N°- (F luoren-9-yIm ethoxycarb o n y l) leu c in e  N - (4 -h y d roxym ethy lpheny l) -
am id e  99
N“-(Fluoren-9-ylmethoxycarbonyl)leucine (283 mg, 0.8 mmol), Et3N (162 mg, 1.6 
mmol) and DMAP (1 mg) were stirred with EEDQ,(198 mg, 0.8 mmol) in DGM (4 
mL) for 30 mins at 0°C. 4-Aminobenzyl alcohol (98 mg, 0.8 mmol) was then added to 
the mixture and allowed to stir for 16 h at RT. The evaporation residue, in EtOAc, 
was washed with H 2O (3x) and brine (2x). Drying, evaporation and column 
chromatography (9 : 1 CHCI3 : hexane) afforded Na-(fluoren-9-ylmethoxycarbonyl) 
leucine N-(4-hydroxymethylphenyl)amide (270 mg, 72%) as a white powder: Rf = 0.85 
(10 : 1 CHCI3 : MeOH); »H NMR (CDCls) 6 0.93 (m, 6H, 2x Leu y-CH3), 1.62-1.77
4-Aminobenzyl alcohol (2.5 g, 20 mmol) in dioxane (13 mL), water (13 mL) and 
NaOH (1M) (20 mL) was cooled to 0°G and allowed to stir. Di-fer£-butyl
(m, 3H, Leu p, y-Hs), 4.10 (t, J  = 6.7 Hz, 1H, Flu 9-H), 4.25-4.45 (m, 3H, Leu a-H + 
FhiCH2), 4.51 (s, 2H, ArCH20), 5.81 (d, J  = 8.2 Hz, 1H, Leu a-NH), 7.10 (t, J  = 7.9 
Hz, 2H, Flu 2,7-H2), 7.23 (t, J  = 7.2 Hz, 2H, Flu 3,6-H2), 7.30-7.40 (m, 4H, Ar-H4), 
7.50 (d, J  = 7.7 Hz, 2H, Flu 1,8-H2), 7.71 (d, J  = 7.4 Hz, 2H, Flu 4,5-H2), 8.84 (s, 1H, 
ArNH). MS (FAB+) m/z 459 (M + H), 441 (M -  OH).
4- (N- (1,1 -Dimethylethoxycarbonyl) am ino)benzyl alcohol 100
H
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pyrocarbonate (6.7 g, 30 mmol) was added in one portion, and the mixture was stirred 
at RT for 12 h. The evaporation residue, in EtOAc, was washed with H 2O (3x). 
Drying, evaporation and purification by column chromatography ( 1 : 1  EtOAc : 
hexane) afforded 4-(N-(l, 1 -dimethylethoxycarbonyl)amino)benzyl alcohol (3.9 g, 89%) 
as a light brown oil. Rf = 0.4 (1 : 1 EtOAc : hexane); NMR (CDCI3) 6 1.51 (s, 9H, 
OC(GH3)3), 2.35 (s, 1H, OH), 4.56 (s, 2H, GH2), 6.71 (brs, 1H, NH), 7.22 (d, J  = 8.3 
Hz, 2H, Ar 2,6-H2), 7.31 (d, J  = 8.3 Hz, 2H, Ar 3,5-H2). MS (FAB+) m /z  223 (M+).
1 - ((1,1 -Dimethylethyl) dim e thyIsilyloxym e thy 1) -4-nitrobenzene 104
To a solution of 4-nitrobenzyl alcohol (5.65 g, 36.9 mmol) in dry DMF (15 mL), were 
added, TBDMS (8.84 g, 58.7 mmol) and imidazole (8.29 g, 122 mmol) and then the 
reaction mixture was stirred at RT for 2.5 h under nitrogen. Evaporation and 
purification by column chromatography (25 : 75 hexane : toluene) afforded 1-((1,1- 
dimethylethyl)dimethylsilyloxymethyl)-4-nitrobenzene (6.4 g, 64%) as yellow crystals: 
mp 30-32°C. (Lit.156 mp 30.5-32.5°C). Rf = 0.4 (25 : 75 hexane : toluene); ]H NMR 
(GDGls) 6 0.11 (s, 6H, SiMe2), 0.94 (s, 9H, OC(CH3)3), 4.82 (s, 2H, CH2), 7.47 (d, J  =
8.4 Hz, 2H, Ar 2,6-H2), 8.18 (d, J  = 8.6 Hz, 2H, Ar 3,6-H2). MS (FAB+) m /Z 268 (M 
+ H). Anal. (Ci3H23NOSi) Calc’d G 65.8% H 9.87% N 5.96% Found C 65.75% H 
9.78% N 5.90%.
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N ,N ’-Bis (4- (d im eth y l(l, 1 -d im ethylethyl) silyloxym ethyl) azoxybenzene 105
l-((l,l-Dimethylethyl)dimethylsilyloxymethyl)-4-nitrobenzene (1.07 g, 4.0 mmol) was 
stirred with sodium borohydride (608 mg, 16.0 mmol) in H 2O (6.0 mL) and MeOH 
(50 mL) in the presence of Pd/G (10%, 100 mg) for 4 h. Filtration (Celite®) and 
evaporation gave a semi-solid, which in EtOAc, was washed with H 2O (3x) and brine 
(2x). Drying and evaporation gave N,N,-bis(4-(dimethyl(l,l-dimethylethyl)silyloxy 
methyl)azoxybenzene (1.50 g, 77%) as a buff oil: Rf = 0.8 (25 : 75 hexane : toluene); 
lH NMR (CDCI3) 6 0.09 (s, 6H, SiMe2), 0.14 (s, 6H, SiMe2), 0.94 (s, 9H, OC(CH3)3), 
0.97 (s, 9H, OC(CH3)3), 4.63 (s, 2H, CH2), 4.83 (s, 2H, CH2), 6.64 (d, J  = 8.2 Hz, 2H, 
Ar 2,6-H2), 7.11 (d, J  = 8.2 Hz, 2H, Ar 3,5-H2), 7.48 (d, J  = 8.2 Hz, 2H, Ar’ 3,5-H2), 
8.19 (d J  = 7.9 Hz, 2H, Ar’ 2,6-H2). MS (FAB+) m /z 487.2815 (M + H) (G26H43 
N203Si2 requires 487.2812).
4-Amino-1 - ((1,1 -dimethylethyl) dim e thylsilyloxym ethyl) benzene 106
l-((l,l-Dimethylethyl)dimethylsilyloxymethyl)-4-nitrobenzene (504 mg, 2.0 mmol) was 
stirred with sodium borohydride (760 mg, 16.0 mmol) in H 2O (6.0 mL) and MeOH 
(50 mL) in the presence of Pd/C (10%, 100 mg) for 5 h at RT. Filtration (Celite®) and 
evaporation gave a semi-solid, which in EtOAc, was washed with H 2O (3x) and brine 
(3x). Drying and evaporation gave 4-amino-1-(( 1,1-dimethylethyl)dimethylsilyloxy- 
methyl)benzene (350 mg, 74%) as a brown oil: Rf = 0.77 (25 : 75 hexane : toluene); *H
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NMR (CDCI3) 6  0.16 (s, 6 H, SiMe2), 1 . 0 1  (s, 9H, OC(GH3)3), 3.60 (br, 2 H, NH2), 4.69 
(s, 2H, CH2), 6 . 6 6  (d, J  = 8 . 6  Hz, 2H, Ar 3,6-H2), 7.16 (d, J  = 8.4 Hz, 2H, Ar 2,6-H2). 
MS (FAB+) m /z  238 (M + H), 237 (M), 180, 106. Anal. (Ci3H2iN 03Si) Calc’d G 
58.5% H 7.92% N 5.36% Found C 58.39% H 7.93% N 5.24%.
1 .l-D im ethyl-3-(4-trifluoroacetam idophenyl)prop-2-yn-l-ol 126
OH
N-(4-Iodophenyl)trifluoroacetamide (700 mg, 2.2 mmol) was stirred with (PPh3)2PdCl2 
(60 mg), Cul (70 mg), 2-methyl-3-butyn-2-ol (0.33 mL, 280 mg, 3.3 mmol) in dry Et3N 
(7 mL) and dry THF (17 mL) at 45°G for 2 d under nitrogen. Filtration (Celite®), 
evaporation and column chromatography (10:1 CHC13: MeOH) gave 1,1-dimethyl-
3-(4-trifluoroacetamidophenyl)prop-2-yn-l-ol (230 mg, 39%) as a white crystalline 
solid: mp 118-120°C. (Lit. “ 2 mp 120-122°C). Rf = 0.4 (10 : 1 CHC13 : MeOH); lH 
NMR (GDG13) 6 1.59 (s, 6H, C(Me)2), 2.48 (br, 1H, OH), 7.37 (d, J  = 8.6 Hz, 2H, Ar
2,6-H2), 7.53 (d, J  = 8.6 Hz, 2H, Ar 3,5-H2), 8.83 (brs, 1H, NH). MS (FAB+) m /z  
271.0820 (M + H) (Ci3Hi2N 0 2F3 requires 271.0820).
N-(4-Iodophenyl)trifluoroacetam ide 129
4-Iodoaniline (1.0 g, 4.6 mmol) was stirred with ethyl trifluoroacetate (5.4 mL, 6.49 g,
45.7 mmol) and Et3N (0.63 mL, 4.6 mmol) in DCM (15 mL) for 16 h at RT. The 
evaporation residue, in EtOAc, was washed with H20  (3x) and saturated sodium
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bicarbonate (3x) and dried. Evaporation gave N-(4-iodophenyl)trifluoroacetamide 
(1.03 g, 66%) as light brown needles: mp 135-137°C. (Lit.142 mp 136-138°C); 
NMR (GDGls) 6 7.33 (d, J  = 8.9 Hz, 2H, Ar 2,6-H2), 7.69 (d, J  = 8.9 Hz, 2H, Ar 3,5- 
H2), 7.91 (brs, 1H, NH); 13C NMR (GDC13) 6 76.85 (Ar 4-C), 114.79 (Ar 2,6-C2), 
135.37 (Ar 3,5-G2), 143.56 (Ar 1-G), [the F3CCO signals were obscured by the noise]. 
MS (FAB+) m/z 315 (M + H).
1,1-Dim e thylethoxy carbonyl N - (4-iodophenyl) carbam ate 131
4-Iodoaniline (1.5 g, 6.9 mmol) was stirred with di-ferf-butyl dicarbonate (2.98 g, 13.7 
mmol) in DGM (30 mL) for 18 h. The evaporation residue, in EtOAc, was washed 
with H20  (3x ) and aq. citric add (3x) and dried. Evaporation gave 1,1-dimethylethoxy 
carbonyl N-(4-iodophenyl)carbamate (2.64 g, 83%) as a colourless oil: *H NMR 
((GD3)2SO) 6 1.47 (s, 9H, OG(CH3)3), 7.29 (d, J  = 7.7 Hz, 2H, Ar 2,6-H2), 7.57 (d, J  =
7.4 Hz, 2H, Ar 3,5-H2), 9.47 (brs, 1H, NH). MS (FAB+) m/z 319.0073 (M + H) 
(CnHi4N02I requires 319.0069).




1,1-Dimethylethoxycarbonyl N-(4-iodophenyl)carbamate (180 mg, 0.56 mmol) was 
stirred with (PPh3)2PdCl2 (15 mg), Cul (20 mg), 2-methyl-3-butyn-2-ol (0.08 mL, 71
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mg, 0.84 mmol) in dry diisopropylamine (2 mL) and dry THF (5 mL) at 45°C for 2 d 
under nitrogen. Filtration (Celite®), evaporation and column chromatography (10:1 
CHCI3 : MeOH) gave 1,1 -dimethyl-3-(4-( 1,1 -dimethylethoxycarbonylamino)phenyl) 
prop-2-yn-l-ol (80 mg, 52%) as a cream solid: Rf = 0.5 (10 : 1 CHCI3 : MeOH); *H 
NMR (CDCI3) 6 1.53 (s, 9H, OC(CH3)3), 1.63 (s, 6H, C(Me)2), 2.41 (br, 1H, OH), 6.77 
(s, 1H, N H ), 7.34 (s, 4H, Ar-H4); 13C NMR (CDCI3) 6 28.35 (OG(GH3)3), 31.56 
(G(Me)2), 65.64 (GOH), 80.86 (GsCCOH), 81.96 (OG(CH3)3), 92.96 (ArC=C), 116.93 
(4-Ar), 118 (2-Ar, 6-Ar), 132 (3-Ar, 5-Ar), 138.47 (1-Ar), 152.52 (G=0). MS (FAB+) 
m/z 275.1522 (M + H) (Ci6H2iN 0 3 requires 275.1521).
Bis(2-(4-nitroplienyl)ethyl)iirea 137
1,1 -Dimethyl-3-(4-(l, 1 -dimethylethoxycarbonylamino)phenyl)prop-2-yn-1 -ol (50 mg, 
0.18 mmol) was stirred with 4-nitrophenyl chloroformate (36 mg, 0.18 mmol) and 
Et3N (40 mg, 0.4 mmol) in DCM (4 mL) for 1 h. 2-(4-Nitrophenyl)ethylamine 
hydrochloride (37 mg, 0.18 mmol) was added and the mixture was stirred for 16 h. 
Evaporation and chromatography (10:1 CHCI3 : MeOH) gave bis(2-(4-nitrophenyl) 
ethyl)urea (17 mg, 27%) as a pale buff solid: »H NMR ((CD3)2SO) 6 2.81 (t, J  = 7.0 
Hz, 4H, 2x ArCH2), 3.26 (dt, J  = 5.7, 7.0 Hz, 4H, 2x NCH2), 5.92 (t, J  = 5.7 Hz, 2H, 
2x NH), 7.47 (d, J  = 8.6 Hz, 4H, 2x Ar 2,6-H2), 8.15 (d, J  = 8.2 Hz, 4H, 2x Ar 3,5- 
H2); 13C NMR ((CD3)2SO) 6 36.37 (CH2), 40.67 (CH2), 123.36 (CH), 130.06 (GH),
146.00 (Cq), 148.38 (Cq), 157.80 (GO). MS (FAB+) m /Z 359.1362 (M + H) 
(G17H 19N4O5 requires 359.1355).
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Prop-2-ynyl N -(2-(4-nitrophenyl) ethyl) c a rb a m a te  140
Propargyl alcohol (1.1 g, 20 mmol) was stirred with 4-nitrophenyl chloroformate (4.0 g, 
20 mmol) in DCM (15 mL) in the presence of Et3N (4.02 g, 40 mmol) for 1 h. 2-(4- 
Nitrophenyl)ethylamine hydrochloride (3.7 g, 20 mmol) was added and the mixture 
was stirred for 16 h. The evaporation residue, in EtOAc, was washed with H 2O (3x) 
and was dried. The evaporation residue was triturated with diethyl ether to give prop-
2-ynyl N-(2-(4-nitrophenyl)ethyl)carbamate (2.0 g, 40%) as a pale yellow solid: Rf = 
0.5 (10 : 1 CHCI3 : MeOH); >H NMR (CDCI3) 6 2.46 (t, J  = 2.5 Hz, 1H, O C H ), 2.94 
(t, J  = 6.9 Hz, 2H, ArCH2), 3.47 (q, J  = 6.7 Hz, 2H, NHCH2), 4.66 (d, J  = 2.3 Hz, 
2H, OCH2), 4.80 (brs, 1H, NH), 7.35 (d, J  = 8.9 Hz, 2H, Ar 2,6-H2), 8.16 (d, J  = 8.8 
Hz, 2H, 3,5-H2). MS (FAB+) m/Z 249.0882 (M + H) (C12H 13N2O4  requires 249.0875).
Na- (Fluoren-9-ylmethoxycarbonyl) glutam ic acid N- (4-iodophenyl) am ide y- 
(1,1 -dim ethylethyl) ester 144
Na-(Huoren-9-ylmethoxycarbonyl)glutamic acid Y-(l,l-dimethylethyl)ester pentafluoro 
phenyl ester (787 mg, 1.33 mmol) was stirred with 4-iodoaniline (292 mg, 1.33 mmol) 
and Et3N (270 mg, 2.7 mmol) in DCM (8 mL) for 5 h. The evaporation residue, in 
EtOAc, was washed with H 2O (3x) and aq. citric acid (3x). Chromatography (2 : 3 
EtOAc : hexane) gave Na-(fluoren-9-ylmethoxycarbonyl)glutamic acid N-(4-iodo
138
phenyl)amide y-(l,l-dimethylethyl)ester (92 mg, 11%) as a white semi-solid: *H NMR 
(CDCls) 6 1.41 (s, 9H, OC(CH3)3), 2.00 (m, 1H, P-H2), 2.11 (m, 1H, P-H2), 2.38 (m, 
1H, y-H ), 2.40 (m, 1H, y-H), 4.18 (d, J  = 6.9 Hz, 1H, Flu 9-H), 4.32 (m, 1H, a-H), 
4.39 (d, J  = 6.9 Hz, 2H, FluCH2), 5.95 (d, J  = 7.5 Hz, 1H, a-NH), 7.28 (m, 4H, Flu
2,7-H2, Ar 2,6-H2), 7.37 (t, J  = 8.0 Hz, 2H, Flu 3,6-H2), 7.57 (m, 4H, Flu 1,8-H2, Ar
3,5-H2), 7.74 (d, J  = 7.7 Hz, 2H, Flu 4,5-H2), 8.76 (brs, 1H, ArNH). MS (FAB+) m /Z 
627.1345 (M + H) (C3oH32N205l requires 627.1356).
N°- (1,1 -D im e thylethoxy carbonyl) glutam ine N-(4-iodophenyl) am ide 145
° V N^H2
MVxx
N“-{l,l-Dimethylethoxycarbonyl)pyroglutamic acid N-(4-iodophenyl) amide (80 mg, 
0.19 mmol) was stirred in THF (5.0 mL) with aq. ammonia (35%, 1.0 mL) for 18 h. 
Evaporation gave N“-(l,l-dimethylethoxycarbonyl)glutamine N-(4-iodophenyl)amide 
as a pale buff solid: ‘H NMR ((CDs^SO) 6 1.38 (s, 9H, OC(CH3)3), 2.10 (dt, J  = 17,
7.0 Hz, 1H, Gin P-H), 2.16 (dt, J  = 17, 7.0 Hz, 1H, Gin P-H), 2.50-2.70 (m, 2H, Gin 
Y-H2), 4.00 (m, 1H, Gin a-H), 6.79 (s, 1H, 6-CONH), 7.09 (d, J  = 7.4 Hz, 1H, a-NH), 
7.29 (s, 1H, 6-CONH), 7.44 (d, J  = 8.9 Hz, 2H, Ar 2,6-H2), 7.64 (d, J  = 8.7 Hz, 2H, 
Ar 3,5-H2), 10.08 (s, 1H, ArNH). MS (FAB+) m /z  448 (M + H), 392 (M -  
Me2C=CH2), 348 (M -  Boc).
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P yroglu tam ic ac id  benzyl e s te r  147
Pyroglutamic acid (25.0 g, 194 mmol) was stirred with Et3N (19.6 g, 194 mmol) and 
benzyl chloride at reflux for 5 d in THF (250 mL). H 2O (200 mL) was added and the 
THF was evaporated. The DCM extract was washed with H 2O (3x) and aq. citric acid 
(3x) and was dried. Evaporation gave pyroglutamic add benzyl ester (31.4 g, 74%) as a 
pale buff oil: NMR (CDCI3) 6 1.98-2.39 (m, 4H, Pyg P, y-H4), 4.16 (dd, J  = 7.7,4.7
Hz, 1H, Pyg a-H), 5.06 (d, J  = 12.4 Hz, 1H, PhCH), 5.07 (d, J  = 12.4 Hz, 1H, 
PhCH), 7.25 (m, 5H, Ph-Hs), 7.49 (s, 1H, Pyg NH). MS (FAB+) m/z 220 (M + H), 91 
(Bn).
Na- (1,1 -Dimethylethoxycarbonyl)pyro glutam ic acid benzyl ester 148
Pyroglutamic acid benzyl ester (31.3 g, 142 mmol) was stirred in DCM (250 mL) with 
di-feri-butyl dicarbonate (62 g, 285 mmol) and Et3N (14.5 g, 142 mmol) and DMAP 
(2.5 g, 4 mmol) for 18 h. The evaporation residue, in EtOAc, was washed with H 2O 
(3x) and aq. copper(II) sulfate (2x) and dried. The evaporation residue was 
recrystallised (cyclohexane) to give N“-(l,l-dimethylethoxycarbonyl)pyroglutamic add 
benzyl ester (34 g, 75%) as pale yellow crystals: mp 60-62°C. (Lit.145 mp 57-59°C); *H 
NMR (CDCI3) 6 1.40 (s, 9H, OC(CH3)3), 2.00 (ddt, J  = 13.1, 9.6, 3.2 Hz, 1H, Pyg P- 
H), 2.30 (m, 1H, Pyg P-H), 2.47 (ddd, J  = 13.6, 8.2, 3.7 Hz, 1H, Pyg y-H), 2.56 (dt, J  
= 13.6, 9.4 Hz, 1H, Pyg y-H), 4.62 (dd, J  = 9.4, 3.0 Hz, 1H, Pyg a-H), 5.18 (d, J  =
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12.3 Hz, 1H, PhCH), 5.19 (d, J  = 12.3 Hz, 1H, PhCH), 7.34 (m, 5H, Ph-H5). MS
(FAB+) m/z 320 (M + H), 264 (M -  Me2C=CH2), 220 (M -  Boc), 91 (Bn).
N°-(1,1 -Dim ethylethoxycarbonyl)pyroglutam ic acid 149
Na-(l,l-Dimethylethoxycarbonyl)pyroglutamic acid benzyl ester (2.0 g, 6.2 mmol) was 
stirred in dry MeOH (50 mL) with Pd/C (10%, 50 mg) under hydrogen for 16 h. 
Filtration (Celite®) and evaporation gave N01^  1,1 -dimethylethoxycarbonyl)pyro 
glutamic acid (1.6 g, 78%) as white crystals: mp 69-72°C (Lit.155 mp 77-80°G); 
NMR (GDGls) 6 1.36 (s, 9H, OC(CH3)3), 2.00 (m, 1H, Pyg P-H), 2.26 (m, 1H, Pyg P-
H), 2.43 (m, 1H, Pyg y-H), 2.51 (m, 1H, Pyg y-H), 4.52 (dd, J  = 9.4, 3.0 Hz, 1H, Pyg 
a-H), 10.87 (br, 1H, OH). MS (FAB+) m /z 230 (M + H), 174 (M -  (CH3)2C=CH2), 
130 (M-Boc).
Na- (1,1 -D im ethylethoxycarbony 1) pyroglutam ic acid pentaQuorophenyl 
ester 150
N“-(1,1 -Dimethylethoxycarbonyl)pyroglutamic acid (22.0 g, 100 mmol) was stirred in 
EtOAc (250 mL) with pentafluorophenol (37 g, 200 mmol) and DGG (22 g, 100 mmol) 
at 0°G for 2 h. Filtration and evaporation gave the N“-(l,l-dimethylethoxy 
carbonyl)pyroglutamic add pentafluorophenyl ester (10.5 g, 44%) as a colourless gum:
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*H NMR (GDCls) 6 1.41 (s, 9H, OC(CH3)3), 2.00 (m, 1H, Pyg p-H), 2.33 (m, 1H, Pyg 
P-H), 2.49 (ddd, J  = 12.7, 9.3, 3.3 Hz, 1H, Pyg y-H), 2.62 (ddd, J  = 12.2,10.2, 9.3 Hz, 
1H, Pyg y-H), 4.65 (dd, J  = 9.5, 3.0 Hz, 1H, Pyg a-H); 19F NMR (CDC13) 6 -160.93 
(dd, J  = 20.1, 16.8 Hz, 2F, 3,5-F2), -156.11 (t, J  = 20.6 Hz, IF, 4-F), -152.57 (d, J  = 
17.2 Hz, 2F, 2,6-F2).
Na-(1, l-D im ethylethoxycarbonyl)pyroglutam ic acid  N-(4-iodophenyI) 
am ide 151
Na-(l,l-Dimethylethoxycarbonyl)pyroglutamic acid pentafluorophenyl ester (3.4 g, 8.6 
mmol) was stirred in DCM (10 mL) with 4-iodoaniline (1.9 g, 8.6 mmol), DMAP (20 
mg) and Et3N (2.6 g, 2.6 mmol) for 16 h. The mixture was washed with aq. citric acid 
(3x) and dried. Chromatography (10 : 1 CHC13 : MeOH) gave Na-(1,1- 
dimethylethoxycarbonyl)pyroglutamic acid N-(4-iodophenyl)amide (702 mg, 19%) as a 
pale buff solid: W  NMR (CDC13) 6 1.45 (s, 9H, OC(CHs)3), 2.22 (m, 1H, Pyg P-H), 
2.36 (m, 1H, Pyg p-H), 2.53 (ddd, J  = 17.6, 9.7, 5.0 Hz, 1H, Pyg y-H), 2.56 (dt, J  = 
16.5, 9.0 Hz, 1H, Pyg y-H), 4.69 (dd, J  = 8.8, 4.1 Hz, 1H, Pyg a-H), 7.41 (d, J  = 8.8 
Hz, 2H, Ar 2,6-H2), 7.60 (d, J  = 8.8 Hz, 2H, Ar 3,5-H2), 8.92 (s, 1H, NH); 13C NMR 
(CDC13) 6 21.91, 28.02, 31.81, 61.22, 84.10, 87.68, 122.02, 137.56, 137.89, 169.66, 
171.32. MS (FAB+) m/z 431.0468 (M + H) (Ci6H2oN20 4I requires 431.0468).
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P yrog lu tam ic  ac id  N -(4-iodophenyl)am ide 156
0
Na-(l,l-Dimethylethoxycarbonyl)pyroglutamic acid N-(4-iodophenyl) amide (250 mg, 
0.56 mmol) was stirred with TFA (2.0 mL) in DCM (3 mL) for 25 min. Evaporation 
gave Pyroglutamic acid N-(4-iodophenyl)amide (172 mg, 93%) as a light brown 
hydroscopic oil: Rf = 0.3 (10 : 1 CHCI3 : MeOH); 1H NMR (CDCI3) 6 1.99 (m, 1H),
Pyg NH), 10.14 (s, 1H, ArNH). MS (FAB+) m /Z 331 (M + H), 484, 637 (M + H + 
nitrobenzyl alcohol clusters).
1,1 -D im e thy lethoxycarbonyl)leucyl)glutam ine N-(4-iodophenyl) 
am ide 159
HG1 was passed through a solution of Na-(l,l-dimethylethoxycarbonyl)glutamine N-(4- 
iodophenyl)amide (300 mg, 0.67 mmol) in MeOH (30 mL) for 30 mins at RT. The 
mixture was then concentrated to yield glutamine N-(4-iodophenyl) amide 
hydrochloride (277 mg, 0.72 mmol) which was then reacted in situ with Et3N (0.2 mL, 
1.44 mmol), DMAP (1 mg) and N“-(l, 1 -dimethylethoxycarbonyl)leucine N- 
hydroxysuccinimide ester (332 mg, 0.89 mmol) in THF (4 mL) and DMF (3 mL) for 16 
h at RT. The evaporation residue, in EtOAc, was washed with H 2O (3x). Drying,
2.16 (m, 2H), 2.34 (m, 1H) (Pyg p, y-H4), 4.14 (dd, J  = 8.2, 4.4 Hz, 1H, Pyg a-H),
7.43 (d, J  = 8.8 Hz, 2H, Ar 2,6-H2), 7.63 (d, J  = 8.9 Hz, 2H, Ar 3,5-H2), 7.86 (s, 1H,
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evaporation and recrystallisation (EtOAc /  hexane) gave N°-(Na-(l,l- 
dimethylethoxycarbonyl)leucyl)glutamine N-(4-iodophenyl) amide (155 mg, 38%) as a 
buff solid: Rf = 0.4 (10 : 1 CHCls : MeOH); *H NMR ((CD3)2SO) 6 0.84 (d, J  = 5.2 
Hz, 3H, Leu y-CHs), 0.86 (d, J  = 6.2 Hz, 3H, Leu y-CH3), 1.37 (s, 9H, OC(GH3)3), 
1.38-1.45 (m, 2H, Leu P-H2), 1.60 (m, 1H, Leu y-H), 1.80-1.95 (m, 2H, Gin P-H2),
2.08-2.16 (m, 2H, Gin y-H2), 3.98 (brq, J  = 7.0 Hz, 1H, Leu a-H), 4.34 (m, 1H, Gin 
a-H), 6.79 (s, 1H, 6-CONH), 6.96 (d, J  = 8.0 Hz, 1H, a-NH), 7.29 (s, 1H, 6-CONH),
7.43 (d, J  = 8.9 Hz, 2H, Ar 2,6-H2), 7.64 (d, J  = 8.8 Hz, 2H, Ar 3,5-H2), 8.03 (d, J  =
8.0 Hz, 1H, a-NH), 10.12 (s, 1H, ArNH). MS (FAB+) m /Z 560.1496 (M + H) (C22H33 
N4O 5I 1 requires 560.1490).
N°-(Na-(Leucy 1)glutam ine N-(4-iodophenyl)am ide trifluoroacetic acid salt 
160
H,N
Na-(Na-(l,l-Dimethylethoxycarbonyl)leucyl)glutamine N-(4-iodophenyl)amide (90 mg, 
16 mmol) was stirred with TFA (1 mL) in DCM (2 mL) for 30 min. Evaporation gave 
Na-(Na-(leucyl)glutamine N-(4-iodophenyl)amide trifluoroacetic acid salt (100 mg, 
94%) as a light brown hydroscopic oil: *H NMR (CD3OD) 6 0.88 (d, J  = 5.7 Hz, 3H, 
Leu Y-CH3), 0.89 (d, J  = 5.4 Hz, 3H, Leu y-CH3), 1.64 (m, 3H, Leu p, y-H3), 1.99 (m, 
1H, Gin P-H), 2.08 (m, 1H, Gin P-H), 2.33 (t, J  = 7.2 Hz, 2H, Gin y-H2), 3.95 (t, J  =
7.2 Hz, 1H, Leu a-H), 4.47 (dd, J  = 8.9, 5.2 Hz, 1H, Gin a-H), 7.24 (d, J  = 8.7 Hz, 
2H, Ar 2,6-H2), 7.48 (d, J  = 8.6 Hz, 2H, Ar 3,5-H2); NMR ((CD3)2SO) 6 0.88 (d, J  
= 6.2 Hz, 3H, Leu y-CH3), 0.90 (d, J  = 5.9 Hz, 3H, Leu y-CH3), 1.40-1.60 (m, 3H, 
Leu p, y-H3), 1.92 (m, 2H, Gin P-H2), 2.16 (m, 2H, Gin y-H2), 3.83 (m, 1H, Leu a-H),
4.42 (m, 1H, Gin a-H), 6.86 (s, 1H, 6-CONH), 7.33 (s, 1H, 6-CONH), 7.43 (d, J  = 8.4
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Hz, 2H, Ar 2,6-H2), 7.66 (d, J  = 8.4 Hz, 2H, Ar 3,5-H2), 8.11 (br, 3H, +NH3). MS
(FAB+) m/z 461 (M + H).
N“-(N“-(N°- (Fluoren-9-ylme thoxycarbony 1) -Ne- (1,1 -dim ethylethoxy 
carbonyl)lysyl)leucyl)gIutamine N-(4-iodophenyl)am ide 161
T
Na-(Fluoren-9-ylmethoxycarbonyl)lysine N®-(1,1 -dimethylethoxycarbonyl) N-hydroxy 
sucdnimide ester (382 mg, 0.68 mmol) was stirred with ^-(^-(leucyljglutamine N-(4- 
iodophenyl)amide trifluoroacetate salt (352 mg, 0.68 mmol), Et3N (205 mg, 2.0 mmol) 
and DMAP (1 mg) in THF (2 mL) and DMF (3 mL) for 14 h. The evaporation residue, 
in EtOAc, was washed with H 2O (3x) and aq. citric acid (3x) and dried. Evaporation 
gave Na-(Na-(Na-(fluoren-9-ylmethoxycarbonyl)-Ne-( 1,1 -dimethylethoxycarbonyl)lysyl) 
leucyl)glutamine N-(4-iodophenyl)amide (243 mg, 41%) as a white solid: *H NMR 
((GD3)2SO) 6 0.80 (d, J  = 6.4 Hz, 3H, Leu y-CH3), 0.84 (d, J  = 6.4 Hz, 3H, Leu y- 
CH3), 1.34 (s, 9H, OC(CH3)3), 1.30-1.95 (m, 11H, Lys P-H2, Lys y-H2, Lys 6-H2, Leu 
P-H2, Leu y-H, Gin P-H2), 2.11 (m, 2H, Gin y-H2), 2.87 (m, 2H, Lys e-H2), 3.94-4.34 
(m, 6H, Lys a-H, Gin a-H, Leu a-H , Flu 9-H, FluCH2), 6.75 (brt, J  = 6.0 Hz, 1H, 
CONHCH2), 6.78 (br, 1H, Gin 6-CONH), 7.27 (br, 1H, Gin 6-CONH), 7.30 (t, J  =
8.0 Hz, 2H, Flu 3,6-H2), 7.40 (d, J  = 8.7 Hz, 2H, Ar 2,6-H2), 7.43 (t, J  = 8.0 Hz, 2H, 
Flu 2,7-H2), 7.47 (d, J  = 7.7 Hz, 1H, a-NH), 7.62 (d, J  = 8.7 Hz, 2H, Ar 3,5-H2), 7.69 
(d, J  = 8.0 Hz, 1H, Flu 1-H), 7.70 (d, J  = 8.0 Hz, 1H, Flu 8-H), 7.87 (d, J  = 7.4 Hz, 
2H, Flu 4,5-H2), 7.93 (d, J  = 7.9 Hz, 1H, a-NH), 8.08 (d, J  = 7.0 Hz, 1H, a-NH),
10.07 (s, 1H, ArNH).
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N“-(Na-(Ne- (1,1 -D im e th y le th o x y c a rb o n y l) ly sy I) le u c y l)g lu ta m in e  N -(4-
iodophenyl) am id e  162
Na-(Na-(Ne-(l, 1 -Dimethylethoxycarbonyl)-Na-(fluoren-9-ylmethoxycarbonyl)lysyl)leucy
l)glutamine N-(4-iodophenyl)amide (179 mg, 19.7 mmol) was stirred with diethylamine 
(0.3 mL) in DMF (2 mL) for 25 min. Evaporation and trituration with diethyl ether 
gave Na-(Na-(Nt-(l, 1 -dimethylethoxycarbonyl)lysyl)leucyl)glutamine N-(4-iodophenyl) 
amide (114 mg, 84%) as white crystals: Rf = 0.2 (10:1 CHCI3 : MeOH); NMR 
((CD3)2SO) 6 0.84 (d, J  = 6.6 Hz, 3H, Leu Y-CH3), 0.88 (d, J  = 6.7 Hz, 3H, Leu y- 
CHs), 1.36 (s, 9H, OC(CH3)3), 1.30-1.96 (m, 11H, Lys p, y, 6-H6 + Leu P, y-H3 + Gin 
P-H2), 2.12 (m, 2H, Gin y-H2), 2.87 (m, 2H, Lys e-H2), 4.25-4.37 (m, 3H, 3x a-H), 
6.75 (m, 1H, Lys e-NH), 6.81 (br, 1H, 6-CONH), 7.30 (s, 1H, 6-CONH), 7.44 (d, J  -  
8.6 Hz, 2H, Ar 2,6-H2), 7.70 (d, J  = 8.0 Hz, 1H, a-NH), 7.64 (d, J  = 8.6 Hz, 2H, Ar
3,5-H2) 7.95-8.13 (m, 3H, a-NH + a-NH2), 8.25 (m, 2H, 2x NH), 10.07 (s, 1H, 
ArNH). MS (FAB+) m/z 689.2549 (M + H) (C2sH46N606l requires 689.2524).
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N °-(l ,1 -D im eth y le th o x y  carb o n y l) g lu ta m in e  N -(2-(4 -n itro p h en y l)e th y l)
am id e  164
Na-(l,l-Dimethyloxycarbonyl)glutamine pentafluorophenyl ester (412 mg, 1.0 mmol) 
was stirred with 2-(4-nitrophenyl)ethylamine hydrochloride (205 mg, 1.0 mmol) and 
Et3N (202 mg, 2.0 mmol) in THF (4 mL) and DMF (0.5 mL) for 16 h. The 
evaporation residue, in EtOAc, was washed with H 2O (3x) and aq. citric add (3x) and 
dried. Evaporation gave Na-(1,1 -dimethylethoxycarbonyl)glutamine N-(2-(4-nitro 
phenyl)ethyl)amide (190 mg, 52%) as a pale yellow solid: NMR ((GD3)2SO) 6 1.36
Na-(l,l-Dimethylethoxycarbonyl)glutamine N-(2-(4-nitrophenyl)ethyl)amide (400 mg,
1.02 mmol) was stirred in TFA (1.0 mL) for 20 min. Evaporation gave a mixture of 
pyroglutamic acid N-(2-(4-nitrophenyl)ethyl)amide and ammonium trifluoroacetate 
(412 mg) as a brown oil: NMR ((CD3)2 SO) 6 1.99 (m, 1H, Pyg p-H), 2.04-2.12 (m,
(s, 9H, OC(CH3)3), 1.61 (m, 1H, P-H), 1.73 (m, 1H, P-H), 2.01 (t, J  = 6.4 Hz, 2H, y- 
H2), 2.85 (t, J  = 6.6 Hz, 2H, ArCH2), 3.25-3.45 (m, 2H, NHCH2), 3.79 (m, 1H, a-H), 
6.74 (brs, 1H, 6-CONH), 6.81 (d, J  = 7.9 Hz, 1H, a-NH), 7.24 (brs, 1H, 6-CONH), 
7.48 (d, J  = 8.7 Hz, 2H, Ar 2,6-H2), 7.88 (t, J  = 5.7 Hz, 1H, NHCH2), 8.13 (d, J  = 8.7 
Hz, 2H, Ar 3,5-H2).
Pyroglutam ic acid N-(2-(4-nitrophenyl)ethyl)am ide 165
147
2H, Pyg p, y-H2), 2.18 (m, 1H, Pyg p-H), 2.87 (t, J  = 6.9 Hz, 2H, ArCH2), 3.32-3.45 
(m, 2H, ArCH2CH2), 3.91 (dd, J  = 8.4,4.5 Hz, 1H, Pyg a-H), 7.16 (t, J  = 51.0 Hz, 4 
H, +NH4), 7.49 (d, J  = 8.7 Hz, 2H, Ar 2,6-H2), 7.78 (s, 1H, Pyg NH), 8.08 (t, J  = 5.7 
Hz, 1H, NH), 8.15 (d, J  = 8.6 Hz, 2H, Ar 3,5-H2).
N- (Benzyloxycarbonyl) glutam ine N- (4-nitrophenyl) am ide 166
N”-(Benzyloxycarbonyl)glutamine (200 mg, 0.71 mmol) was dissolved in dry THF (4 
mL) and dry DMF (2 mL) at 0°C and allowed to stir for 5 min. To this mixture, 
pivaloyl chloride (94 mg, 0.78 mmol) and Et3N (0.25 mL, 1.78 mmol) were added and 
the mixture was stirred for 30 min. 4-Nitroaniline (97 mg, 0.71 mmol) was added and 
the mixture was brought to RT and stirred for 3 h. The evaporation residue, in 
EtOAc, was washed with H20  (3x). Drying, evaporation and chromatography 
(CHCI3) gave Na-(benzyloxycarbonyl)glutamine N-(4-nitrophenyl)amide (148 mg, 
52%) as a cream-coloured powder: mp 206-208°G. Rf = 0.8 (10 : 1 C H C I3 : MeOH);
NMR ((GD3)2SO) 6 1.76-1.88 (m, 1H, P-H), 1.80-2.00 (m, 1H, P-H), 2.08-2.28 (m, 
2H, y-H2), 4.10-4.20 (m, 1H, a-H), 5.10 (s, 2H, PhCH2), 6.82 (brs, 1H, 6-CONH), 
7.32 (brs, 1H, 6-CONH), 7.34-7.41 (m, 5H, Ph-H5), 7.74 (d, J  = 7.4 Hz, 1H, a-NH), 
7.85 (d, J  = 7.4 Hz, 2H, Ar 2,6-H2), 8.30 (d, J  = 7.4 Hz, 2H, Ar 3,5-H2), 10.70 (s, 1H, 
CONHAr). MS (FAB+) 401 (M + H). [a]D = + 50.0°.
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G lu tam ine N -(4-nitrophenyl) am id e  h y d ro b ro m id e  167
Na-(Benzyloxycarbonyl)glutamine N-(4-nitrophenyl)amide (60 mg, 0.15 mmol), AcOH 
(1 mL) and HBr (30% in AcOH) (1 mL) were stirred for 25 min and then 
concentrated. Et20 (8 mL) was added and the suspension was stirred for 5 min. The 
ether layer was then decanted off and the process repeated 10 times. This solid was 
dried to yield glutamine N-(4-nitrophenyl)amide hydrobromide (42 mg, quantitative) 
as a buff gum; NMR ((CD3)2SO) 6 2.00 (brs, 2H, P-H), 2.10 (brs, 2H, P-H), 2.30 
(brs, 2H, y-H*), 4.20 (brs, 1H, a-H), 7.00 (brs, 1H, 6-CONH), 7.50 (brs, 1H, 6- 
CONH), 8.00 (brs, 2H, Ar 2,6-H2), 8.40 (brs, 2H, Ar 3,5-H2), 8.50 (brs, 3H, +NH3),
11.40 (brs, 1H, ArNH). MS (FAB+) 268 (M + H).
N°- (N°- (1,1 -D im ethylethoxycarbonyl)leucy 1) glutam ine N- (4-nitrophenyl) 
am ide 168
NH,
Na-(1, l-Dimethylethoxycarbonyl)leucine N-hydroxysuccinimide ester (50 mg, 0.15 
mmol), Et3N (60 pL, 0.45 mmol) and DMAP (5 mg) were stirred with glutamine N-(4- 
nitrophenyl)amide hydrobromide (40 mg, 0.15 mmol) in CH2CI2 (3 mL), THF (0.5 
mL) and DMF (0.5 mL) for 16 h. The evaporation residue, in EtOAc, was washed
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with H 2O (3x). Drying, evaporation and recrystallisation (EtOAc /  hexane) gave Na- 
(Na-(l,l-dimethylethoxycarbonyl)leucyl)glutamine N-(4-nitrophenyl)amide (29 mg, 
41%) as a light orange powder: Rf = 0.5 (10 : 1 CHGI3 : MeOH); *H NMR (CDCI3) 6 
0.78-0.96 (m, 6H, Leu y-(CH3)2), 1.38 (s, 9H, OC(GH3)3), 1.44-1.58 (m, 2H, Leu 0- 
H2), 1.58-1.70 (m, 1H, Leu y-H), 2.00-2.38 (m, 2H, Gin P-H2), 2.40-2.54 (m, 2H, Gin 
y -H2), 3.90-4.05 (m, 1H, Gin a-H), 4.61-4.71 (m, 1H, Leu a-H), 5.25 (d, J  = 5.5 Hz, 
1H, Leu-NH), 6.50 (s, 1H, Gin 6-CONH), 6.65 (s, 1H, Gin 6-CONH), 7.80 (d, J  = 9.3 
Hz, 2H, Ar 2,6-H2), 7.85 (d, J  = 8.5 Hz, 1H, Gin a-NH), 8.10 (d, J  = 9.3 Hz, 2H, Ar
3,5-H2), 10.25 (brs, 1H, ArNH). MS (FAB+) 480 (M + H).
N°- (1,1 -D im ethylethoxycarbonyl) glutam ine N- (4-(3-hydroxypropynyl) 
phenyl) am ide 169
.OH
Na-(1,1 -Dimethylethoxycarbonyl)glutamine N-(4-iodophenyl)amide (300 mg, 0.7 
mmol) was heated at 55°C for 2 d with Cul (30 mg), (PPh3)2PdCl2 (20 mg), dry DEA (3 
mL) and propargyl alcohol (101 mg, 1.0 mmol) in dry DMF (5 mL) under Argon. 
Filtration, evaporation and chromatography (CHCb) gave Na-(l,l-dimethylethoxy 
carbonyl)glutamine N-(4-(3-hydroxypropynyl)phenyl)amide (116 mg, 46%) as a white 
solid: lH  NMR ((CD3)2SO) 6 1.35 (s, 9H, OC(CH3)3), 1.80 (m, 1H, P-H), 2.10 (m, 1H, 
P-H), 3.32 (m, 2H, y-H2), 3.99 (m, 1H, a-H), 4.25 (d, J  = 5.7 Hz, 2H, CH20), 5.28 (t, 
J  = 5.7 Hz, 1H, OH), 6.77 (brs, 1H, 6-CONH), 7.09 (d, J  = 7.0 Hz, 1H, a-NH), 7.27 
(brs, 1H, 6-CONH), 7.34 (d, J  = 8.7 Hz, 2H, Ar 2,6-H2), 7.59 (d, J  = 8.8 Hz, 2H, Ar
3,5-H2), 10.12 (brs, 1H, ArNH). MS (FAB+) m /z  376.1801 (M + H) (Ci9H22N30 5 
requires 376.1794).
150
N °-(l,1 -D im e th y le th o x y c a rb o n y l)g lu ta m in e  N -(4 -(3 -(2 -(4 -n itropheny l)
ethy lam inocarbonyloxy) p ro p -1 -yny 1) phenyl) am id e  170
,NH.
Na-( 1,1 -Dimethylethoxycarbonyl)glutamine N-(4-iodophenyl)amide (900 mg, 2 mmol) 
was stirred with (PPh3)2PdCl2 (60 mg), Gul (90 mg), propargyl N-(2-(4- 
nitrophenyl)ethyl)carbamate (625 mg, 2.5 mmol) in dry diisopropylamine (9 mL) and 
dry DMF (10 mL) at 55°G for 3 d under Argon. Filtration (Celite®), evaporation and 
column chromatography (10 : 1 CHCb : MeOH) gave N°-( 1,1-dimethylethoxy 
carbonyl)glutamine N-(4-(3-(2-(4-nitrophenyl)ethylaminocarbonyloxy)prop-1 -ynyl) 
phenyl)amide (520 mg, 43%) as a brown semi-solid: Rf = 0.4 (10:1 CHCls: MeOH); 
*H NMR ((GD3)2SO) 6 1.37 (s, 9H, OC(GH3)3), 1.70-1.92 (m, 2H, Gin P-H2), 2.11 (m, 
1H, Gin y-H), 2.13 (m, 1H, Gin y-H), 2.88 (t, J  = 6.9 Hz, 2H, ArCH2), 3.24-3.34 (m, 
2H, ArCHzCHg), 4.01 (m, 1H, Gin a-H), 4.81 (s, 2H, CH 20), 6.78 (s, 1H, 6-CONH),
7.09 (d, J  = 7.4 Hz, 1H, a-NH), 7.28 (br, 1H, 6-CONH), 7.37 (d, J  = 8.9 Hz, 2H, Ar
2,6-H2), 7.48 (d, J  = 8.7 Hz, 2H, Ar’ 2,6-H2), 7.49 (d, J  = 7.0 Hz, 1H, NH), 7.62 (d, J  
= 8.7 Hz, 2H, Ar 3,5-H2), 8.13 (d, J  = 8.8 Hz, 2H, Ar’ 3,5-H2), 10.15 (br, 1H, ArNH). 
MS (FAB+) m/z 568 (M + H).
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Na-(Na-(l,l-D im eth y le th o x y carb o n y l)leu cy l)g lu tam in e  N -(4-(3-(2-(4-nitro
phenyl)ethylam inocarbonyloxy)prop-l-ynyl) phenyl) am id e  172
Glutamine N-(4-(3-(2-(4-nitrophenyl)ethylaminocarbonyloxy)prop-1 -ynyl)phenyl) 
amide hydrochloride (231 mg, 0.4 mmol) was stirred with Na-( 1,1-dimethylethoxy 
carbonyl)leudne N-hydroxysuccinimide ester (151 mg, 0.4 mmol), Et3N (122 mg, 1.2 
mmol) and DMAP (1 mg) in THF (1 mL) and DMF (3 mL) for 16 h. The evaporation 
residue, in EtOAc, was washed with H2O (3x) and aq. citric acid (3x) and was dried. 
Evaporation gave N“-(Na-(l,l-dimethylethoxycarbonyl)leucyl)glutamine N-(4-(3-(2-(4- 
nitrophenyl)ethylaminocarbonyloxy)prop-l-ynyl)phenyl) amide (85 mg, 29%) as a light 
brown gum: Rf = 0.5 (10 : 1 CHCI3 : MeOH); »H NMR ((CD3)2SO) 6 0.85 (d, J  = 5.2 
Hz, 3H, Leu y-CH3), 0.86 (d, J  = 6.1 Hz, 3H, Leu y-CH3), 1.37 (s, 9H, OC(CH3)3), 
1.60-2.20 (m, 7H, Leu p, y-H3 + Gin p, y-H4), 2.45 (m, 2H, ArCH2), 2.85 (t, J  = 6.5 
Hz, 2H, ArCH2CH2), 4.00 (m, 1H, Leu a-H), 4.36 (m, 1H, Gin a-H), 4.82 (s, 2H, GH 
20), 6.78 (s, 1H, 6-CONH), 6.96 (m, 2H, 2x a-NH), 7.30 (br, 1H, 6-CONH), 7.37 (d, 
J  = 8.9 Hz, 2H, Ar 2,6-H2), 7.52 (d, J  = 8.2 Hz, 2H, Ar’ 2,6-H2), 7.67 (d, J  = 8.6 Hz, 
2H, Ar 3,5-H2), 8.05 (m, 1H, NH), 8.14 (d, J  = 8.6 Hz, 2H, Ar’ 3,5-H2), 8.22 (br, 1H, 
NH).
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N0-(1,1 -D im ethylethoxycarbonyl)phenylalanine N-(4-iodophenyl)am ide 
175
N“-( 1,1 -Dimethylethoxycarbonyl)phenylalanine (2.5 g, 4.42 mmol) was stirred in dry 
EtOAc (20 mL) at 0°C with pivaloyl chloride (533 mg, 4.42 mmol) and Et3N (0.61 mL,
4.42 mmol) for 3 h. 4-Iodoaniline (968 mg, 4.42 mmol) in EtOAc (10 mL) was added 
and the mixture was brought to RT and stirred for 16 h. The evaporation residue, in 
EtOAc, was washed with H 2O (3x). Drying, evaporation and chromatography (9 : 1 
EtOAc : hexane) gave Na-(l,l-dimethylethoxycarbonyl)phenylalanine N-(4-iodo- 
phenyl)amide (900 mg, 45%) as a brown oil: Rf = 0.85 (10:1 CHCI3 : MeOH); *H 
NMR (CDCI3) 6 1.42 (s, 9H, OC(GH3)3), 3.13 (d ,J = 7.2 Hz, 2H, Phe 0-H2), 4.43 (m, 
1H, Phe a-H), 5.06 (br, 1H, ArNH), 7.15 (d, J  = 8.5 Hz, 2H, Ar 2,6-H2), 7.21-7.34 
(m, 5H, Ph-Hs), 7.58 (d, J  = 8.7 Hz, 2H, Ar 3,5-H2), 7.77 (bid, J  = 7.0 Hz, 1H, a- 
NH). MS (FAB-) m/z 465.0667 (M - H) (C2oH22N2OsI requires 465.0675).
Phenylalanine N-(4-iodophenyl) am ide trifluoroacetic acid sa lt 176
Na-(l,l-Dimethylethoxycarbonyl)phenylalanine N-(4-iodophenyl)amide (125 mg, 26 
mmol) was stirred with TFA (1 mL) in DCM (2 mL) at RT for 30 min. Evaporation 
gave phenylalanine N-(4-iodophenyl)amide trifluoroacetic add salt (170 mg, 71%) as a
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light brown oil: Rf = 0.4 (10 : 1 CHCI3 : MeOH); NMR (GD3OD) 6  3.09 (dd, J  = 
13.8, 7.7 Hz, 1H, Phe p-H), 3.18 (dd, J  = 13.8, 6 . 8  Hz, 1 H, Phe P-H), 4.15 (dd, J  = 
7.7, 6 . 8  Hz, 1 H, Phe a-H), 7.16-7.26 (m, 7H, Ph-Hs + Ar 2,6-H2), 7.53 (d, J  = 8.7 Hz, 
2H, Ar 3,5-H2). MS (FAB+) m /z 734 (2x M + H), 368 (M + H).
Na-(1,1-Dimethylethoxycarbonyl) alanine pentafluorophenyl este r 177
N“-(l, 1 -Dimethylethoxycarbonyl)alanine (1.89 g, 10 mmol) in EtOAc (30 mL) was 
cooled to 0°C. Pentafluorophenol (1.84 g, 10 mmol) in EtOAc (10 mL) was added at 
0°C and the mixture were stirred for 30 min. DGG (2.06 g, 10 mmol) was added and 
the mixture was stirred for 2 h. The suspension was filtered (G elite®) and the filtrate 
was kept at 0°C for 24 h. Filtration and evaporation yielded N®-(1,1- 
dimethylethoxycarbonyl)alanine pentafluorophenyl ester (3.56 g, quantitative) as a 
colourless gum. This was used without further purification: JH NMR (CDCI3) 6 1.47 
(s, 9H, OC(CH3)3), 1.59 (d, J  = 6.0 Hz, 3H, Ala-CHs), 4.66 (quintet, J  = 6.0 Hz, 1H, 
a-H), 5.06 (d, J  = 6.0 Hz, 1H, a-NH); 19F NMR (CDCI3) 6 -162.03 (dd, J  =21.0, 18.4 
Hz, 1.8F, 3,5-F2), -161.89 (m, 0.2F, 3,5-F2), -157.49 (t, J  = 21.0 Hz, 0.9F, 4-P), -157.34 
(m, 0.1F, 4-10, -152.98 (d, J  = 20.3 Hz, 0.2F, 2,6-F2), -521.51 (d, J  = 18.4 Hz, 1.8F,
2,6-F2). MS (FAB+) m /Z 356.0991 (M + H) (C14H 15NO 4F5 requires 356.0921).
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N°-(N°-(1 ,1 -D im e th y  le th o x y  c a r  b o n y  l)a la n y l)  p h e n y la la n in e  N -(4 -io d o
pheny l)am ide 179
Phenylalanine N-(4-iodophenyl)amide trifluoroacetate salt (170 mg, 0.35 mmol) was 
stirred with Na-(1,1 -dimethylethoxycarbonyl)alanine pentafluorophenyl ester (120 mg,
0.35 mmol), EtsN (107 mg, 1 mmol) and DMAP (1 mg) in THF (4 mL) for 16 h. The 
evaporation residue, in EtOAc, was washed with H 2O (3x) and aq. citric acid (3x) and 
was dried. Evaporation and chromatography (10 : 1 CHCI3 : hexane) gave Na-(Na- 
(l,l-dimethylethoxycarbonyl)alanyl)phenyl alanine N-(4-iodophenyl)amide (120 mg, 
64%) as a white wax: Rf = 0.8 (10 : 1 CHCI3 : MeOH); lH NMR (GDCls) 6 1.36 (d, J  
= 7.2 Hz, 3H, Ala-Me), 1.42 (s, 9H, OC(CH3)3), 3.11 (dd, J  = 13.6, 6.4 Hz, 1H, 
Phe P-H), 3.27 (dd, J  = 13.3, 5.5 Hz, 1H, Phe P-H), 4.07 (dq, J  = 5.0, 7.0 Hz, 1H, Ala 
a-H), 4.81 (ea. q, J  = 6 Hz, 1H, Phe a-H), 5.02 (br, 1H, Ala a-NH), 6.81 (d, J  = 7.0 
Hz, 1H, Phe a-NH), 7.12-7.36 (m, 5H, Ph-H5), 7.26 (d, J  = 8.7 Hz, 2H, Ar 2,6-H2), 
7.52 (d, J  = 8.7 Hz, 2H, Ar 3,5-H2), 8.57 (s, 1H, ArNH). MS (FAB-) m /z 536 (M - H).
M ethyl 6-am inohexanoate hydrochloride 182
Thionyl chloride (2.0 mL) was added slowly to 6-aminohexanoic acid (4.00 g, 30.5 
mmol) in MeOH (30 mL) at 0°G and the mixture stirred at RT for 4 d. Evaporation 
yielded methyl 6-aminohexanoate hydrochloride (5.47 g, 99%) as white crystals: mp 
120-122°G. (Lit.151 mp 120-121°C); W  NMR ((GD3)2SO) 6 1.22-1.34 (m, 2H, 4-H2),
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1.45-1.59 (m, 4H, 3,5-H4), 2.28 (t, J  = 7.4 Hz, 2H, 2-H2), 2.71 (t, J  = 7.4 Hz, 2H, 6- 
H2), 3.60 (s, 3H, CH3), 8.10 (brs, 3H, +NH3); 13C NMR ((GD3)2SO) 6 23.02 (4-C), 
25.00 (5-G), 27.01 (3-C), 34.08 (6-C), 39.08 (2-C), 52.02 (GH3), 174.00 (Gq). MS 
(FAB+) m /z 146 (M + H).
M ethyl 6-(5-dim ethylam inonaphthalenesulfonam ido)hexanoate 183
HN
H,C.
Dansyl chloride (190 mg, 0.7 mmol) was added to a solution of methyl 4- 
aminohexanoate hydrochloride (126 mg, 0.7 mmol) and Et3N (0.29 mL, 2.1 mmol) in 
dry THF (4 mL) and DMF (1 mL). The solution was then left to stir for 16 h at RT. 
Evaporation and chromatography (10 : 0.5 CHC13 : MeOH) yielded methyl 6-(5- 
dimethylaminonaphthalenesulfonamido)hexanoate (190 mg, 72%) as a light green oil: 
Rf = 0.76 (10 : 1 CHC13 : MeOH); lH  NMR (CDC13) 6 1.10-1.50 (m, 6H, 3,4,5-H6), 
2.15 (t, J  = 7.4 Hz, 2H, 2-H2), 2.86 (s, 6H, N(CH3)2), 2.88 (q, J  = 7.4 Hz, 2H, 6-H2), 
3.62 (s, 3H, CH3), 4.96 (t, J  = 6.2 Hz, 1H, dansyl-NH), 7.18 (d, J  = 7.7 Hz, 3’-H), 7.52 
(t, J  = 8.6 Hz, 1H, 5*-H2), 7.56 (t, J  = 8.4 Hz, 1H, 2’-H), 8.22 (dd, J  = 8.4 Hz, J  = 1.5 
Hz, 1H, 4’-H), 8.31 (d, J  = 8.8 Hz, 1H, l ’-H), 8.54 (d, J  = 8.4 Hz, 1H, 6VH). MS 
(FAB+) m /z 379 (M + H).
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6- (5 -D im ethy lam in o n ap h th alen esu lfo n am id o )h ex aiih y d razid e  184
^NH,
Hydrazine hydrate (355 mg, 7.08 mmol, 0.34 mL) was added to a solution of methyl 6- 
(5-dimethylaminonaphthalenesulfonamido)hexanoate (765 mg, 2.02 mmol) in dry 
methanol (10 mL) and allowed to stir for 16 h at RT. In addition, excess hydrazine 
hydrate (355 mg, 7.08 mmol, 0.34 mL) was added to the mixture and stirred for a 
further 2 d. Evaporation yielded 6-(5-dimethylaminonaphthalenesulfonamido)hexan- 
hydrazide (752 mg, 98%) as a light brown oil: Rf = 0.48 (10:1 CHCI3 : MeOH); *H 
NMR (CDCls) 6 1.11 (m, 2H, 4-H2), 1.28 (m, 4H, 3,5-H4), 1.85 (t, J  = 7.4 Hz, 2H, 2- 
H2), 2.74 (m, 2H, 6-H2), 2.82 (s, 6H, N(GH3)2), 7.25 (d, J  = 7.4 Hz, 1H, 3’-H), 7.58 (t, 
J  = 8.5 Hz, 1H, 5*-H), 7.61 (m, 1H, 2’-H), 7.86 (br, 1H, dansyl-NH), 8.08 (dd, J  = 7.1,
1.2 Hz, 1H, 4’-H), 8.29 (d, J  = 8.6 Hz, 1H, l ’-H), 8.45 (d, J  = 8.6 Hz, 1H, 6’-H), 8.87 
(s, 1H, CONH); i3C NMR (GDCI3) 6 24.72 (CH2), 25.67 (GH2), 28.92 (CH2), 33.25 
(CH2), 42.33 (GH2), 45.10 (N(GH3)2), 115.14 (GH), 119.19 (GH), 123.63 (CH), 127.82 
(CH), 128.22 (CH), 129.04 (GH), 129.35 (Cq), 136.17 (Cq), 151.36 (dansyl 5-C), 
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APPENDIX
(Figures 24 — 28)
A man who dares to waste one hour o f time 
- has not discovered the value o f life.
- Charles Darwin
APPENDIX










Figure 25. A common hormone antagonist used in hormone therapy in the treatment of prostate 
cancer
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Vinblastine (23) (refer to Schem e 3, p30)
cfes-Acetyl-Vinblastine (23)
(the complete chemical structure)
Figure 26. The complete chemical structure of vinblastine (23)
Figure 27. A 3D model1 of a^oxy compound (105)
2
'  H
Figure 28. A 3D model1 of lactam (156)
tThe structures were created using Sybyl 7.1 Expert Molecular Modeling software and the structures 
where minimized using a conjugate gradient method as implemented within Sybyl 7.1.
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